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Abstract
The protease aminopeptidase O (ApO) was isolated during a gene trap
screen designed to identify novel developmentally regulated genes involved in
cardiovascular development. The aims of this thesis were to characterise the
gene trap integration, determine the full-length open reading frame (ORF) and
to investigate any functional domains that the gene contained. Additionally,
germline transmission of the gene trap demonstrated expression in the
vasculature of mice. Work was undertaken to investigate if there was a
phenotype in the homozygous gene trap mice with particular emphasis on
whether this gene was involved in the process of new blood vessel formation
(angiogenesis).
Initially, 5' RACE (Rapid Amplification of cDNA Ends) generated a 206
bp sequence that aligned with expressed sequence tag data to build a contig
with a partial ORF of 177 amino acids. Additional rounds of 5'RACE
generated a full length open reading frame of 823 amino acids. The nucleotide
and protein sequence are highly conserved between mouse, rat and human.
The gene encodes a catalytic domain characteristic of the Ml family of
aminopeptidases and contains a C-terminal armadillo repeat sequence and a
putative nuclear localisation signal (NLS). The NLS was experimentally
confirmed by transfection of eGFP-ApO constructs demonstrating that the
signal localised the fusion protein to the nucleoli.
The gene trap ES cells were injected into blastocysts and transmitted
through the germline. Generation of homozygous animals resulted in normal,
healthy, viable mice with no apparent phenotype. Expression analysis by lacZ
staining and RNA in situ indicated that ApO expression was restricted to the
cardiovasculature of embryos and adult tissues. The possibility that the ApO
may be involved in the process of angiogenesis was investigated using the
aortic ring assay. Northern blot analysis has shown that there are tissue
specific isoforms and RT-PCR analysis has revealed that the catalytic domain
and nuclear localisation signal can be removed by alternative splicing. An
antibody was raised against purified full length murine APO protein and the
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During a screen designed to identify novel regulated genes in
cardiovascular development, the gene trap GT411 ES clone was isolated. This
thesis describes the characterisation of this gene trap integration and the
subsequent analysis of the mouse gene that had been trapped. The gene was
originally identified to be a novel aminopeptidase but during the course of the
research its human orthologue was cloned and named Aminopeptidase O
(APO) (Diaz-Perales et al., 2005). Knowledge about APO is still in its infancy
and although the gene has been characterised with regard to structure, little is
known about how it functions physiologically.
From protein sequence analysis, several domains have been predicted.
Firstly, it contains a protease domain indicating that it is a member of the Ml
family of aminopeptidases. These enzymes are involved in a number of
important biological processes including angiogenesis, maintenance of blood
pressure and inflammatory pathways (Haeggstrom, 2004; Mitsui et al., 2004;
Sato, 2003). Secondly, prediction of an armadillo repeat structure suggests
that ApO may be implicated in the transport of proteins to the nucleus (Malik
et al., 1997). Furthermore, characterisation of a putative nuclear localisation
signal sequence (NLS) using eGFP-ApO fusions demonstrated that the protein
can localise to the nucleoli.
Germline transmission of the GT411 ES cells demonstrated LacZ
reporter expression in developing embryonic and adult vasculature. This is
important because the gene trap vector marks endogenous gene expression.
Understanding the function of ApO therefore might provide insight into
vascular biology in both normal developmental and pathological conditions.
These could include processes such as angiogenesis and the maintenance of




Proteolytic enzymes are a group of structurally and functionally diverse
proteins that have the common ability to hydrolyse peptide bonds (Neurath,
1999). The specific cleavage of substrates mediated by proteases is vital to
every cell and organism. Proteolytic processing events regulate the activity of
many proteins, for example, the regulation of transcription factor activity and
the appropriate intra or extra cellular localisation ofmany proteins (Lamkanfi
et al., 2006; Pickart, 2004; Tuteja, 2005). Proteases control essential
biological processes such as DNA replication, cell cycle progression, cell
proliferation, differentiation and migration, immunological reactions,
ovulation, angiogenesis, haematopoiesis and apoptosis (Adams, 2003;
Haeggstrom, 2004; Roy et al., 2006; Yamazaki et al., 2004). Given the
importance of these proteolytic processing events in the control of these
biological processes, it is not surprising that deficiencies or alteration in the
regulation of enzymes underlie important human pathologies such as arthritis,
cancer, neurodegenerative and cardiovascular disease (Egeblad and Werb,
2002; Hoi et al., 2005; Middleton et al., 2004; Oudit et al., 2003).
1.1.1 Enzyme classification
Several databases, such as the MEROPS and the Degradome have been
established and serve as a resource for information on proteases. The
MEROPS database (http ://www.merops.ac.uk) includes details of
approximately 3000 individual proteases from multiple organisms. They are
essentially classified into six groups which are defined by the proteases
catalytic activity. They are namely the aspartic, cysteine, metallo, serine,
threonine and a group which are of unknown catalytic type. Within each
group the enzymes are further classified into families on the basis of
significant similarities between protein sequences in the part called the active
site that is most directly responsible for the protease activity (Rawlings et al.,
2002). The group ofmetalloproteases, for example, consists of approximately
2
75 different families and each family can have a considerable number of
members.
The Degradome database (www.uniovi.es/degradome) specifically
includes details on peptidases present within the human, rat and mouse
genomes with particular emphasis on accession numbers and chromosome
locations. The proteases are grouped into five different classes with regard to
their mechanism of catalysis (Puente et al., 2003) and classified into families
in accordance with the MEROPs database.
1.1.2 Aminopeptidase O (APO)
The human gene for APO was cloned in 2005 with one paper published
to date (Diaz-Perales et al., 2005). It was cloned during a bioinformatic
analysis specifically targeted at identifying genomic sequences containing
novel aminopeptidases. The full length cDNA for this enzyme was predicted
by comparison with the structure of other aminopeptidases and then verified
by RT-PCR experiments on a brain cDNA library. Purification of the
recombinant putative catalytic domain of APO and incubation with
fluorogenic synthetic substrates demonstrated that it exhibits significant
proteolytic activity with an N-terminal arginine residue, and to a lesser extent,
aparagine. The enzymatic activity was strongly inhibited by o-phenanthroline,
a known metalloprotease inhibitor, but was not inhibited by 4-(2-aminoethyl)-
benzenesuphonyl fluoride or E-64 which are common inhibitors for serine and
cysteine proteases respectively (Diaz-Perales et al., 2005).
The expression of APO in heart and testis, tissues in which the renin
angiotensin system (RAS) plays important roles, prompted Diaz-Perales to
investigate the putative involvement of APO in the processing of peptides in
this pathway (Mitsui et al., 2004). Recombinant human APO was incubated
with angiotensin III (Ang III) and although the reaction proceeded slowly it
did generate angiotensin IV.
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1.1.3 General introduction of aminopeptidases
Aminopeptidases are enzymes that catalyse the sequential removal of
amino acids from the amino terminus of proteins or peptides (Taylor, 1993).
They are metalloproteases because they require a metal ion usually zinc but
colbalt is used by some in their catalytic active site such as MetAP2 (Griffith
et al., 1997). They are widely distributed in the plant, bacterial, fungi and
animal kingdoms (Taylor, 1993). The enzymes have broad substrate
specificity and in mammals perform a wide variety of biological processes
involving angiogenesis, blood pressure regulation and inflammatory
immunological responses (Haeggstrom, 2004; Sato, 2004; Wright et ah,
1990).
1.1.4 The Ml aminopeptidases
The Ml aminopeptidases contain the conserved catalytic domain with a
zinc-binding site (HEXXHX-E18). Essentially, based upon protein structural
motifs, they can be organised into four groups, namely the membrane bound,
Armadillo repeat (ARM), cytosolic and secreted aminopeptidases (Figure 1.1a
and 1.1b).
1.1.5 Armadillo (ARM) domain aminopeptidases
It has been proposed that the ARM aminopeptidases are a sub-family of
the Ml aminopeptidases which diverged from an evolutionary ancestor to
give rise to this specific group. They are aminopeptidase O, leukotreine A4
hydrolase, aminopeptidase B and aminopeptidase B-like (Diaz-Perales et ah,
2005).
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Figure 1.1a: Schematic diagram of the Ml family of aminopeptidases
organised by domain structure.
I Transmembrane domain I I Catalytic Ml domain ' i Armadillo repeat
c) Cytosolic aminopeptidases






Figure 1.1b: Schematic diagram of the Ml family of aminopeptidases
organised by domain structure.
i 1 Signal peptide Catalytic Ml domain
1.1.6 ARM domain
The ARM aminopeptidases contain a C-terminal armadillo repeat
structure. This is a tandem copy of a degenerate imperfect repeat within a
protein sequence motif that forms a conserved three-dimensional structure.
The sequence motif is typically about 42 amino acids and a single ARM motif
consists of three a helices (HI, H2 and H3) which interact extensively with
one another to form a right handed super-helix of helices. Structurally they
have been likened to HEAT repeats which consist of 2 helices (HI and H2)
(Andrade et al., 2001). The armadillo repeat sequence was first identified in
Drosophila melanogaster segment polarity gene known as Armadillo (Peifer
et al., 1993), but this structure is also present in other proteins such as its
orthologue /3-catenin (Huber et al., 1997), the plant plakophilins
(Klymkowsky, 1999) and the family of nuclear transport proteins called the
importins (Malik et al., 1997).
Importin a, a protein involved with nuclear transport, contains ARM
repeats which bind to the nuclear localisation signals of other proteins to
transport them to the nucleus through the nuclear pore complex (Conti and
Izaurralde, 2001; Gorlich, 1997).
Although no specific function of the ARM repeat has been attributed to
these enzymes, the ARM repeat structure allows for protein-protein
interactions and proteins that have this structure are involved with processes
such as nuclear cytoplasmic transport, maintenance and control of the
cytoskeleton (Coates, 2003). The LTA4 hydrolase ARM repeat fold has been
confirmed by crystallography studies (Thunnissen et al., 2001). It has recently
been published that LTA4 hydrolase can localise to the nucleus of type II
alveolar epithelial cells in rat, mouse and human cells (Brock et al., 2005).
7
1.1.7 Bi-functionality of catalytic sites
Some proteases exhibit the ability to cleave different substrates and this
has led to the proposition that the catalytic activities are exerted via specific
but overlapping sites. Proteases that have this ability are termed bi-functional
and include enzymes such as the hepatitis C virus NS2-3 protease and the
aminopeptidase leukotriene A4 hydrolase (Haeggstrom, 2004; Lorenz et ah,
2006). In the case of LTA4 hydrolase the enzyme exhibits epoxide hydrolase
activity for LTA4 and aminopeptidase activity (Orning et al., 1994). LTA4
hydrolase is involved in inflammatory processes as a key mediator of the 5-
lipoxygenase pathway where it hydrolyses the peptide LTA4 into LTB4, a
molecule that stimulates the adherence and aggregation of leukocytes to the
endothelium (Haeggstrom, 2004).
Analysis of the LTA4 hydrolase protein sequence confirms that it
contains the characteristic Ml aminopeptidase catalytic domain
(HEXXH18E). The purified enzyme was able to hydrolyse short peptides with
a preference for those with N-terminal Ala and Arg residues in standard
aminopeptidase assays (Orning et al., 1994). Although it has not been
experimentally verified, it is generally assumed that the aminopeptidase
activity is involved in the processing of peptides related to inflammation and
host defence (Haeggstrom, 2004).
From structural studies it has been determined that the two separate
catalytic sites require the use of the zinc ion and some common residues, but
also have distinct residue usage, such as Asp 375 in the epoxide hydrolase
reaction and Glu 296 and Tyr 383 for the aminopeptidase reaction (Kester and
Matthews, 1977; Rudberg et al., 2004).
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1.1.8 Domain structure and chaperone folding models
Many membrane and secretory proteins have pro-domains at their N or
C-termini that can undergo post translational proteolytic cleavage. It has been
demonstrated that these domains act as intramolecular chaperones responsible
for the correct folding of their cognate catalytic domain. Deletion of the N-
terminal propeptides of the enzymes subtilisin (Ikemura et al., 1987) and
alpha lytic protease (Baker et al., 1992) and the C- terminus in the protein
intestinal enzyme sucrase-isomaltase (Jacob et al., 2002) results in an inactive
enzyme (Silen et al., 1989; Zhu et al., 1989).
Aminopeptidase A is a type II integral membrane glycoprotein consisting
of 945 amino acids. Proteolytic fragmentation studies of purified pig APA
showed that the protein existed in vivo as two polypeptides of 107 and 45 kDa
(Hesp and Hooper, 1997). N-terminal sequencing of the 107 kDa fragment
demonstrated that it was the N-terminal extracellular catalytic domain ofAPA
from residues 43-602 whereas the 45 kDa fragment corresponded to the C-
terminus of APA from residues 603 to 942. In addition the rat hippocampus
has a short variant of APA produced by alternative splicing lacking the C-
terminal domain. This variant displayed no APA activity when produced in
COS-1 cells (Lee et al., 2000). Similarly, a recombinant form of the N-
terminus in the absence of the C-terminus did not have enzymatic activity and
remained blocked in the endoplasmic reticulum (Ofner and Hooper, 2002a).
This suggests that the C-terminus may be required for the correct folding of
APA. A study was performed with the production of recombinant protein N-
terminal fragment 1-598 and a separate clone coding the C-terminal fragment
595 to 945 and the proteins were expressed either separately or in trans. It was
found that co-expression of the N and C-terminal fragments resulted in an
active enzyme localised at the membrane.
A similar study has been conducted on the membrane bound M 1
aminopeptidase APN (CD 13). It also has a C-terminal domain that promoted
maturation and cell surface expression indicating that this mechanism of
9




The vascular endothelium is the layer of squamous epithelial cells that is
in direct contact with the blood. It forms a continuous lining of the
cardiovascular system (i.e. the heart and all the vessels contained within it)
and is ideally positioned to monitor bloodborne or locally produced stimuli.
The vascular system consists of a massive network of tubular channels
carrying nutrients and waste products between blood and tissue. Vessel walls
of arteries and veins consist of specialised connective tissues with elastin and
collagen as their major constituents. Major arteries carry blood direct from the
heart and have thick elastic walls composed mainly of elastin, while the
smaller arteries are rigid containing more collagen. In contrast, veins have
thinner walls, less dense connective tissue and a larger lumen than their
arterial counterparts. They have fewer smooth muscles and are equipped with
valves to prevent back flow of blood (Figure 1.2). Capillaries connect arteries
to veins and contain only one layer of endothelial cells with an underlying
basement membrane and are defined as a vessel small enough to allow a
single blood cell to pass through. These thin walls permit rapid exchange of









Figure 1.2: Vascular wall components of the major vessels
(Adapted fromHeart Development Harvey and Rosenthal 1999)
1.2.2 Embryogenesis of the vasculature
The development of the embryonic vascular system is highly conserved
between vertebrates. It begins with the appearance of angioblasts (endothelial
precursor cells) that differentiate from the mesoderm and proliferate within
previously avascular tissue. These angioblasts coalesce to form a primitive
tubular network by a process termed vasculogenesis (Yancopoulos et al.,
2000). This primary network, which includes some of the major vessels in the
embryo such as the aorta and major veins and a homogeneous capillary
network, undergoes maturation through a secondary process called
angiogenesis (Figure 1.3). This is new vessel formation from pre-existing
microvessels and is a complex phenomenon which requires the following
sequential steps: detachment of prexisting pericytes for vascular
destabilisation, breakdown of extracellular matrix (ECM), migration,
proliferation, tube formation by endothelial cells and then reattachment of
pericytes for vascular stabilisation (Folkman, 2002).
1.3 Disease and angiogenesis
The vasculature in the normal adult mammal is quiescent with only 1 in
10,000 endothelial cells actively dividing at any given time (Hobson and
Denekamp, 1984). The exceptions to this are the highly ordered processes of
wound healing and the female reproductive cycles (ovulation, menstruation,
implantation and pregnancy). Endothelial cells are able in response to the
appropriate stimulus, to actively proliferate to form new vessels by
angiogenesis (Hanahan and Folkman, 1996).
Angiogenesis plays a significant role in the progression ofmany diseases,
like solid tumour growth, diabetic retinopathy, rheumatoid arthritis and
atherosclerosis (Brooks et al., 1998). Solid tumours promote tumour cell
proliferation and invasiveness by the acquisition of new blood vessels which
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Figure 1.3: Schematic representation of the major processes involved in
vascular development. (Adapted from Heart Development Harvey and Rosenthal 1999)
and generate paracrine stimuli. Failure by a tumour to gain a blood supply
arrests growth and the tumour remains dormant and unable to expand more
than a few millimetres (Carmeliet and Jain, 2000).
1.3.1 Angiogenic switch hypothesis
There is evidence that angiogenesis is regulated by both inducers and
inhibitors of endothelial cell proliferation and migration. This has give rise to
the 'angiogenic switch' model whereby a quiescent endothelial cell if given
the correct signal can actively proliferate (Bergers et al., 2000; Hanahan and
Folkman, 1996).
1.3.2Angiogenic activator
It has been observed that solid tumours can be implanted either in an
avascular region, such as the cornea or on a characteristically vascularised
surface, such as the chick chorioallantoic membrane, and in each case elicit
the formation of new capillaries (Hanahan and Folkman, 1996). This
suggested that tumours release diffusible activators of angiogenesis that could
signal a quiescent vasculature to begin capillary sprouting. A number of
inducers of angiogenesis have been detected such as basic fibroblast factor
(bFGF) and the vascular endothelial growth factors (VEGFs), and the
angiopoietins (Davis et al., 1996; Dumont et al., 1994; Suri et al., 1996)
1.3.3 Vascular endothelial growth factor (VEGF) and its
receptors
Vascular endothelial growth factors (VEGFs) of which there are seven
(VEGF-A, B, C, D, E, F and placental growth factor (PIGF)) are the major
regulators of endothelial cell proliferation which occur during the process of
vasculogenesis and angiogenesis (Meyer et al., 1999; Nicosia, 1998; Suto et
al., 2005). The vascular endothelial growth factors (VEGFs) act through their
receptors (VEGFR1, 2, and 3,) (de Vries et al., 1992; Folkman and Klagsbrun,
14
1987; Millauer et al., 1993) although some members are able to bind another
group of receptors neuropillin 1 and 2 (Nrp-1 and 2) (Cebe-Suarez et al.,
2006).
The VEGF mitogen causes a signal transduction cascade through binding
to the VEGFR tyrosine kinase receptors involving, for example,
phospholipase C-protein kinase signalling pathways which regulate the
processes of angiogenesis (Shibuya, 2006). One of the consequences of this is
the up-regulation of various proteolytic enzymes including the urokinase
plasminogen activator and matrix metalloproteinases and aminopeptidases
which are required to breakdown basement membrane and extracellular
matrix (ECM) (Kato et al., 2001; Mazzieri et al., 1997)
1.3.4 Angiogenic inhibitors
The evidence for endogenous angiogenic inhibitors has come from work
on a non tumoriginic hamster cell line that became tumoriginic with a
mutation that inactivated a tumour suppressor gene. Comparisons of the cell
lines containing or missing the suppressor gene revealed that the non
tumoriginic line released high levels of a potent angiogenesis inhibitor. The
inhibitory activity was purified and shown to be a truncated form of
thrombospondin (TSP1) (Good et al., 1990).
In cancer patients, the removal of a carcinoma alone or in combination
with other therapies may be curative. However, the removal of some tumours
such as breast carcinomas and colon carcinomas, can be followed by the rapid
growth of distant metastases. It has been suggested, therefore, that the primary
tumour site is inhibiting the other distant tumours. It is thought that whilst a
primary tumour can stimulate angiogenesis in its own vascular bed, it can
inhibit angiogenesis in the vascular bed of another metastasis (O'Reilly et al.,
1994a).
This hypothesis was proven when an endogenous 38 kDa protein was
purified from the serum and urine of mice with Lewis lung carcinoma and
shown that it was a cleavage fragment of plasminogen. The fragment was
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called angiostatin and structurally consisted of the first four of five highly
homologous looped multiple disulphide bonded domains, termed kringle
domains (O'Reilly et al., 1994b). Purified angiostatin has been demonstrated
to be a potent inhibitor of endothelial cell (EC) proliferation (Cao et al.,
1996). Angiostatin prevents angiogenesis by binding to integrin alpha-v-beta3
where it inhibits interaction with matrix ligands reducing cell adhesion and
attachment properties of the EC which are a necessary requirement for
endothelial cell survival and migration (Tarui et al., 2001).
A key component of the angiogenic process is the involvement of
proteases that are able to degrade extra cellular matrix and control cellular
processes such as cell cycle and proliferation (Roy et al., 2006). Several
protease systems have been demonstrated to be involved in angiogenesis and
these include the matrix metallo proteases (MMPs), the 'A Disintegrin and
Metalloprotease Domain family (ADAMs), urokinase plasminogen activator
(uPA), and the aminopeptidases (Egeblad and Werb, 2002; Roy et al., 2006;
Sato, 2003).
1.3.5 Matrix metalloproteases (MMP) and angiogenesis
MMPs are zinc dependent proteolytic enzymes belonging to family M10
and are principally involved with the breakdown of extracellular matrix. They
are synthesised as latent enzymes which can be activated upon proteolytic
cleavage through a cysteine switch consensus sequence in the propeptide
domain (Springman et al., 1990).
Once activated, the activity of the MMPs is controlled and tightly
regulated predominantly by a group of structurally related endogenous
inhibitors known as tissue inhibitors ofmetalloproteases (TEMP 1, 2 ,3 and 4)
and RECK (Moses, 1997; Takahashi et al., 1998). These specific inhibitors
reportedly bind directly to MMPs and inhibit their proteolytic action (Hajitou
et al., 2001). The important role of MMP-2 and MMP-9 has been
demonstrated in both normal and tumour neovascularisation (Fang et al.,
2000; Vu et al., 1998) and siRNA mediated target RNA degradation ofMMP-
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9 inhibited formation of both capillary like structures in both in vitro and in
vivo models of angiogenesis (Lakka et al., 2005).
1.3.6 A Disintegrin and Metalloprotease domain (ADAMs)
proteases.
These are a family of zinc dependent integral membrane and secreted
glycoproteins. They contain multiple domains and like the MMPs are
activated through a cysteine switch mechanism. These enzymes have diverse
roles including ECM degradation, for example ADAM 10 cleaves collagen
type IV (Millichip et ah, 1998), and they have also been implicated in
diseases such as arthritis and cancer (Black et ah, 1997; Chubinskaya et ah,
2001; Seals and Courtneidge, 2003).
1.3.7 Serine protease uPA
Urokinase plasminogen activator (uPA) belongs to a large serine protease
family and specifically the SI family. It is a highly specific enzyme which
catalyses the membrane bound inactive proenzyme plasminogen (pig) into the
active enzyme plasmin which cleaves components of the ECM (Mazar et ah,
1999). UPA has its own specific cell surface receptor uPAR which greatly
enhances the action of uPA on Pig (Ragno, 2006). UPAR is found localised to
regions of cell contact (Limongi et ah, 1995) and the leading edge of invading
monocytes (Estreicher et ah, 1990). An additional role of the uPAR receptor
is to initiate signalling cascades that require receptor occupancy, for example,
integrins represent one set ofmolecules that are able to interact with uPAR on
the cell surface. Immunolocalisation and co-immunoprecipitation have
identified uPAR in complex with several integrin families (Reinartz et ah,
1995; Wei et ah, 1996). Control of these proteases is by the specific
inhibition to plasmin with alpha2 antiplasmin and uPA by PAI-1 and PA-I2
(Lijnen, 2001).
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1.3.8 Aminopeptidases in angiogenesis and cancer
Two distinct families of aminopeptidases have been reported to be
involved in angiogenesis including the M24 type 2 methionine
aminopeptidase (MetAP2) and the Ml zinc dependent aminopeptidases
comprising the membrane bound APA, aminopeptidase N (APN), and the
cytoplasmic adipocyte-derived leucine aminopeptidase (A-LAP) also known
as puromycin insensitive leucyl specific aminopeptidase (PILSAP) (Sato,
2003).
The methionine aminopeptidases (MetAPs) are a family of cytosolic
metalloproteases responsible for the cleavage of the initial methionine from
the N-termini of nascent proteins. Eukaryotes express two forms of MetAPs,
types 1 and 2. MetAP2 has stimulated a lot of interest in relation to
angiogenesis as it has been shown to be a target of the potent inhibitor of
endothelial cell proliferation, TNP470, the synthetic derivative of fumagillin
(Griffith et al., 1998; Griffith et al., 1997).
Evidence for APA involvement with angiogenesis has come from several
observations. Firstly, that the expression of the enzyme is up-regulated in
vessels of human tumours (Marchio et ah, 2004) and secondly, that APA
knockout mice fail to mount the expected angiogenic response to growth
factors and hypoxia. Additionally, specific APA peptide inhibitors and an anti
APA monoclonal antibody suppress EC migration and proliferation (Marchio
et ah, 2004).
Further evidence for aminopeptidase involvement in the process of
angiogenesis is from the APN also known as CD 13 which has been reported
to be expressed in the surface of endothelial cells (EC) of new vessels and
tumours but not in quiescent vessels (Fukasawa et ah, 2006). Specific
inhibition of APN with a monoclonal antibody and functional inhibitors
(bestatin) prevented capillary network formation in endothelial cell in vitro
assays. Furthermore, siRNA mediated interference of APN transcripts in
human umbilical vein endothelial cells (HUVEC) prevented capillary tube
formation on Matrigel (Fukasawa et ah, 2006; Pasqualini et ah, 2000). There
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data support its involvement in angiogenesis and it has been presumed that it
is involved in the degradation of extracellular matrix.
PILSAP is a cytoplasmic aminopeptidase and is also implicated in the
process of angiogenesis. The human gene was isolated from a cDNA screen
(Schomburg et ah, 2000) whilst the mouse orthologue was isolated in a
subtractive screen to identify genes that were up-regulated during the in vitro
differentiation ofmurine embryonic stem cells into EC cells (Miyashita et ah,
2002). Both PILSAP and its mouse orthologue (mPILSAP) have been found
to be induced in endothelial cells following vascular endothelial growth factor
(VEGF) stimulation and is expressed in ECs during angiogenesis in vivo
(Miyashita et ah, 2002; Yamazaki et ah, 2004). Further supporting evidence
of this proteases involvement in the process of angiogenesis was provided by
an antisense oligodeoxynucleotide to mPILSAP. It was found that EC
proliferation, migration and network formation both in vitro and in vivo were
attenuated. It has been proposed that PILSAP may mediate its effect through
cell cycle pathways as the cells were arrested in the G1 cell cycle phase
(Miyashita et ah, 2002; Yamazaki et ah, 2004).
1.4 The renin angiotensin system (RAS)
The renin angiotensin system (RAS) regulates blood pressure, endocrine
processes and behaviour at both the systemic and local tissue level when
angiotensinogen is cleaved by the protease renin to generate decapeptide
angiotensin I (Ang I). This is converted to angiotensin II (Ang II) by
angiotensin converting enzyme (ACE) (Kim and Iwao, 2000) where it causes
vasoconstriction of the endothelium increasing vascular resistance and
increase in blood pressure.
Ang II can be catabolised into Angiotensin III (Ang III) by
aminopeptidase A (Reaux et ah, 1999). Ang III can be proteolytically
converted to Angiotensin IV (Ang IV) by other aminopeptidases including
placental leucine aminopeptidase (P-LAP) and aminopeptidase O (APO)
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(Diaz-Perales et al., 2005; Tsujimoto et al., 1992; Wright et al., 1990) (Figure
1.4).
1.4.1 Aminopeptidases and the control of blood pressure
The evidence that APA can be regarded as an important candidate
responsible for the conversion of Ang II to Ang III comes from systemic
administration of purified APA into spontaneous hypertensive rats (SHRs)
(Mizutani et al., 1987). This has the effect of decreasing blood pressure whilst
the addition of an APA specific inhibitor (amastatin) elevates blood pressure
in normotensive rats (Ahmad and Ward, 1990).
A study with APA knockout mice demonstrated the baseline systolic
blood pressure was significantly elevated in the null mice when compared to
wild type littermate controls. Furthermore the infusion of Ang II increased the
systolic blood pressure to a greater extent in APA knockout mice (Mitsui et
al., 2003). These findings support the role APA might have in the
maintenance of vascular tone homeostasis.
Supporting evidence for APO involvement in the RAS was in an in vitro
assay where recombinant human APO was incubated with angiotensin III
(Ang III) and although the reaction proceeded slowly it did generate
angiotensin IV. The APO enzyme assay was performed with the recombinant
catalytic domain and not the entire protein. The authors acknowledge that
because of this, further experiments would be required to confirm the putative
activity of the enzyme under physiological conditions (Diaz-Perales et al.,
2005). The vasoactive peptides of the renin angiotensin system are
systemically transported in the blood and are either enzymatically cleaved by












Figure 1.4: Schematic representation of the renin angiotensin pathway.
Proteolytic cleavage of angiotensinogen by renin releases Ang I which is
subsequently cleaved by angiotensin converting enzyme (ACE) to
release the peptide Ang II which exerts its effect on the endothelium to
raise blood pressure by causing vasoconstriction. Ang II is subsequently
cleaved by a series ofproteases that control homeostasis.
protease APO does not have a transmembrane domain or signal peptides to
direct it to the cell membrane. It is therefore unlikely that this enzyme is
physiologically able to participate directly in the catabolism of the systemic
vasoactive peptide Ang III. Furthermore, APO enzyme assay was performed
with the recombinant catalytic domain rather than the entire protein. The
authors acknowledge that because of this, further experiments would be
required to confirm the putative activity of the enzyme under physiological
conditions ((Diaz-Perales et al., 2005). and it is therefore important to be
cautious about over interpreting the significance of this data.
1.4.2 Clinical evidence for aminopeptidase involvement in
blood pressure regulation
Blood pressure regulation and pathogenesis have been extensively
studied in pregnancy with regard to preeclampsia. This is a hypertensive
disorder that affects at least 5-8% of all pregnancies (Page, 2002). The
symptoms include high blood pressure, the presence of protein in the urine,
oedema, sudden weight gain, headaches and changes in vision. The condition
usually occurs after 20 weeks gestation, although it can be present earlier. It is
estimated that preeclampsia and other hypertensive disorders ofpregnancy are
responsible globally for approximately 76,000 deaths per annum (Page,
2002).
There is growing evidence from clinical studies of aminopeptidases
involvement during pregnancy. Foetuses produce high levels of the vasoactive
peptides such as Ang II compared to their mothers. It has been shown that
maternal APA increases during normal pregnancy whilst those with
preeclampsia show a variety of changes. For example, in mild preeclampsia,
APA levels are elevated whilst levels in those with full blown preeclampsia
APA levels are decreased (Mizutani et al., 1995; Mizutani and Tomoda,
1996).
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Another Ml aminopeptidase is placental leucine aminopeptidase (P-
LAP) so-called because it was believed to be expressed only in this tissue,
although has now been shown to have a broad tissue distribution (Rogi et al.,
1996). PLAP is believed to play a role in blood pressure regulation by
hydrolysing vasopressin (AVP) and Ang III (Matsumoto et al., 2000;
Tsujimoto et al., 1992). Once again most of the knowledge of this enzyme
comes from studies conducted during pregnancy. Membrane bound PLAP is
released into maternal blood flow via proteolytic cleavage by other proteases
such as the ADAMs and the metalloproteases (Iwase et al., 2001; Ofner and
Hooper, 2002b). During normal pregnancy the serum levels of PLAP
gradually increases. However, in mild preeclampsia patients PLAP levels are
very high whilst in severe cases there is a dramatic decrease in the levels of
PLAP (Mizutani and Tomoda, 1996). These findings are not dissimilar to data
acquired for APA.
1.4.3 Renin angiotensin system and cancer
There is increasing evidence that peptides Ang II and Ang III known to
control blood pressure may also play vital roles in other cellular processes
such as the regulation of cell proliferation, angiogenesis and inflammation
(Miyajima et al., 2002; Uemura et al., 2003) and this has led to the suggestion
that these molecules may be implicated in cancer (Deshayes and Nahmias,
2005).
At the molecular level Ang II and Ang III stimulate specific receptors,
namely, Ang II type 1 receptor (AT1R) and Ang II type 2 receptor (AT2R)
that reside on the cell surface (Nouet and Nahmias, 2000). Stimulation of
AT1R has been shown to induce cell proliferation in human cancer cells
(Uemura et al., 2003) (Fujimoto et al., 2001), by activating various
intracellular cascades of protein kinases usually associated with growth factor
stimulation. ATR1 transactivates the EGFR in prostate and breast cancer cells
leading to extracellular regulated kinase (ERK) activation, phophorylation of
a signal transducer and activation of a transcription factor STAT3 and
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activation of protein kinase C (PKC) (Greco et al., 2003; Uemura et al., 2003)
(Figure 1.5). Another aspect of Ang II and Ang III is the effect of AT1R
stimulation on the upregulation of vascular endothelial growth factor (VEGF)
and its receptor VEGFR2, which are major players in the process of
angiogenesis (Imanishi et al., 2004; Otani et al., 2001) (Figure 1.5).
Ang IV may also be implicated in cancer as it has been demonstrated in
vitro to increase cell proliferation of rat anterior pituitary cells (Pawlikowski
and Kunert-Radek, 1997). It is another proteolytically generated peptide from
the RAS pathway and it is cleaved by the aminopeptidase PLAP. These data
support a more recent view of the RAS being not only involved in blood
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Figure 1.5: Schematic illustration of the renin angiotensin system and its
cleavage products involvement with proliferation and angiogenesis.
Signal transduction cascades mediated through the binding ofAng II and
Ang III at the cell membrane to receptors AT1R and AT2R where they instigate a
signal transduction cascade through the EGFR receptor leading to an increase in cell
proliferation and angiogenesis (adapted from Kurdi et al 2005).
1.5 Mutagenesis
1.5.1 Mutagenesis strategies in the mouse
With the human and mouse genomic sequence databases publicly
available, the next major goal is to determine the function of genes. The
approach taken by the mouse genetics community is to mutate every gene in
the mouse genome termed 'genome saturation' and to identify any resulting
phenotype.
To this end, several mutagenesis strategies have been developed which
include: the use of the chemical mutagen ethylnitrosourea (ENU) (Favor and
Neuhauser-Klaus, 2000; Russell et al., 1979), gene targeting (Thomas and
Capecchi, 1986) and gene trapping (Gossler et al., 1989).
1.5.2 Ethylnitrosourea (ENU) Mutatgenesis
The chemical mutagen ethylnitrosourea (ENU) introduces point
mutations into spermatogonial stem cells. They are used in phenotypic driven
screens where mutants that have specific phenotypes are chosen (Quwailid et
al., 2004) or where region specific mutations that lie on a particular genomic
interval are selected for further analysis. To identify the gene that is mutated
requires appropriately designed breeding schemes and these are often costly
and time consuming to carry out. The use ofbalancer chromosome technology
has been used to simplify the ENU screening strategy by reducing the amount
of labour required (Yu and Bradley, 2001).
1.5.3 Gene targeting
Gene targeting involves the genetic modification of ES cells through the
introduction of a vector that contains two homology arms specific to the locus
of interest. Homologous recombination facilitates the replacement of the
targeted allele with the vector sequence. The targeted ES cell can then be used
to generate germ line transmiting mice that can be studied for a phenotype
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(Thomas and Capecchi, 1986) (Doetschman et al., 1987; Thomas and
Capecchi, 1987; Wong and Capecchi, 1987). To date, gene targeting has
contributed approximately 3600 mutants that corresponds to about 15%
coverage of the mouse genome (Skarnes, 2005).
Gene targeting is both labour intensive and time consuming since it
requires the construction of the targeting vector and the screening of a large
number of ES cell clones to identify the correctly targeted allele. It is
unsuitable for high-throughput methodologies although recombineering
strategies have been developed to assist in the making of the targeting
construct (Carlson and Largaespada, 2005) (Testa et ah, 2003).
1.5.4 Gene trapping
Another mutagenesis strategy, gene trapping (Evans et ah, 1997), entails
the random introduction into ES cells (via electroporation or retroviral
infection) of a DNA vector that has a selectable marker to screen for
integrations and a reporter gene that mimics the endogenous gene expression.
A consequence of the integration is that the endogenous gene may potentially
be mutated and the subsequent transmission of the trapped ES cell line to the
germ line allows phenotypic analysis in mice (Gossler et al., 1989)
The basic principle of gene trapping involves a vector with a splice
acceptor site (SA) immediately upstream of a reporter gene (lacZ) followed
by a neomycin resistance (neo) selectable marker. The random integration of
these vectors into a genomic locus downstream of a functional endogenous
promoter results in a fusion transcript between the integrated gene and the
lacZ reporter gene (Friedrich and Soriano, 1991; von Melchner et al., 1992).
The consequences of the gene trap integration are 1) the ES cell gene trap
clone can be characterised in vitro before germ-line transmission 2) the fusion
transcript between the gene and vector will mimic endogenous gene
expression which can be assessed by reporter gene activity at the insertion
locus and 3) the fusion transcript serves as PCR templates for 5'RACE
allowing identification of the gene that has been trapped (Stanford et al.,
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2001). This technique has been used extensively and lends itself to high-
throughput protocols. Furthermore, the ES cell clones bearing random
integrations can be stored for future use (see section 1.5.7).
1.5.5 Gene trap vector development
The basic gene trap vector consisted of a splice acceptor followed by
lacZ reporter gene and a poly A signal. The vector also included a neo
selection gene driven by a PGK promoter (Gossler et al., 1989). This vector
was subsequently adapted to include an ATG up-stream of the lacZ gene
which resulted in a three-fold increase in the number of /3gal clones probably
due to the detection of out-of-frame splicing events (Hill and Wurst, 1993). A
drawback of this particular vector was that the promoter driving the neo
selectable marker resulted in increased background since intergenic
integrations were also isolated (Forrester et al., 1996) To circumvent this
problem, the /Sgeo vector containing a fused neo to the 3' end of the lacZ gene
was developed (Friedrich and Soriano, 1991). This had the effect of placing
the neo selectable marker under the control of the promoter of the endogenous
trapped gene, thus reducing the background intergenic integrations.
1.5.6 Technical issues and limitations
Gene trapping has been successfully used to mutate and identify genes
(Zhou et al., 2004) (Torres et al., 1997). However, it is possible that the gene
trap reporter may not recapitulate the endogenous gene expression and, for
this reason, it should be confirmed by RNA in situ hybridisation with a probe
specific to the endogenous gene (Deng and Behringer, 1995; Pall et al., 2004).
Gene trap integrations may occur anywhere in a gene and those that take
place at the 3'end are more likely to generate a hypomorphic allele (a protein
that retains its function and does not result in a phenotype) (Herrick and
Cooper, 2002). It is also possible for the gene trap vector to be spliced around
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generating the wild type transcript resulting in a milder or absent phenotype
(Skarnes et al., 1992) (Sam et al., 1998).
Another limitation is that it is not uncommon for the gene trap vector to
integrate multiple times within a genetic locus. This can complicate analysis
of the integration event and cause uncertainty about whether other genes at
the locus are also affected (Pall et al., 2004).
1.5.7 Large scale screens
A few centres have performed high throughput screens with the aim of
generating a worldwide mutant resource and are collectively known as the
International Gene-trap Consortium (IGTC). These academic groups have
generated 27,000 tags, covering 32% of the genome (Skames et al., 2004).
The IGTC aims to make the ES cell lines available to the public without
restriction and this consists of The Bay Genomics Gene Trap Project
(www.http:/baygenomics.ucsf.edu/) and The Gene Trap Project of the
German Human Genome Project (www.http://tikus.gsf.de). A biotechnology
company, Lexicon Genetics, has also created a large library of ES cell lines
(OmniBank: http://www.lexicon-genetics.com) and claim to have achieved
close to 60% coverage of the genome with the generation of 200,000 tags. A
comparison between the IGTC and Lexicon gene trap data indicates that 20%
of the trapped genes in the public database are different from Lexicon
(Skarnes et al., 2004).
1.5.8 ES cell directed gene trap screens
Gene trap screening strategies have been developed to exploit the unique
capacity for ES cells to differentiate in vitro in to different lineages enabling
the selection of gene trap clones for germline transmission that are likely to be
involved in the development of a particular lineage (Stanford et al., 1998). An
In vitro pre-selection screen for genes responsive to retinoic acid (RA), the
active metabolite of vitamin A was performed to enrich for insertions into
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genes that are involved with embryogenesis (Forrester et al., 1996). The
application of RA as a cytokine to embryos (Conlon and Rossant, 1992;
Kessel and Gruss, 1991; Morriss-Kay et al., 1991) or to differentiating ES
cells in culture (Kondo et al., 1992) can alter the expression of
developmentally regulated genes. For example RA enhances differentiation
into neural lineages but represses commitment to haematopoietic and cardiac
fates (Bain et al., 1996; Wobus et al., 1997). The gene trap screen that
resulted in the GT411 ES cell clone was an RA in vitro pre-selection screen
designed to enrich for genes involved in the development of the
cardiovasculature (Forrester et al., 1996).
1.5.9 The gene trap screen that isolated GT411
E14 ES cells were electroporated with the gene trap vector pGTOl, 2.
The vector consisted of a splice acceptor (SA) derived from the engrailed -2
gene, a Pgalactosidase reporter gene fused to a promoterless neomycin
selectable marker (Pgeo) (Figure 1.6). Colonies which were resistant to G418
were picked and replica plated prior to incubation with RA. Clones which
showed repression of reporter gene in response to the RA were differentiated
into 'beating' cardiomyocytes, which were recorded on video and then stained
again with X-gal. Those clones that demonstrated /3gal staining in the
'beating' regions were selected for further analysis. The GT 411 ES cell line
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Figure 1.6: Gene trapping, a) The gene trap vector as used in this study consisted
of a splice acceptor(SA), /3geo {LacZ reporter fused to neomycin resistance gene)
and a polyadenylation signal (Poly A) integrates randomly into the intron of a gene,
b) The gene trap vector is regulated by the endogenous genes promoter and enhancer
sequences. The presence of the splice acceptor in the construct and the endogenous
splice donor from exon 1 results in a fusion transcript between the trapped gene and
vector, c) Translation of the mRNA results in a fusion protein.
E=enhancer, P= promoter, SD= splice donor.
Chapter 2:
Materials and methods
2.0 Material and methods
2.1 Molecular techniques
The preparation of standard solutions and general molecular techniques
described in this section were carried out in accordance with Molecular
Cloning Laboratory Manual as a source reference unless otherwise stated
(Sambrook 1989).
2.1.1 Polymerase chain reaction (PCR)
This method was used for a variety of purposes ranging from 5'RACE,
RT-PCR and generating full-length clones. A typical PCR reaction was as
follows: 10X PCR Buffer supplemented with MgCl2 (1.5mM), dNTP's (10
mM), primer A and primer B (10/zM), Template DNA (lOOng), Taq
Polymerase (1 unit) and made up to a final volume of 50pl with ddH20. PCR
was performed on a Peltier DNA Engine.
2.1.2 Gel purification of PCR products
Bands were excised from low melting point agarose and purified by
either one of two methods; either by a spin prep method (see TA cloning) or
by melting the agarose in 500pl of ddH20 at 70°C for 10 minutes with
occasional vortexing. To this mix, 1ml of a DNA binding resin (Promega)
was added and incubated for 2 minutes at RT. The slurry was captured with a
commercial filter and then washed with 2ml isopropanol (80%) and the filter
dried by spinning in a microfuge (12,000 g) for 2 minutes. To elute the DNA
of the resin through the filter, 50pl of ddH20 was applied and incubated for 1
minute. The filter was then spun at full speed (12,000 g) for 1 minute and the
eluted DNA was collected in a microfuge tube.
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2.1.3 Manual cycle sequencing
PCR products were prepared for sequencing with 1/xl of exonuclease I
(10 units/ yu.1) and 1/d of shrimp alkaline phosphatase (2 units/ /d) incubated at
37°C for 15 minutes, followed by heat inactivation at 80°C for 15 minutes.
The cleaned PCR product was then sequenced using the 33P dideoxy
terminator kit (Amersham Pharmacia Biotech) in accordance with the
manufacturer's protocol.
2.1.4 Denaturing gel electrophoresis of sequencing products
An 8% glycerol tolerant gel stock comprised the following reagents;
24ml acrylamide (BDH 30% stock 3% bis-acrylamide), Urea (50g), 5ml of
20X glycerol tolerant buffer (Tris base, 216g Taurine 72g, Na2EDTA.H20 4g)
and 100ml was made up with ddH20.
The Biorad gel cast system was set up according to manufacturer's
guidelines. To the 8% glycerol tolerant gel mixture, 1ml of 10% ammonium
persulphate and 25 /zl TEMED (N,N.N',N'-tetramethylethylenediamine) was
added and the mix was poured into glass plates. The sharks tooth comb was
inserted and the gel was allowed to set for two hours.
The gel was pre-run in IX glycerol tolerant buffer at 70 watts for 1 hour.
To the cycle sequencing products, 4/d of stop solution (95% formamide,
20mM EDTA, 0.05% bromphenol blue and 0.05% xylene cyanol FF) was
added prior to heating the samples to 70°C for 5 minutes. The wells of the gel
were flushed to remove urea and then loaded with the samples; each reaction
was loaded G,A,T,C. The gel was run until the bromphenol blue was near the
bottom of the gel. The apparatus was dismantled and the gel adhered to 3mm
Whatman paper before drying on a gel drier for two hours. Autoradiography
was carried out overnight at room temperature.
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2.1.5 Fluorescent ABI Sequencing
Sequencing reactions were cleaned as described above if a PCR product
was used otherwise 0.5 pg of plasmid DNA was sent to ICAPB Edinburgh
University Sequencing Service with the appropriate primer. Sequences were
returned as a text file and analysed appropriately.
2.1.6 TA cloning (Invitrogen)
PCR products were run on low melting point agarose gels containing
ethidium bromide and visualised with a UV spectrophotometer. Bands were
excised and placed in a SNAP microfuge tube and centrifuged at full speed
(12,000 g) for 1 minute. The agarose was retained by the filter paper barrier,
whilst DNA was collected in the microfuge tube. The captured DNA (2gl)
was then used in the TA cloning procedure with vector PCR4-TOPO
(Invitrogen) according to manufacturer's protocol.
The reaction was placed at room temperature for 5 minutes and then put
on ice. The reactions were subsequently transformed into DH5 alpha bacteria
(see below) spread on the appropriate antibiotic selection plates and incubated
at 37°C overnight. Colonies were selected for further analysis and
characterised by sequencing (see transformation procedure below).
2.1.7 Preparation ofDNA inserts
PCR products were cut with the appropriate restriction enzyme/s for each
particular cloning strategy. Products were run on 0.8% low melting point
1XTBE gels and bands were excised under UV light (250nm). Excess agarose
was trimmed away and the band was placed in an eppendorf with 500/xl of
distilled water, heated to 70°C to melt the agarose for 10 minutes and
vortexed on a whirlimix. The protocol used was a Promega DNA purification
kit which involves adding a charged bead that binds DNA in solution and
applying this to a column to capture the beads followed by washes to remove
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contaminants and finally an elution step was carried out with ddH^O to elute
the DNA from the bead.
2.1.8 Restriction digest
DNA was cut with the appropriate restriction enzyme and buffer. The
reaction was incubated at the appropriate temperature for the enzyme (usually
37°C) for a minimum of 4 hours. Double enzyme restriction digest for
directional cloning was carried out in a similar manner, but using an enzyme
buffer that gave optimal cutting for both enzymes. DNA could then be
isolated by gel purification.
2.1.9 Ligations
Ligation reactions were set up with a vector to insert molarity ratio of 1:3
with a rapid DNA ligation kit (Roche). Vector DNA and insert DNA (1:3
molar ratio, respectively) were dissolved in lx concentration DNA dilution
buffer (vial 2) in a total volume of 10 pi. To this mixture, 10 pi of 2X T4
DNA ligation buffer (vial 1) was added followed by 1 pi T4 DNA ligase (vial
3) and the entire solution was incubated for 5 minutes at RT. The ligation
reactions were then immediately used in bacterial transformations.
2.1.10 Transformation of bacterial cells
Frozen aliquots of competent cells (DH5 alpha or BL21) were thawed on
ice prior to use. The cells were mixed with 3pi of the ligation reaction in a
pre-chilled eppendorf and left on ice for 30 minutes. The cells/ligation mix
was heated in a water bath set at 42°C for 40 seconds and then placed back on
ice for 2 minutes. To each transformation tube, 250 pi of SOC medium was
added and then the tubes were placed in an orbital shaker at 37°C at 225 rpm
for 1 hour. The cells were pelleted at low speed in a centrifuge (2000 g)
before being resuspended in lOOpl of L-broth and spread on to LB-agar plates
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with the appropriate antibiotic for positive selection. Plates were placed in a
37°C incubator overnight.
2.1.11 Glycerol stocks
For long term storage, 8% glycerol stocks of bacterial clones were made
by taking 20pi of a mini prep culture to 1 ml of 8% glycerol in L broth and
stored in a minus 80°C freezer.
2.1.12 Plasmid preparation (Miniprep and Maxiprep)
A single colony from a freshly streaked plate was used to innoculate 5ml
of L-broth containing the appropriate antibiotic. The culture was grown
overnight at 37°C in an orbital shaker (225 rpm). The cells were harvested by
centrifugation 3,000 g for 10 minutes. The supernatant was discarded in
accordance with local biohazard guidelines and the pellet was then used to
extract plasmid DNA with the Mini-prep extraction kit (Promega) following
the manufacturer's protocol.
Large scale DNA plasmid purification (Maxi-Prep) was treated in the
same way as a mini prep except that after the overnight incubation, 400pi of
the LB mini prep was used to seed a 400ml flask and shaken in an orbital
shaker at 225rpm, 37°C for 16 hours. The cells were harvested in a centrifuge
at 3000 g for 10 minutes and then the plasmid was extracted using a Quiagen
Maxi prep kit in accordance with the manufacturer's handbook.
2.1.13. Sub-cloning
Plasmid vectors were cut with the restriction enzyme required for the
cloning application. The linearised vector was then treated with 1 unit of
shrimp alkaline phosphatase (SAP) for 15 minutes at 37°C to prevent re-
circularisation. The SAP was inactivated by heating at 80°C for 15 minutes.
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2.1.14 Phenol extraction and ethanol precipitation
The vector was extracted with an equal volume ofphenol/chloroform and
then precipitated with 0.1 volume of 3M sodium acetate pH 5.3 and 2
volumes of ethanol (-70°C) for 30 minutes. Following precipitation the DNA
was pelleted by centrifugation (12,000 g) at 4°C for 20 minute, washed in
70% ethanol, air-dried and resuspended in an appropriate volume of TE.
2.1.15 Isolation of genomic DNA from tissues/cells
The tissue was chopped into small pieces with a sterile razor blade (cells
are homogenised with a narrow guage needle) and placed in a microfuge tube.
500/d of lysis buffer (lOOmM Tris-HCl pH 8.5, 5mM EDTA, 0.2% SDS,
200mM NaCl and lOOpg/ml proteinase K. This was incubated at 55°C
overnight. The microfuge tube was spun at 12,000 g for 10 minutes. The
supernatant was removed to a fresh microfuge tube and extracted with 500/xl
phenol chloroform, mixed briefly and centrifuged at 12,000 g for 1 minute.
The aqueous layer was taken and mixed with an equal volume of isopropanol
to precipitate the DNA. It was spun at 12,000 g for 20 minutes to pellet the
DNA. The pellet was washed with 70% ethanol, air dried before resuspending
in 500/tl of ddH20. The DNA concentration was determined on
spectrophotometer (OD26o)-
2.1.16 Random primed labelling of probes
All experiments involving radioactivity were carried out in designated
areas following local rules and guidelines to minimise exposure and avoid
contamination. DNA fragments were purified by elution from agarose gel
bands and labelled with P for hybridisations for Northern or Southern blots.
Random-primed labelling was performed with a "High Prime" kit as
recommended by Roche: 25ng of DNA was mixed with ddH20 to a final
volume of 11 pi, denatured at 90°C for 10 minutes in a screw cap tube, snap
cooled on ice and condensate spun down by centrifugation. On ice, 5pi high
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prime mix (1 unit/pl Klenow polymerase; 0.125mM of each dATP; dGTP and
dTTP; 50% v/v glycerol) and 4pl of 50pCi [alpha 32P] dCTP (3000Ci/mMol)
aqueous solution were added to the denatured DNA and the reaction was then
incubated at 37°C for 10 minutes. The reaction was stopped by heating to
65°C for 10 minutes. After this time, 80ja 1 of ddLLO was added to the tube
and unincorporated nucleotides were removed by centrifugation through a
Sephadex G-50 column at 3000 g for 2 minutes.
2.1.17 Southern blot
Genomic DNA (lOug) was restriction digested overnight at the
appropriate temperature for the enzyme used. The products were resolved on
a 1% TBE agarose gel. The gel was stained and destained with ethidium
bromide. A photograph was taken with a ruler along the side of the gels, so
that the distance of the markers could be calibrated. The gel was placed in
denaturing solution (0.5M NaOH; 1.5M NaCl) for 20 minutes and then
neutralised with neutralisation solution (1.5M NaCl; 0.5M Tris.HCl pH 7.4)
for 30 minutes. The gel was transferred to a membrane Hybond N+ as
described in Maniatis by a wet blot capillary method. After overnight blotting
the membrane was marked for orientation, rinsed in 2XSSC (pH 4.4) and
baked at 80°C for 2 hours.
2.1.17.1 Prehybridisation and hybridisation
The ULTRAhyb (Arnbion) was preheated in a water bath at 68°C and the
buffer swirled until all precipitated material had dissolved. The membrane
was prehybridised with 10ml ULTRAhyb for 30 minutes at 42°C in rotating
Techne hybridisation bottles in Techne Hybridistion HB-1 ovens.
The probe was denatured for 10 minutes at 90°C, cooled on ice and
centrifuged and then added to the blot with fresh hybridisation buffer.
Routinely 107 counts per minute of a probe in a 10ml hybridisation were used
for hybridising to a standard (13X1 lcm) midi-gel blot. It was incubated at
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42°C overnight in a rotating Techne hybridisation bottle in Techne
Hybridisation HB-1 oven.
2.1.17.2 Washing
The hybridisation buffer was discarded and the blot was washed twice in
0.1 %SDS, 2XSSC pH 4.5 for 5 minutes each. Then the blot was washed in
0.1%SDS, 0.1%SSC pH 7.4 at 55°C. At this point the blot was monitored
with a Geiger counter to assess the background level of radiation. The
washing and monitoring continued until the Geiger counter readings were
very low. The membrane was wrapped in Saran plastic before being exposed
to X-ray film at -70°C with an intensifying screen, initially for 24 hours. If the
band signal was low the time of exposure was increased accordingly.
2.1.17.3 Stripping DNA and RNA blots
Blots were stripped in O.OlxSSC pH 4.5, 0.01% SDS at 70°C to remove
bound radiolabelled probe. The buffer was changed frequently until the
radioactive counts dropped to background levels. Stripped blots were then
exposed to autoradiographic film for 1 week to check that the probe had been
removed prior to re-hybridisation
2.1.18 Preparation ofRNA
RNA is extremely susceptible to degradation by RNases. Care must be
taken to avoid contamination of samples. Gloves should be warn, barrier tips
used with pipettes and fresh tubes/glassware that have been treated to remove
RNases.
2.1.19 Preparation of diethylpyrocarbonate (DEPC) water
lml of DEPC was added to 1 litre of autoclaved water, mixed thoroughly
and left in a 37°C water bath for 2 hours. In order to inactivate it, the DEPC
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water, was autoclaved. Care must be taken when using DEPC as it is
carcinogenic
2.1.20 RNA extraction
Tissues were dissected and directly frozen in liquid nitrogen. RNA
isolation from tissues and cells grown as a monolayer were homogenised
(Polytron) in Trizol (Invitrogen) and then total RNA was extracted following
the manufacturer's protocol (in fumehood). Specifically, 1 ml of Trizol was
used per 50mg of solid tissue or in the case of cells grown as a monolayer, 1
ml of Trizol was sufficient to cover a 3.5 cm diameter dish. The homogenates
were incubated for 5 minutes at room temperature (RT) before the addition of
0.2 ml chloroform. Tubes were sealed and shaken vigorously for 15 seconds
and then incubated for 15 minutes at RT. The tubes were centrifuged at
12,000 g in 4°C for 10 minutes. The upper phase (60%) contains the RNA
fraction and this was precipitated with 0.5ml of absolute isopropanol.
Samples were incubated for 10 minutes prior to centrifuging at 12,000 g for
10 minutes at 4°C. The RNA pellet was washed with 1 ml of 75% ethanol and
then centrifuged at 5000 g for 5 minutes at 4°C. The pellet was allowed to air
dry (care being taken not to over dry the pellet as it can be difficult to
resuspend RNA) and then it was resuspended in 100/d ofRNase free water.
Quality was assessed by gel electrophoresis (0.8% TBE agarose gels) and
the RNA concentration determined by UV spectrophotometry.
An Oligotex mRNA mini extraction kit (Qiagen) was used in accordance with
the manufacturer's guidelines to isolate messenger RNA. Samples were
treated identically and diluted to the same concentration (ljug/jtil). A typical
reaction was 100 jul of total RNA (l/ig/jul), 150 /d of dd H20, 250 /d of
Oligotex binding buffer (OBB) and 15 /d ofOligotex resin beads.
This reaction was incubated at 70°C for 3 minutes, then at RT for 10
minutes. The Oligotex bead/RNA mix was loaded onto a column. The column
was washed with wash buffer and then centrifuged at 10,000 g to remove
unbound RNA and excess buffer. The mRNA was eluted from the column
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with pre-warmed oligotex elution buffer (two elutions each 50jiil). To
determine the amount of mRNA extracted, it was assumed that I fig of total
RNA contains 5% mRNA, thus lOOpg of total RNA would yield 5pg mRNA.
2.1.21 Northern blot analysis
2.1.21.1 Electrophoresis
The electrophoresis tank and gel casting apparatus and 50pl well capacity
comb were cleaned thoroughly with DEPC water prior to washing in a 3%
solution of hydrogen peroxide for 10 minutes. The equipment was washed
again in DEPC water and dried. A 150 ml midi agarose gel was cast in a fume
hood. The gel consisted of 3ml 20mM phosphate buffer (11.5 ml Na2HP04
(IMolar pH 7.0) and 8.5 ml Na2H2P04 pH 7.0 made up to 1 litre), 2.25g of
agarose, 25.5ml ultrapure formamide (Sigma) and 121 ml of DEPC water.
(The formamide was added after the agarosemix had cooled).
In order to prepare RNA for loading onto the agarose gel, it was prepared
as follows: 16.5jj.1 ultrapure formamide, 5pl formaldehyde, 6pi of 20mM
phosphate buffer and 15pl of mRNA (3jag). To this mix, 7ul of loading dye
(bromophenol blue EDTA) was added and heated to 70°C for 10 minutes and
then cooled on ice.
The RNA sample was loaded onto the formamide agarose gel and was
electrophoresed at 90 volts for 3 hours at RT. The Marker lane was removed,
washed in 0.1M ammonium acetate, stained in ethidium bromide (0.5mg/ml),
destained and then photographed. RNA lanes were washed in distilled water
and then placed in 0.05M sodium hydroxide/1.5M sodium chloride for 30
minutes. The gel was neutralised in 0.5M Tris/HCl pH7.4/1.5M NaCl for 20
minutes. The mRNA was transferred from the gel to a nylon membrane
(hybond N+ Amersham/Pharmacia) in a 10XSSC (pH 4.4) wet transfer set-up
overnight in a blotting sandwich (Maniatis).
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The blotting apparatus was dismantled and the membrane baked in an
oven at 80°C for 2 hours. The membrane was stored at room temperature prior
to hybridisation (see sections Southern blotting)
2.1.22 RT-PCR
First strand cDNA synthesis was performed on 250pg mRNA using
superscript Reverse Transcriptase (Invitrogen). After cDNA synthesis, the
25pi reaction volume was brought to 50pl with ddH20. For each PCR
reaction, lpl of cDNA was used. A typical PCR condition was as follows: 2
minutes at 94°C for 1 cycle, followed by 15 seconds at 94°C, 30 seconds at
55°C and 2 minutes at 72°C for 30 cycles.
2.1.23 Rapid amplification of cDNA ends (5'RACE)
5' RACE was carried out on mRNA isolated from 11.5 dpc wild type
mouse embryos. Using a Gene Racer kit (Invitrogen), cDNA was generated as
described in the manual. First round RACE-PCR was carried out with P/3 and
anchor primer API (Invitrogen) and then nested with P/2 and anchor primer
AP2 under the following 'touch down' PCR conditions using Thermozyme
Taq (Invitrogen) as described in the product protocol.
1 cycle 5 cycles 5 cycles 25cycles
2min 94° C 15 sec 94°C 15 sec 94°C 15 sec 94°C
30 sec 72°C 30 sec 70°C 30 sec 68°C
2 min 72°C 2 min 72°C 2 min 72°C
Products were cloned into the TA cloning vector (Invitrogen) and sequenced.
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2.2 Protein Methods
2.2.1 Electrophoresis and Western blotting procedures
For SDS-PAGE, proteins from tissues or cells were solubilised in sample
buffer (62.5mM Tris-HCl pH6.8, 1% SDS 0.1M glycerol, B-mercaptoethanol
(0.25%) and traces of bromophenol blue before separation on 10%
polyacrylamide (Laemmli, 1970).
The commercial blotting apparatus (Biorad) was arranged in accordance with
the manufacturer's guidelines and transferred at 100mA for 1 hour. Western
blot analysis was carried out after separation of proteins by SDS-PAGE and
then the protein was transferred onto the PVDF membrane at 200ma for 1
hour in transfer buffer (Tris 3.03g, glycine 14.4g, 20% methanol made up to 1
litre with ddEEO) that had been prepared by a brief wash with methanol
(change in colour was noted from opaque white to translucent grey), followed
by a wash in ddH20 for 2 minutes and then the membrane was soaked in
transfer buffer (Tris glycine 20% methanol) for 5 minutes before proceeding
to blotting.
Proteins were blocked in 5% milk 0.1% Tween 20 in IX PBS for lhour
at RT. The primary antibody was added to the membrane in a sealed bag at
the appropriate dilution (example 1/1000) in 1XPBS 0.1% Tween 20 for 1
hour at RT with vigorous shaking. The membrane was washed vigorously in
large volumes of 1XPBS 0.1 % Tween 20 three times for 5 minutes each. The
appropriate secondary HRP conjugated antibody was diluted 1/1000 in
1XPBS 0.1% Tween 20 and added to the membrane in a sealed bag and
placed on a shaker for 1 hour at RT, followed by extensive washes to remove
unbound antibody prior to chemi-luminescent detection (ECL Amersham
Pharmacia Biotech) as described in the manufacturer's protocol and
eventually visualised on photographic film.
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2.2.2 Stripping blots
The blot was incubated in stripping buffer (2% w/v SDS, 62.5mM Tris-
HC1 pH 6.8, lOOmM /3-mercaptoethanol for 30 minutes at 60°C. The
membrane was washed twice in PBS for 10 minutes each. The blot was then
tested with fresh ECL to determine if the stripping procedure had been
successful.
2.2.3 In vitro translation
This was carried out following manufacturer's protocol for the T7
coupled transcription/translation system (Promega). Plasmids were linearised
with the appropriate restriction site downstream of the stop codon (NOTI).
The DNA was phenol extracted and ethanol precipitated prior to the in vitro
translation.
The following reaction was set up: vector DNA (lyu.g//xl), radiolabelled
S35 methionine, amino acid (minus Methionine) mix, RNase inhibitor, rabbit
reticulocyte. This reaction mix was incubated for 1 hour at 30°C and then
incubated at 60°C to stop the reaction.
2.2.4 Electrophoresis
(See electrophoresis section 2.2.1 as for Western blotting). After
electrophoresis, the gel was soaked in a fixative solution (7% acetic acid, 7%
methanol and 1% glycerol) for 30 minutes. The gel was then placed onto
3mm Whatmann paper and dried for 1 hour. The dried gel was exposed to
photographic film over night at RT.
2.2.5 Protein induction
The bacterial expression vector pGEX 4T-1 containing a cloned in-frame
region of the ApO gene was transformed into a protease deficient bacteria
strain (BL21). A positive clone was selected and grown overnight in 5ml LB
supplemented with 50mg/ml ampicillin in a shaking orbital incubator set at
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37°C and 225 rpm. A 500 ml LB culture (50mg/ml ampicillin) was seeded
with 500/d of the overnight culture and grown till in log phase (optical
density OD6oo equivalent 0.6) at 37 °C and 225 rpm. At this stage IPTG was
added to the culture (final concentration 0.4mM) to induce the bacterial
promoter to transcribe an N-terminal GST tagged ApO fragment for 3 hours.
2.2.6 Purification of GST-ApO
2.2.6.1 Mechanical lysis
The bacteria were pelleted by centrifugation at 3000 g for 10 minutes at
4°C. The pellet was resuspended in 5ml of PBS containing protease inhibitors
(complete EDTA free cocktail, Roche), aliquotted into five 1 ml eppendorfs
and kept on ice. The bacteria were lysed mechanically by sonication on ice
using a micro tip with the power at mid range for 15-20 second bursts. It is
important to keep the samples cold during sonication to avoid heat
denaturation of proteins. When the cells have been lysed there is an
observable colour change of the sample and lysis can also be confirmed by
viewing a fraction of the sample under a microscope. The bacteria cells
appear irregular in morphology.
2.2.6.2 Sample preparation
The removal of insoluble protein aggregates and the membrane fraction
was achieved by centrifugation at full speed for 10 minutes. The upper
soluble fractions were recovered (contains soluble proteins), and were diluted
in 20ml binding buffer (PBS pH 7.3 (140mM NaCl, 2.7mM KC1, lOmM
Na2HP04, 1.8mM KH2PO4, pH 7.3 and protease inhibitors). A large volume
is required to reduce sample viscosity and prevent the column clogging.
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2.2.6.3 Purification
This stage was carried out at RT unless otherwise stated. The glutathione
sepharose 4B (1 ml GSTrap FF columns Amersham Pharmacia Biotech) was
connected to the peristaltic pump set at flow rate of 1 ml per minute and the
column was equilibriated with 5 ml of binding buffer (140mM NaCl, 2.7mM
KC1, lOmM Na2HPC>4, 1.8mM KH2PO4, pH 7.3 and protease inhibitors). The
sample was applied to the column. Following this the column was washed
with 20 ml of binding buffer to remove unbound contaminating proteins. The
elution of the bound proteins was achieved with 5mls of elution buffer
(50mM Tris-HCL, lOmM reduced glutathione, pH 8.0). Fractions of the
elution were collected and the concentration of the GST fusion protein was
estimated by measuring the absorbance at 280nM. The GST tag can be
approximated using the conversion A28o equivalent to 1 corresponds to
approximately 0.5mg/ml.
2.2.7 Concentrating proteins
Two different methods were used:
1). Centricon spin columns (Millipore) with the appropriate molecular weight
cut off (MWCO) in accordance with the manufacturer's guidelines. The
protein sample was loaded into the retention vial and this was inserted into
the filtrate vial and centrifuged (3000 g) for 1 hour at RT.
2). Protein was loaded into a dialysis membrane of appropriate MWCO and
placed in a vessel to which high molecular weight polyethylene glycol (PEG)
was poured. The PEG absorbed water through the dialysis membrane leaving
the protein concentrated.
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2.2.8.1 His tag purification
2.2.8.2 Protein induction
The ApO 2.3 kb transcript was subcloned into pET32a N-terminal His tag
bacterial expression vector. This was transformed into a protease deficient
bacteria strain (BL21) by heat shock method (see section 2.1.10). A positive
clone was selected and grown overnight in 5ml LB supplemented with
50mg/ml ampicillin in a shaking orbital incubator set at 37°C and 225 rpm. A
500 ml LB culture (50mg/ml ampicillin) was seeded with 500pi of the
overnight culture and grown until log phase (optical density OD6oo equivalent
0.6) at 37°C and 225 rpm. At this stage IPTG was added to the culture (final
concentration ImM) to induce the His tagged APO protein expression for 5
hours.
2.2.8.3 Purification of insoluble aggregates from inclusion
bodies
The cells were harvested by centrifugation at 3000 g for 10 minutes. The
supernatant was decanted. The cell pellet was resuspended in 200ml PBS and
then sonicated with maxi probe (set at medium setting) for 5 minutes. The
sample was centrifuged 3000 g to collect inclusion bodies and cellular debris.
The supernatant was removed and the cell pellet resuspended in 25 ml of
IX binding buffer (0.5M NaCl, 20mM Tris-HCl, 5mM imidazole pH 7.9)
containing 6M urea. The sample was incubated on ice for 1 hour to dissolve
the protein and then centrifuged at 12,000 g (Sorval) to remove insoluble
material. The supernatant was filtered through a 0.45/tm membrane.
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2.2.9 Dialysis
The sample was dialysed through a membrane of (molecular weight cut
off 10 kDa) overnight at 4°C in 5 litres of PBS to remove the 6M urea
denaturant. The sample was then concentrated by the PEG method so that the
final volume was approximately 10 ml (see section 2.2.7).
2.2.10 Batch method purification
The resin was prepared by taking 1ml of the slurry (Novagen) and
centrifuged to remove the supernatant. The resin was washed in 2ml ddHhO,
centrifuged at 500g for 1 minute. This step was then repeated. The resin was
washed three times in 2ml of charge buffer (50mM N1SO4) and then washed
twice in 2ml of binding buffer (0.5M NaCl, 20mM Tris-HCl, 5mM imidazole
pH 7.9).
The dialysed concentrated sample was added to the charged resin and
incubated overnight on a rotating wheel at RT.
The resin was washed three times in 30ml of binding buffer and then two
times in 50ml wash buffer (0.5M NaCl, 20mM Tris-HCl, 60mM imidazole
pH 7.9)
The protein was eluted from the resin with elution buffer (1M imidazole,
500mM NaCl, 20mM Tris-HCl pH 7.9). After a final centrifugation at 500 g
the supernatant was removed to a fresh tube.
2.2.11 Irreversible binding of purified HisTag protein to
activated cyanogen bromide sepharose
The APO-His tagged protein was concentrated on a Centricon column
(molecular weight cut off 10 kDa) and spun at 3000 g for 1 hour. The
concentrated protein was desalted on an NAP-10 column (Amersham
Pharamcia Biotech) and then diluted into coupling buffer (0.1M NaHC03,
0.5M NaCl pH 8.3).
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lml of the dried cyanogen bromide (CnBr) matrix was prepared by
adding this to 5ml of ImM HC1 for 2 hours. The activated sepharose was
centrifuged at 3000 g for 1 minute and then washed with three changes of
coupling buffer (0.1M NaHCC>3, 0.5M NaCl pH 8.3). The purified His tag
protein was bound to the activated CnBr overnight at 4°C on a rotating wheel.
The activated CnBr was then treated with 5 sequential washes of a high
pH Tris buffer (0.1M Tris-HCl, 0.5M NaCl pH 8.0) and low pH acetate buffer
(0.1M sodium acetate, 0.5M NaCl, pH 4). This had the effect of deactivating
any charged unbound CnBr preventing more proteins binding irreversibly to
the matrix.
The rabbit serum (2.5 ml) was diluted into 25 ml PBS and then filtered
through a 0.45/rM membrane. The diluted serum was added to the cyanogen
bromide matrix and incubated overnight at 4°C.
The cyanogen bromide matrix was washed 6 times in 50ml of PBS to
remove unbound proteins. The bound antibody was removed from the His tag
APO with the addition of 2 ml elution buffer (0.1M glycine pH 2.7). The
beads were spun 3000 g for 2 minutes and the supernatant transferred to a
tube containing 500/xl neutralisation buffer (1.5M Tris pH 8.8). The purified
antibody was stored in the -20°C freezer after the addition of sodium azide
(0.01%).
2.2.12 Antibody production
lmg of the purified GST-APO protein was supplied to Cell Diagnostics
(Scotland), who raised an antibody in a single rabbit. The animal was bled
prior to administering the antigen (preimmune) and then after the antigen was
injected subcutanously at weeks 8, 12 and 16.
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2.2.13 Immunoprecipitation
Cells were lifted from the tissue culture plate with trypsin (2.3.2). The
cells were centrifuged at 1000 g for 5 minutes. The pellet was washed twice
with PBS prior to lysing with 1ml of lysis buffer for 30 minutes at 4°C and
centrifugation at full speed for 15 minutes. The supernatant was removed to a
microfuge tube and pre-cleared with 20[i\ of protein A (1 mg/ml Roche). The
microfuge was spun at 1000 g for 10 minutes and then the sample supernatant
was split between two microfuge tubes (500/xl each). To one tube, 5/fr of
antibody was added and incubated overnight at 4°C on a rotating wheel.
50/xl of Protein A was added to both tubes and incubated at 4°C for two
hours. The tubes were centrifuged at 1000 g for 2 minutes and then washed
with 1 ml of PBS on a rotating wheel for 5 minutes. This procedure was
repeated six times. 50/xl of sample buffer (62.5mM Tris-HCl pH6.8, 1% SDS
0.1M glycerol, G-mercaptoethanol 0.1%) was added to each of the tubes and
they were heated at 90°C for 10 minutes tubes. The samples were then
Western blotted and probed with appropriate antibodies (see section 2.2.1).
2.3 Cell culture
2.3.1 Thawing cells
Vials of frozen COS7 cells were taken directly from storage at -140°C
and thawed quickly at 37°C in a waterbath. Cells were transferred to warm
GMEM (Invitrogen) medium and centrifuged at 200g for 5 minutes. The
medium was removed and the pellet resuspended with fresh medium prior to
seeding a 25cm2 flask. The medium was replaced after 8 hours to remove
dead cells.
2.3.2 Transfection ofDNA into mammalian cells
1/ig of Vector DNA was diluted in 50/d of serum free Opti-MEM
(Invitrogen). 5/xl of Lipofectamine 2000 (Invitrogen) was mixed with 50/d of
serum free Opti-MEM and incubated for 5 minutes at room temperature.
After the 5 minute incubation the lipofectamine was combined with the vector
DNA and incubated for 20 minutes at RT. Then the vector/lipofectamine mix
was added to the cells and incubated for 48 hours at 37°C in a humidified 5%
CO2 atmosphere.
2.3.3 Cell fractionation
A nuclear and cytoplasmic extraction kit was used following the
manufacturer's protocol. COS7 cells were removed from the culture dish with
trypsin (0.025% trypsin, 0.1% chicken serum and 1.3mM EDTA in PBS). The
cells were spun in a centrifuge at 1000 g for 5 minutes. The pellet was washed
twice with PBS. To an estimated packed cell volume of 20/xl in a 1.5ml
microcentrifuge tube, 200/tl reagent cytoplasmic extraction reagent CER I
was added. The tube was vortexed for 15 seconds to fully resuspend the pellet
and incubated on ice for 10 minutes. To this mix, 11/d of reagent cytoplasmic
extraction reagent II (CER II) was added. The tube was vortexed for 5 second
and then placed on ice for 1 minute. The tube was vortexed again for 5 second
and then centrifuged at maximum speed (10,000 g) for 5 minutes. The
supernatant containing the cytoplasmic fraction was transferred to a fresh tube
and stored. The pellet containing the nuclei was resuspended in 100/d ice cold
nuclear extraction reagent (NER) by vortexing for 15 seconds every 10
minutes over a total 40 minutes incubation time. The nuclear fraction was
centrifuged at maximum speed (10,000 g) for 10 minutes. The supernatant
containing the nuclear proteins was transferred to a fresh tube and stored with




The GT411 gene trap was transmitted through the germline by injection
of C57/B16 blastocysts (Jennifer Nichols at ISCR). Chimaeric males were
back-crossed for 3 generations to wild type MF1 out bred females before
intercrossing heterozygous animals. Adult animals were genotyped by
staining an ear-punch biopsy or the yolk sac respectively for /3gal activity.
Homozygous and heterozygous animals for the gene trap integration were
distinguished by the speed of appearance and the intensity of the staining
reaction. The reliability of this genotyping method was confirmed by breeding
analysis.
2.4.2 Cryostat sections
Tissues were freshly dissected, placed in OTC, immediately frozen in
liquid nitrogen prior to sectioning on a cryostat following which 10pm
sections were cut at blade temperature at -20°C. The sections were lifted onto
commercially bought slides (super frost VWR), air dried at RT. For long term
storage the slides were kept at -20°C.
2.4.3 Bgal staining method
The /3gal staining protocol requires the tissue or cells to be fixed (fix
solution 0.2% glutaldehyde, 5mM EGTA pH 7.3, 2mM MgC^ in PBS pH
7.3) for 10 minutes at room temperature. The embryos were then washed
three times in wash buffer (2mM MgCl2; 0.01% deoxycholate; 0.02% Nonidet
(NP40) in PBS pH 7.3), for 10 minutes each at room temperature. Finally, the
tissues were stained in filtered X-gal stain (lmg/ml X-gal dissolved in di¬
methyl formamide, 5mM potassium ferrocyanide and 5mM potassium
ferricyanide in wash buffer) until the desired level of staining was reached.
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The reaction was stopped by several rinses in wash buffer and then samples
were stored at 4°C (Gossler et ah, 1989).
2.4.4 Dissection of embryos
Timed matings were set up for the collection of embryos at specific
stages of gestation (day of plug designated as day 0.5). Pregnant females were
culled by a schedule one method (cervical dislocation). The uterus was
dissected and placed in cold phosphate buffer (PBS). The extra embryonic
tissues were removed and the foetus collected.
2.4.5 Aortic ring assay (Nicosia and Ottinetti, 1990a) (Nicosia
and Ottinetti, 1990b)
Adult mice were killed by CO2 gas exposure and aorta were dissected and
gently flushed with cold PBS using a hypodermic needle to remove excess
blood. The aorta was cut into 1mm cylindrical sections, embedded in Matrigel
(Beckton Dickinson) in accordance with manufacturer's guidelines. They
were then covered with an endothelial basal medium with growth
supplements provided with the media (Clonetics) and incubated at 37°C, 5%
CO2, 20% oxygen. The aortic sprouts were monitored regularly over the next
12 days using light microscopy.
2.4.6 Microscopy and photography
Cells were examined with a Leitz Labovert light or Zeiss Axiovert 25
flourescence microscope. eGFP was visualised with UV light through Zeiss
filter #44. Embryo dissections were performed using a Zeiss Stemi 2000-C
dissecting microscope. Cells and embryos were photographed with an
Axiocam digital camera using AxisVision 3.1 software.
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Chapter 3:
Molecular characterisation of the
gene trap integration GT411
3.1 Introduction
The gene trap integration GT411 had been isolated from a screen to
identify novel genes involved in cardiac and vascular development. Using
5'RACE and EST databases, a partial open reading frame (ORF) had been
determined. This chapter describes 5'RACE and RT-PCR experiments
performed to generate a full length ORF. Northern blot analysis was carried
out on tissues to gain insight into the expression and availability of tissue
specific transcripts. Bioinformatic analysis of the cDNA and protein
sequences enabled homology and functional characterisation of the gene. The
mouse and human gene were mapped and candidate disease databases
searched.
3.2 Results
3.2.1 Identification of the trapped gene by 5'RACE-PCR
To identify the gene associated with the GT411 gene trap integration
primers complementary to the gene-trap vector (EN2) were used to identify
206 base pairs (bp) of sequence in a 5'RACE experiment (Townley et al.,
1997) (Figure 3.1a). This sequence was used to screen the DNA databases
and a contig of overlapping ESTs (accession nos: AA560030, AA003012 and
AA755402) was generated that coded for an ORF of 177 amino acids (Figure
3.1b) (this work was done by Dr J.Wallis).
Studies reported in this thesis began by performing further 5' RACE
analysis on this sequence to obtain the full-length coding sequence of the
trapped gene. Experiments were performed on random primed first strand
cDNA from 11.5 day post coitus (dpc) whole embryos with PCR primer P3
and anchor primer API using a Gene Racer kit (Invitrogen) (primer sequences
appendix Table 2). This was followed by nested PCR with primer P2 and
anchor primer AP2. Three fragments were obtained of approximate sizes 650,
750 and 500 bp, (fragment 1, 2 and 3 shown schematically in Figure 3.1c,
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3.Id and 3.1e respectively) and were TA cloned (Invitrogen kit) and
sequenced.
Fragment 1 and 2 were identical except that band 2 extended further 5'
and the reading frame was maintained in-frame with the 3' end of the gene.
Fragment 3 had a different 5' end to bands 1 and 2. Sequencing and database
analysis of the genomic DNA revealed that it represented unspliced message
and that the sequence at the 5' end was part of an intron (data not shown). To
clarify this further, Northern blot analysis, using a 300 bp probe (N3) that
was specific to the 5' end of this sequence failed to show a signal, supporting
the finding that it did not represent a true transcript (data not shown).
Additional rounds of 5'RACE were carried out with primers P20 to
anchor primer API and nested PCR with primers P21 to anchor primer AP2
on 11.5 dpc embryo cDNA. The resulting band was TA cloned and
sequenced. A putative methionine start codon with an in-frame stop codon
upstream was found in this fragment and this was predicted to be the start of
the translated gene (Figure 3.If). An alternative transcript was also identified
in further RT-PCR experiments (Figure 3.1g, section 3.4.2).
3.2.2 Verification of predicted transcripts by RT-PCR
To confirm the cDNA structure that was predicted by 5'RACE, extensive
RT-PCR analysis was performed with gene specific primers using first strand
cDNA generated from RNA isolated from day 11.5 dpc embryos (Figure
3.2a).
In most instances amplicons of the predicted size were obtained (Figure
3.2b) and subsequent sequencing of the bands confirmed their identity (data
not shown). However, using primers P26 - P36, two bands were obtained.
The smaller was the expected size (459 bp) and the other a larger band of
1393 bp (Figure 3.2b lane 1). Following cloning and sequencing the smaller
band (459 bp) was shown to be the expected sequence (Figure 3.If), whilst
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frame with the 3' end of the gene (Figure 3.1g). This sequence was highly
conserved between mouse, rat and human both at the amino acid and
nucleotide sequence and was further supported by EST data (Accession
numbers, DV645899, BF100003 and BU512973). This new transcript would
have a different putative start codon (Figure 3. If and 3.1g).
Another alternative splicing event of a 144bp exon at nucleotide position
2262 bp was observed with primer pairs P23 - P24, P23 - P3 and P14 - PI 1
(Figure 3.2b lanes 4, 5 and 7). Interestingly, this exon contains the predicted
nuclear localisation signal and lends support to the idea of differentially
spliced tissue specific transcripts affecting their distribution and function
within a cell (chapter 5). Using a primer within this alternatively spliced (144
bp) exon P9 to the downstream primer, P3, a predicted single PCR product of
130bp was obtained (Figure 3.2b lane 6).
3.2.3 Generation and analysis of full-length clones
To study the gene in more detail full-length clones were generated and
cloned into a range of vectors (Table 1, Appendix 1.2). A full-length clone
(Figure 3.1g) was made by RT-PCR with primer pairs P26 and ECR followed
by nested PCR with primer pairs PECOR1 (at the putative start codon) and
PNOT1 (primer at stop codon) using adult heart cDNA. The 2.3kb PCR
product was cloned into a mammalian expression vector pCDNA3.1. It was
sequenced in its entirety to confirm identity and to ensure the absence of RT-
PCR generated mutations. However, surprisingly, sequencing revealed that
the clone was an alternatively spliced variant removing a 297bp exon. This
exon encoded the putative aminopeptidase catalytic domain. The EST
database also has transcripts that lacked the exon encoding the catalytic
domain (AK027581, NM 032823) which supports their authenticity.
To investigate this further, PCR primers specific to the catalytic domain







































































Figure3.2:RT-PCRanalysisofthemou eaminop ptidaseOen .
a)cDNAstructureofApOndp ime sus df rRT-PCR(notdr wntscale),b- ta withprimerairsacrossthgene(sblfospecificdeta ls).A e ksindicatealt r at veplicing
AP2, Gene Racer kit, Invitrogen). No new additional transcripts to those
already described were detected and further analysis of the bioinformatic
databases concurred with these findings.
The possibility existed that the transcript containing catalytic domain
might be expressed to perform a particular biological function during a
particular stage of development or process and that alternative splicing may
be a mechanism to regulate protein function. Transcripts containing that
sequence encoding this domain might therefore not be present in the RNA
sample used. RNA was extracted from a wider range of tissues, including
embryonic stem cells (ES cells), 11.5 day post coitus (dpc) embryos and adult
tissues and PCR performed with primers spanning the catalytic domain (P38-
P15). All the PCR products were identical and sequencing revealed that none
of them contained sequence that encoded catalytic domain (data not shown).
Gene specific primers within the putative catalytic domain were then
used in the following over lapping PCR reactions P26 to P21, P55 to P3 and
P55 to PNOTI (Figure 3.2b lanes 8, 9 and 10). Products of the correct
predicted sizes were obtained on a range of tissues (heart, lung and ES cell).
Sequencing confirmed them to contain their respective part of the putative
catalytic domain. Furthermore, the EST database has transcripts that contain
this domain (Accession numbers, AK057450, BU512973 and BY708307).
Two faint bands were also seen at approximate position 842 bp and 1050
bp (Figure 3.2b lane 8 (marked by asterisks)). Although these bands were not
sequenced the 842bp band would have been predicted since this would be the
expected size of the PCR product missing the alternatively spliced 934 bp
exon. The other band might represent another splice variant as yet not
determined.
There are 2 polyadenylation signals (PA (AATAAA)) in the 3'UTR of
the ApO gene. They are at position 3238 and 3822 (Appendix 1.4), and this
corresponds to 490 bp and 1174 bp downstream of the termination codon
respectively. Polyadenylation signals can stabilise RNA molecules and can be
a mechanism for gene control such as where an immunoglobulin gene can
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produce alternative transcripts by alternative RNA splicing and use of
different poly A signals (Early et al., 1980b). Using PCR primers (P38 - ECR
and P38 - P19)(Figure 3.2a) specific to different regions of the 3'UTR and by
performing nested PCR, it did not appear that there was a preference for a
particular Poly A signal with any given transcript. Furthermore, transcripts
did not contain sequence encoding the catalytic domain which suggests that
the poly A used does not affect the stability of a transcript with regard to the
catalytic domain.
3.2.4 Genomic structure of the ApO locus
The genomic structure of ApO locus was determined by screening the
mouse public database with the cDNA sequence. The entire predicted cDNA
was homologous to parts of a contiguous region of chromosome 13
(AC069013). The gene structure was determined by placing the exons in
order and calculating the intron sizes (Figure 3.3a and 3.3b). The exon
structure was confirmed with the HGMP NIX software programme.The gene
consists of 16 coding exons (conserved across species) and the entire murine
genomic region spans approximately 320 kb. The intron sizes range from 100
bp, (between exon 12 and 13), to the largest at 50 kb (between 5'UTR and
coding exon 1 (http://genome.ucsc.edu.)). Bioinformatic analysis has
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3.2.5 Genomic integration site
It was predicted that the vector had integrated into the intron between
exons 15 and 16 because the sequence originally identified by 5'RACE was
identical to the 3' end of exon 15.
To determine the exact site of the genomic integration, a PCR reaction
was carried out with an ApO gene specific primer and a gene trap vector
specific primer (Exon F- EN2). The PCR product was sequenced to confirm
the site of integration (data not shown). This information was used to design a
genotyping assay for the GT411 gene trap mice (Appendix 1.1).
3.2.6 Northern blot analysis
Northern blot analysis was used to examine the expression of ApO in
mRNA isolated from a range of adult tissues. Using a C-terminal probe (Nl),
two predominant transcripts of approximately 2.1 and 2.3 kilobases (kb) were
detected in all tissues tested and it is presumed that these are the + and -
catalytic domain isoforms, although they could also be the +/- 144bp splice
variant. In addition other transcripts ranging in size between 3.2 kb and 4.6 kb
were also detected (Figure 3.4a).
The same filter was stripped and re-hybridised with a probe (N2),
specific to the alternatively spliced isoform (934bp) at the N-terminus. Some
of the larger transcripts that were detected with probe Nl were also detected
with probe N2 (figure 3.4b red asterisks).
Interestingly, however, some of the larger transcripts seen with the Nl
probe were not detected with probe N2. For example, in heart the larger
transcripts are absent indicating the possibility of additional tissue specific
transcripts that as yet have not been determined (figure 3.4a and b). A Gapdh
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3.2.7 Protein homology search
A bioinformatic blastP analysis with the murine APO peptide sequence
has 40% homology to a protease called aminopeptidase B. This protein is
involved in processing mechanisms during spermatid differentiation and in
inflammatory processes (Cadel et al., 1997). The consensus catalytic domains
are conserved and both have the putative armadillo repeat motif. Additionally,
two other aminopeptidase proteins also have this structural motif namely,
LTA4 hydrolase and aminopeptidase B-like. It has been suggested the
presence of this 170 residue C-terminal domain may define a novel subfamily
of aminopeptidases which have been termed ARM aminopeptidases (Diaz-
Perales et al., 2005).
3.2.8 Predicted Aminopeptidase O protein structure
Using protein databases, (Simple Modular Architecture Research Tool
(SMART) and other software at the Expasy site (http://www.expasy) the
protein had a predicted consensus sequence typical of the zinc aminopeptidase
Ml family. This sequence has the essential zinc binding site HEXXH(X) 18E
(amino acid position 480 Figure 3.6) with a second glutamic acid residue
(E)18 amino acids downstream (http://www.bi.bbsrc.ac.uk/Merops)
(Rawlings et al., 2002).
Further analysis of the protein revealed an armadillo (ARM) repeat motif
at the C-terminus identified by the SMART programme (smart.embl-
heidelberg.de).
3.2. 9 Nuclear localisation signal (NLS)
A putative nuclear localisation sequence (NLS) was not predicted by
bioinformatics programmes, but selected by eye on the basis that the protein
sequence consists of a region of highly basic amino acid residues at position
693-703 (RRPRKRKRGKR) near to the C-terminus of the gene (description
of the experimental evidence and biological relevance of the NLS are
66
discussed in chapter 5). Interestingly the 144bp exon that contains the putative
NLS can be spliced out (Figure 3.2b lanes 4, 5 and 7) and this may be a
regulatory mechanism for gene function.
3.2.10 Conservation ofApO between species
A comparison of the mouse APO amino acid sequence revealed that it
was 72%, 95% and 38% homologous to the human, rat and puffer fish
respectively. The putative peptidase domain HEXXH-Ei8 is totally conserved
between all these species (Figure 3.5). An additional homologue has been
found in Xenopus tropicalis, and although there are some gaps (missing
regions), the sequence similarity is 48% between mouse and frog over the
defined region (data not shown).
The putative start codon for the longer transcript, MetDIK (amino acid
position 1) was considered to be the initiation codon as there was an in-frame
stop codon 11 amino acids upstream. This initiation codon is conserved in
mouse, human and rat and there is a good Kozak consensus sequence in the
context of this initiation codon (Kozak, 2002). Two additional amino acids,
MetEPD are present in the sequence derived from fish (Figure 3.5). In mouse,
human and rat the protein would have an 823 amino acid ORF with a
calculated protein mass of 90 kilo Daltons (kDa) whilst in fugu the ORE
would be 825 amino acids.
The shorter major transcripts (2.1 and 2.3 kb) could use a variety of
different initiation codons. Different start sites effectively lead to variant
isoforms, potentially with different functions but it is not an uncommon
phenomenon (Yan et al., 1998). It was considered that the start codon at
position 332 MetPMPAS was a good candidate because of its proximity to a
good Kozak sequence (Figure 3.5) and it is conserved between species. The
protein generated from this initiation codon would be 491 amino acids (with
catalytic domain) and would have a calculated protein mass of 60 kDa.
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Figure 3.5: Protein sequence alignment of APO between mouse, rat,
human and fugu.
The two putative start sites are shown in green and purple, the
conserved catalytic domain (HEXXH(X)isE) in red and the nuclear
localisation signal (NLS) RRPRKRKRGKR in blue and armadillo repeat
in orange.
3.2.11 Mapping the Aminopeptidase O gene in mouse and
human
At the beginning of the project, bioinformatic mapping of the human
aminopeptidase O gene was found on chromosomes, 9 and 18 and at that time
it was considered important to clarify this ambiguity. The accurate
chromosome location of the gene would enable phenotypic and linkage
mapping searches of disease databases.
Using human genomic PCR primers HGT411/5 and HGT411/6 on a
human/mouse/hamster somatic cell hybrid panel the human gene was mapped
to chromosome 9 (Figure 3.6a). Additionally, with the same PCR primers, the
human homolog was fine mapped on the Gene-bridge 4 human/hamster
radiation hybrid panel (Gyapay et al., 1996)(Figure 3.6b). The human gene is
found at q22 chromosome 9, a region syntenic to mouse chromosome 13.
The experimental mapping has since been confirmed by analysis of the new
published mouse (http://genome.ucsc.edu. chromosome 13 (61300451-
616357741)) and human (http://genome.ucsc.edu. chromosome 9 (94568538-
94928995)).
Fluorescent in situ hybridisation (FISH) analysis was performed using a
labelled PAC clone (583C16) on mouse metaphase chromosomes. The ApO
gene was mapped to chromosome 13 CI (M.Lee MRC) (Figure 3.7).
3.2.12 Online Mendalian Inheritance ofMan (OMIM)
Phenotypic and linkage mapping services have not as yet revealed any
candidate human genetic diseases to this locus although this region is deleted
in certain cancer types including basal cell and oesophageal carcinomas,
(Lichun et al., 2004)bladder (Obermann et al., 2004; Simoneau et al.,
2000)and ovarian cancer (Byrom et al., 2004).
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Figure 3.6: Genomic mapping of human aminopeptidase O gene.
a) PCR with primers HuP5-HuP6 on human somatic cell hybrid library.
The PCR product (250bp) in lane 9 indicates that human APO is located on
chromosome 9. Hu =human DNA, Mu = mouse DNA and Ha =hamster DNA.
M= molecular weight marker
b) Radiation hybrid test PCR with primers HuP5-HuP6 showing human
specific amplification.
(1), hamster DNA, (2) human DNA and (3) negative control.
M 1 2 3
Figure 3.7 Fluorescent in situ hybridisation (FISH) of mouse metaphase
chromosomes.
Arrows point to hybridised probe on chromosome 13 in green
3.3 Discussion
An aminopeptidase, a member of the Ml family of metallopeptidases,
has been identified by gene-trapping. The ORF was determined by 5'RACE
and alternative splice transcripts were demonstrated by RT-PCR. The gene is
ubiquitously expressed in the range of tissues tested by Northern blot.
Furthermore, analysis by Northern confirmed that there are alternative
transcripts detected with probes to different regions of the gene. A particularly
interesting observation was that the larger transcripts which were initially
observed in the heart lung and kidney with the N1 probe were absent in the
heart tissue with the N2 specific probe. This raises the possibility of tissue
specific transcripts which may be driven from tissue specific promoters
(Hughes and Brady, 2005a; Hughes and Brady, 2005b) or by tissue specific
splicing mechanisms (Xu et ah, 2002).
The human gene was recently cloned and called Aminopeptidase O
(Diaz-Perales et ah, 2005). The Northern data from Diaz-Pereles indicates
that there are two transcripts 5kb and 7.5 kb in human tissues. The expression
of these transcripts is seen in pancreas, liver, placenta, heart and testes. The
Northern was hybridised with a short 377 bp probe that spans C-terminal
region (nt 2101-2477). Northern analysis in this study, with a 980 bp C-
terminal probe (nt 2260-3240) indicated that there are two major transcripts
2.1 kb and 2.3kb that are present in all tissues. There are also longer
transcripts, ranging from 3.4 kb- 4.6 kb which are seen mainly in heart, lung,
liver and kidney. There are differences between the two sets of Northern
analysis, in particular the two major transcripts 2.1 and 2.3 reported in this
study are not reported in human tissue (Diaz-Perales et al., 2005). This could
indicate technical variation, for example, only a small portion of the blot is
visible in the Diaz-Pereles figure and it is conceivable that the smaller RNA
transcripts (2.1 and 2.3 kb) have not been shown. Alternatively, this may
reflect variant species isoforms, for example the protease ADAM 28 in mice
has reportedly three isoforms whilst the human has two. The isoforms have
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different subcellular localisation and tissue expression (Howard et al., 2000;
Roberts et al., 1999).
It is evident from both Northern blot analysis and RT-PCR data that ApO
has alternatively spliced isoforms. Interestingly, there is alternative splicing of
the functional domains which include the catalytic domain and NLS. The
mechanism of alternative splicing is believed to occur in up to 60% of human
genes (Modrek, 2002) and effectively generates more transcripts from a single
gene leading to greater diversity and functional complexity (Graveley, 2001).
Much of the evidence for alternative splicing has been derived from analysis
of the EST databases. It is possible that sequences present within the
databases are artefacts from splicing as several studies have been conducted
to evaluate the authenticity of splicing variants by comparing the splicing
conservation between mouse, rat and human genomes and concluded that a
significant portion of alternative splicing in the EST databases is not
functional and might result from aberrant splicing (Modrek, 2002; Sorek et
al., 2004). Through alternative splicing there are 8 possible isoforms for the
ApO gene (Figure 3.8). However, in reality splicing is extensively regulated
(Joseph, 1995) and so it is unlikely that all of the variations depicted would be
generated.
Alternative mechanisms such as the differential use of polyadenylation
sites can also affect the pattern of splicing yielding polypeptides with different
C-termini. For example, immunoglobin heavy chains (IGM) can either be
membrane bound or secreted depending upon sequences at the C-terminus.
There are two polyA signals in the IgM transcriptional unit. One of these is
located within an intron and the other is at the end of the coding region. If
transcription terminates at the intronic pA, the IgM is secreted whilst if
transcription is terminated later to include the entire ORF which encodes a C-
terminal hydrophobic membrane anchor, the protein is not secreted but
sequesters in the membrane (Early et al., 1980a). Aminopeptidase O has two
polyadenylation signals within the 3'UTR and although alternative transcripts









Figure 3.8: Possible alternative splicing of the ApO gene.
There are 8 possible isoforms that could be generated by alternative splicing of
the 934 bp, catalytic domain and NLS exons.
observed it does remain a possibility and could be a mechanism of gene
regulation. Translation efficiency of eukaryotic mRNAs depends upon
structural features of the 5 untranslated regions (5'UTR) and the nucleotide
sequences flanking the translation start codon (Kozak, 2002). At position 1
there is the putative start codon in the alternatively spliced 934 bp exon and it
is predicted to be the initiation codon for the large transcripts. Shortly
upstream from this start codon there is an in-frame stop codon which supports
its credibility as the putative start codon for this transcript. With regard to the
major predominant transcripts (2.1 and 2.3 kb) there are a number of possible
start codons. The prediction that the AUG at position 332 is the authentic
start codon was based upon a strong Kozak sequence and that this amino acid
residue was conserved between species. Other methionine residues which
could act as the initiation codon, for example, are Met 272, Met 291, Met
308, Met 324. These were excluded because they either had a poor Kozak
consensus sequence or were not conserved in other species.
In most cases translation of eukaryotic mRNAs is initiated at the first
available AUG of the 5'UTR, although exceptions to this rule have been
described (Geballe and Morris, 1994). In this study it was shown that
upstream AUG codons, although not uncommon, occur significantly less
frequently than expected by pure chance. It has been hypothesised that there is
positive selection against in-frame methionine residues upstream of the true
start codon. These residues have been shown to affect the efficiency of
translation (Geballe and Morris, 1994; Rogozin et al., 2001). It may be that
ApO upstream AUGs work in a similar fashion.
DNA that contains secondary structure can be difficult to amplify by
PCR, as it can obstruct the DNA polymerase during extension of the template.
The possibility that secondary structure within the catalytic domain may
prevent polymerase extension would offer a plausible explanation for the
difficulties in obtaining full length transcripts with this domain (Shi and
Jarvis, 2006). Although this experiment was not done, PCR additives (10%
DMSO) can be used to amplify difficult templates (Benita et al., 2003).
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Indeed, further evidence that secondary structure may be responsible for the
difficulty in obtaining full-length transcript encoding the catalytic domain,
comes from the original 5'RACE experiment. Using the primers P2 and P3
the initial 5' RACE experiment did not extend through the sequence that
encodes the catalytic domain (Figure 3.1c and 3.Id).
With the advent of the entire human and mouse genomes sequence
publicly available (http://www.ncbi.nlm.nih.gov) (Lander et al., 2001) and
Celera (http://www.celera.com) (Venter et al., 2001), it is now possible to
determine both the cDNA and genomic structure of almost any gene with
increasing ease. One still has to confirm any bioinformatics prediction with




Expression analysis and phenotypic
analysis of mice carrying the GT411
gene trap integration
4.1 Introduction
As a consequence of the gene trap vector integration it is predicted that
the endogenous ApO promoter would regulate the expression of the /3geo
gene. Using LacZ staining the endogenous gene expression was examined. In
addition, the integration can obliterate normal gene function and possibly
cause a mutagenic effect in germ line embryos. To this end a detailed analysis
of both embryonic and adult expression by a comparative phenotypic analysis
between wild type, heterozygote ApOGt4,IFor/+ and homozygote
ApOg'41'For/Gt4'1For mice tissues was undertaken.
4.2 Results
4.2.1 Animal breeding and phenotype analysis
The GT411 gene trap integration was transmitted through the germline
by injection of the ES cells into C57/B16 blastocysts. Chimaeric males were
backcrossed for three generations to wild type MF1 outbred females before
intercrossing heterozygote ApOGt4I,For/+ animals. Adult animals and embryos
were genotyped by staining ear punch biopsy or the yolk sac respectively for
/3gal activity. Homozygote ^pQGt411For/Gt4UFor ancj heterozygote ApOGt4,IFor/+
were distinguished by the speed of appearance and the intensity of the staining
reaction. The reliability was confirmed by breeding analysis.
4.2.2 Northern blot analysis of the gene-trap fusion transcript
To assess the transcriptional consequences of the gene trap integration, a
Northern blot was performed with wild type, heterozygous ApOGt4,,For/+ and
homozygous ApOc,t4"For/Gt4"For mRNA, that had been extracted from day
11.5 pc whole embryos and on 1 month old adult hearts (Figure 4.1b and c).
The probe N1 spanned the gene trap integration site (Chapter 3, Figure 3.4a,).
Two predominant transcripts (2.1 and 2.3kb) were present in the wild type









b) +/+ +/- -/- C) +/+ +/_
Figure 4.1: Northern blot of analysis of wild type, heterozygous
ApO Gt4I1For/+ and homozygous ApOGt411For/Gt4UFor tissues.
a) Diagram ofApO cDNA showing gene trap integration site and
position of probe (Nl) used in Northern analysis (not drawn to scale).
b) Poly A+ RNA extracted from day 11.5 pc embryos with probe N1
which spans the gene trap integration site.
c) Poly A+ RNA extracted from 1 month old adult heart using
probe N which spans the gene trap integration site.
Gapdh was used as loading controls.
A 5kb transcript was observed in RNA isolated from heterozygote
ApOG,4"For/+ and homozygote Ap0Gt4''For/Gt4'1For tissues and was the
expected size for the GT411-/3geo fusion transcript. Furthermore, the
heterozygote band was approximately half the intensity of the homozygote
which is expected because it would carry one copy whereas the homozygote
would carry two copies. There was no evidence for splicing around the gene
trap vector to produce a wild type transcript which could result in a
hypomorphic allele (Voss et al., 1998). Thus from the data shown, the gene
trap vector was functioning in the predicted manner. It was noted that the
longer transcripts seen previously by Northern (Figure 3.4a and b, chapter 3)
were not observed on these particular blots. Possible reasons for their absence
could include, for example, that less RNA has been loaded on to the gel or
that the transfer was less efficient.
4.2.3 Phenotypic analysis
Breeding of the gene trapped transgenic mice resulted in the generation
of apparently healthy homozygous ApOG'4l,For/Gl4I1For offspring at the normal
Mendelian ratio. Homozygous males mated with homozygous females also
resulted in apparently normal healthy offspring. This would indicate that the
gene trap integration has not resulted in a gross mutant phenotype perhaps
because the gene is still functional or that there is genetic redundancy with
another gene able to compensate for it (Prince and Pickett, 2002). Another
possibility is that there is a subtle phenotype which would be detectable with
a specific assay or observation, for example the matrix metallo protease
MMP2 knockout mice develop normally except for a subtle delay in growth
(Itoh et al., 1997).
To assess the possibility of a cardiovascular phenotype heart and kidney
were dissected and the body weight, heart and kidney weight were compared
between wild type and heterozygotes ApOGt4"For/+ and homozygotes gene
trap ApOGt4,IF°'/Gt4I,For. T-test calculations indicated that there were no
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significant statistical differences between the wild type and gene trap mice
(Figure 4.2).
4.2.4 Embryonic expression and phenotypic analysis
Embryos were collected at day 8.5, 9.5 and 10.5 pc. They were stained
for /3 galactosidase (/3gal) activity and a comparison of the vasculature
between heterozygotes ApOGt4I1For/+ and homozygotes gene trap
ApQG,4,,For/Gl4,,For embryos was undertaken.
Day 8.5 pc embryos have /3gal expression in the dorsal aortae. There were
no apparent morphological differences between them (Figure 4.3) The only
notable dissimilarity between the embryos was the less intense blue staining
seen in heterozygote ApOGt4"For/+, which was attributed to there being only
one copy of the /3gal gene. In the experimental design, heterozygote
ApOG,4"For/+ embryos were left staining for a longer period to try to stain
them equivalently. This was true also for the day 9.5 and 10.5 pc embryos
(see below).
A preliminary analysis of day 9.5 pc did not indicate any substantive
differences between heterozygote ApOG,4"For/+ and homozygous
ApOGt4UFor/c't4"For gene trap embryos. The dorsal aorta appeared to develop
normally and intersomitic vessels were present between somites in the normal
segmented pattern. There was a highly arborised capillary network formed
from dorsal sprouts from the intersomitic vessels (Figure 4.4). There was also
notable staining in the limb bud, tail bud and forebrain.
/3gal expression in day 10.5pc embryos had extensive staining in the
capillary plexus of the head and throughout the body and endothelial staining
in the intersomitic vessels. A comparison of heterozygotes ApOG,4"For/+ and
homozygote ApOG'411For/Gt4nFor gene trap embryos did not show significant
differences (data not shown).
A comparison of a /3gal and riboprobe stained day 9.5 pc embryos
demonstrated staining of the intersomitic vessels, tail bud and forebrain
(Figure 4.5). This would indicate the lacZ stain does truly mimic the
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endogenous expression ofApO. There was also strong staining in the tail bud
and forebrain which was also seen by lacZ staining (in situ performed by Dr
J.Wallis).
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Wild type Heterozygotec'4//F<"/+ Homozygote Gt4iiFor/Gt4UFor P*
(n3) (n3) (n3)
Body weight, g 24.3 +/- 0.8 23.7+/-0.81 24.2 +/-0.7 NS
Heart weight, mg 214+/-0.02 220+/- 0.02 219+/-0.004 NS
Kidney weight, mg 536+/-0.013 552+/- 0.017 550+/-0.039 NS
*P>0.05 was considered not significant
Figure 4.2 Phenotypic analysis by comparative mean values and
T-test calculations of tissues.
Total body weight, heart and kidney weight of 1 month old wild type, heterozygous
and homozygous mice.
Figure 4.3: Comparative expression of /3galaetosidase
staining of day 8.5 pc embryos.
ApQ G t41 lFor/+ ApO ^ t41 lFor/ G t41 lFor
Da=dorsal aorta, Ht=heart, Tb=tail bud, Ys= yolk sac
Figure 4.4: Comparative expression of day 9.5 pc gene trap mice
by /3gal expression.
ApOGt4,IFor/+ (heterozygote) (a), ApO Gt4iiFor/Gt4iiFor (homozygote)(b).
Lb=limb bud, Tb=tail bud, fb^fore brain, Cp=capillary plexus,
Iv=intersomitic vessel
a)
Figure 4.5: Comparison oiApO-GT^W fusion and endogenous
ApO expression.
9.5.dpc /5gal stained ApOGt4"For/Gt41IForembryo (a), 9.5dpc in situ (ribo
probe Nl) (b). Iv= intersomitic vessels, Tb=tail bud, Fb=forebrain
4.2.5 Aortic ring assay
Although there was no obvious defect in the development of blood
vessels in the embryo, it was felt to be worth assessing whether there was a
defect in the growth of adult endothelial cells using the aortic ring assay.
Growth of aortic sprouts within this three dimensional matrix were compared
with aorta from wild type, heterozygous and homozygous GT411 mice. The
aortic were monitored daily from day 0 to day 12.
Angiogenic sprouts first appeared on day 4 and on subsequent days
microvessels were seen to elongate and undergo significant branching.
Comparisons by manual processing and observation did not indicate
significant differences between the wild type, heterozygote and homozygote
gene trap mice. It was concluded that there were not any gross morphological
differences or changes in the rates of new vessel growth or branching
observed between the aortic explants (mice number n =3 for each, Figure 4.6
a, b, and c).
To confirm that these sprouting structures were new vessels, a
fluorogenic labelled acetylated low density lipoprotein (Cambio), which
specifically stains endothelial cells was used (Eter and Spitznas, 2002), (data
not shown). Moreover, ApO expression in these vessels was confirmed by
both LacZ staining (4.6 d and e) and RT-PCR (4.7 b) with RNA purified from
the aortic sprouts. The primer pairs EcoRI-P36 and EcoRI-P28 demonstrate
that ApO transcript with the alternatively spliced 933 bp exon is expressed in
the developing aortic sprouts of adult mice. The primer pair PEcoRI-P21
indicates that a transcript containing the putative catalytic domain was
expressed in the developing aortic sprouts. Primer pair PEcoRI-P15
generated a single PCR band and sequencing confirmed it was the isoform
minus the catalytic domain. This data concurs with the analysis of clones in
section 3.2.3.
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a +/+ b +/- c -/-
Figure 4.6: Aortic ring assay using aortae isolated from adult mice.
wild type (a), ApO G,4IIFor/+ (b) and ApO0'4"For/GtFor (c).
/3gal stained microvessels from aortic ring assay.
Wild type (d), Heterozygote ApO G,4"For/+ (e).
mv= microvessel
PEcoRI
Lane Primers Size bp
1 PEcoRI - P36 1230
2 PEcoRI - P28 1370
3 PEcoRI- P21 1580
4 PEcoRI-PI5 1920
Figure 4.7: RT-PCR ofRNA from aortic ring assay
Schematic representation ofApO cDNA (not to scale) with PCR
primers (a).
RT-PCR on RNA purified aortic sprouts and primer table indicating
sizes of fragments (b).
4.2.6 Adult expression "
Cryostat sections of adult tissues were stained for pgal reporter gene
activity (Figure 4.8). In heterozygous ApOGt41IFor + and homozygous
y4pQG,4"For/Gl4"For mice, the Pgal expression was seen in the vessels of heart,
spleen and kidney skeletal muscle and lung. The wild-type tissues did not
express the Pgal reporter gene.
A comparative analysis of the tissues with the histology web site
(http://www.siumed.edu/~dking2/crr/rsguide.htm) was carried out. In the
heart there was expression of Pgal in the vasculature and cardiomyocytes. It is
possible to see the striated intercalating discs of the muscle fibre (Figure 4.8).
In the kidney /Sgalactosidase staining was observed in the glomeruli,
interlobular arteries and afferent arterioles but not in the peritubular
capillaries which would pervade the entire tissue.
The spleen has /Sgalactosidase staining in large irregular thin walled
blood vessels called the splenic sinusoids and in other vessels too.
iSgalactosidase staining of lung results in discrete irregular shaped
pockets that appear to form a lumen. These are reminiscent of veins and
arteries. The irregular shape may be an artefact of the crysectioning caused by
destruction of the morphology during the preparation.
To verify that the /3gal was labelling vessels, an in situ with an anti Flk-1
antibody was used on adult spleen. The Flk-1 was very similar to the /3gal
staining indicating that these are vessels (Figure 4.9 a and b). To confirm that
the /3gal staining was truly in the vessels a double labelling with anti bodies to
Flkl and /3gal should be performed.
Endothelial and haematopoietic cells have a common progenitor termed
the haemangioblast (Huber et al., 2004) and recent evidence also suggests
that smooth muscle cells may differentiate from this common progenitor too
(Ema et al., 2003). Haematopoietic tissue was tested from gene trap mice to
see whether aminopeptidase O was expressed. Cytospins were made from
adult bone marrow and stained for /Sgalactosidase activity. The finding was
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Figure 4.8: Expression of they4/>6>-GT411 gene trap from 1 month
old adult tissues.
/3gal stained cryosections of adult tissues from wild type,
ApO Gt4,1For/+ and ApO G>4"F°r/Gt4iiFor gene trapped mice,
ch = chamber, v = vessel, gm = glomeruli, aa = afferent arteries,
la = interlobular arteries, id = intercalated discs, ss = splenic sinusoid
Figure 4.9: Comparative expression analysis of Flk 1 Immunohistochemistry
and /3gal stained spleen
a) Cryosection of adult spleen FITC labelled vessel with
anti Flk-1 antibody
b) /3gal stained heterozygous Gt4l'For/+ cryostat section adult spleen
that the haematopoietic tissues did not have /Sgalactosidase activity
demonstrating that ApO was not expressed in this tissue (data not shown).
4.3 Discussion
The ApO gene is expressed in ES cells, and during embryogenesis (8.5,
9.5 and 10.5 dpc embryos) and in the vasculature of a range of adult tissues.
Interestingly, in heart a diffuse lacZ staining was observed and this was
presumed to indicate cardiomyocyte staining. The prospect that the vascular
expression of the aminopeptidase O gene is restricted to a subset or specific
type of endothelial cell remains a possibility, as it appears to be expressed in
the larger vessels but not in the capillaries. For example the ephrin receptor
tyrosine kinases are expressed on different types of vessel with ephrin-B2
selectively marking arterial endothelium whilst ephrin-B4 reciprocally marks
venous endothelium (Gerety et al., 1999). To determine ifApO is expressed in
a particular endothelial cell double labelling experiments could be performed
with an APO specific antibody and another antibody that marks a specific cell
type.
The riboprobe whole mount in situ appears to recapitulate the reporter
gene expression demonstrating that the /3-gal activity authentically marks the
expression of the endogenous gene in the developing vasculature.
Embryogenesis proceeds normally, resulting in apparently normal healthy
homozygous A1pQGt4,IFor/Gt41,For offspring at the normal Mendelian ratio.
Analysis of embryos and adult tissues did not indicate a phenotype in the
morphological structure of the vasculature when comparing wild type and
gene trap mice.
Furthermore, using the aortic ring assay, the aorta derived from wild type,
heterozygous ApOGt4IlFor/+ and homozygous ApOGt4,IFor/Gt4,,For gene trap
animals were indistinguishable. A manual comparison of the microvessels,
however, is both tedious and subjective. Computer image analysis software
has since been developed which may greatly enhance the applicability of this
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method and allow more accurate and detailed analysis to be undertaken in
future (Blacher et al., 2001).
The integration is near to the 3' end of the gene, removing the last 46
amino acids. It is possible that the truncated fusion protein retains its normal
function despite being fused to the /3gal reporter gene and removing an ARM
repeat. Another possibility is that there is genetic redundancy where another
gene is able to alleviate the effects of a mutated gene because it has
overlapping function (Nowak et ah, 1997; Shastry, 1995). At the protein
sequence level aminopeptidase O shows the highest sequence similarity to
aminopeptidase B. To test if there is genetic redundancy between these two
proteins one could generate a homozygous ApO and ApB double knockout.
The assessment of a mouse phenotype might demonstrate overlapping
functions of these two proteins. This approach has been taken with the Hox
genes. For example HoxB3 and HoxB4 double knockout has a more severe
phenotype than the single gene knockout for HoxB4 suggesting that these two
proteins have similar function in haematopoiesis (Bjomsson et ah, 2003; Brun
et ah, 2004).
The Northern blots on heterozygous ApOG,4UFor/+ and homozygous
ApOGt4l,For/Gl4,1For gene trap embryos and adult heart tissue with the N1 probe
demonstrate that the gene trap vector is not spliced out to generate wild type
transcript resulting in hypomorphic allele. The presence of wild type
transcript, even at low levels can ameliorate a possible phenotype (Voss et ah,
1998). It is possible, however, that there are alternative transcripts which
would not use the C-terminal region of the gene and would therefore not be
trapped by the gene trap integration. The use of additional probes on Northern
blots and more extensive 3' RACE would help to address this possibility.
The discovery that ApO has a specific vascular expression is interesting
because of the relationship between angiogenesis and diseases such as cancer.
If a tumour could be prevented from acquiring a blood supply by the action of
a drug that specifically inhibits processes such as cell proliferation and
angiogenesis this could be offered as a therapy in the treatment of cancer. The
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development of molecules that specifically inhibit APO would be of interest
as they could then be used to assess the effect on in vitro endothelial cell
proliferation assays and on in vivo models of cancer. For example, methionine
aminopeptidase 2 which is specifically inhibited by TNP-470 has been
demonstrated to reduce endothelial cell proliferation in vitro (Antoine et al.,
1994; Satchi-Fainaro et al., 2004). Moreover clinical trials with TNP-470




Cellular localisation studies of the
mouse aminopeptidase O protein
5.1 Introduction
Proteins contain sequences that determine their ultimate destination, for
example signal peptides of metalloproteases enable proteins to traverse
membranes to be secreted from a cell (Das et al., 2003). In other
circumstances a signal peptide may direct the protein across a specific
membrane of an organelle as is the case for mitochondria (Rapaport, 2003).
Of particular interest in the context of this thesis are the nuclear localisation
signals (NLS) because a manual comparison of the murine APO protein
sequence with known NLSs (Williams, 2003) indicate the presence of a
putative signal sequence between residues 694-670 (Figure 3.5). Proteins
which translocate to and from the nucleus do this by traversing the nuclear
envelope through a proteinacous complex called the nuclear pore complex
(NPC). This structure comprises over 100 different proteins (in higher
eukaryotes) termed nucleoporins (NUPS) (Wente, 2000). The transport
signals show considerable variation in complexity from short peptide motifs
like the classical monopartite basic NLS (Kalderon et al., 1984) and the
leucine-rich nuclear export sequence (Wen et al., 1995) up to large protein
domains and even multicomponent signals such as those involved in U-
snRNA transport (Bogerd et al., 1999).
The nucleus is a membrane bound structure which contains a number of
domains or sub-compartments which include nuclear cajal bodies, nuclear
speckles, transcription and replication foci, chromosomal territories and the
non membrane bound proteinacous complex nucleolus (Handwerger and Gall,
2006). The latter are the only visible structure when viewed under light
microscopy because of the highly refractile nature due to their denseness.
Initially it was established as the ribosome factory where rRNA transcripts are
processed and assembled with ribosomal proteins to form ribosomes (Moss
and Stefanovsky, 2002). Recently, however, other roles have been defined
which include cell cycle regulation, DNA damage repair, pre-mRNA
processing (Desterro et al., 2003; Olson et al., 2002; Pederson, 1998; Tsai and
McKay, 2002) and as a 'molecular sink' to retain proteins and prevent them
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from interacting with downstream partners until a particular stage of cell cycle
or metabolic state (Leung et al., 2003).
To investigate whether the NLS predicted from the sequence analysis of
APO was functional, several approaches were taken. In the first instance, an
assessment of the putative NLS protein conservation between different
species was carried out. eGFP-ApO constructs with and without the putative
NLS sequence were then cloned and the subcellular localisation assessed
using the eGFP tag in transiently transfected COS 7 cells.
5.2 Results
5.2.1 Cellular localisation of APO protein
Bgal staining of the GT411 ES cell line indicated that the APO-/3GAL
fusion protein localised in distinct punctate regions within the cell (Figure
5.1a). To further characterise the subcellular localisation, an N-terminal
eGFP-tagged full length ApO construct (nucleotide 278-2748, minus the
catalytic domain, Appendix 1.4) was transfected into COS 7 cells. The cells
were viewed with fluorescence microscopy and the eGFP-APO protein also
localised to punctate regions within the nucleus which were believed to be the
nucleoli (Figure 5.1b).
Owing to the difference in density between the nucleolus and the
surrounding nucleoplasm, the nucleoli were readily visible under bright field
(white light) phase microscopy (Figure 5.2 a) and it was these structures,
when viewed with fluorescent microscopy, that fluoresced green with eGFP
tagged APO fusion protein (Figure 5.2 c). Fibrillarin is a protein which
primarily localises to the nucleoli (Newton et al., 2003) where it is a structural
component of a small nuclear ribonucleoprotein (SnRNP) particle involved in
the post transcriptional modification by methylation of rRNA (Decatur and
Fournier, 2003) and it was as a positive control to mark the nucleolus. It was
cloned by RT-PCR into the eGFP expression vector using the primers Pfibl-
Pfib2 (Table 1, Appendix 1.2). COS 7 cells were transfected with the eGFP-
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fibrillarin construct. Under white light the nucleoli were visible (Figure 5.2 b)
and the nucleoli were green under fluorescent microscopy (Figure 5.2 d).
To confirm that the eGFP signal was indeed within the nucleus a virtual
section of the cell was compiled. Sequential images of transfected cells were
taken on a microscope with a motorised camera to generate a cross section of
the cell (Figure 5.3 a). The images were computationally manipulated and
represented as a side profile. In this way a three dimensional image was
generated. The eGFP signal was confirmed using this technique as being
within the nucleus (Figure 5.3 b, c and d).
5.2.2 Fractionation of COS 7 cells
Cytoplasmic and nuclear fractions were separated with a spin kit (Pierce)
from COS 7 cells that had been transfected with the eGFP-APO fusions (ApO
1-stop (Minus catalytic domain) and ApO 552-stop). The eGFP and the eGFP-
APO fusion proteins are present in both the cytoplasmic and nuclear fractions.
It would appear that eGFP-APO is enriched in the nuclear fraction as
determined by Western blotting (Figure 5.4).
5.2.3 How does the APO protein traffic to the nucleoli?
Manual comparison of the APO protein sequence with known nuclear
localisation signals (NLS) indicated the presence of a putative NLS between
residues 694-670, but interestingly standard bioinformatics programmes did
not identify this domain. To test whether this putative NLS motif could guide
the murine APO protein to the nucleolus, various eGFP constructs with and
outwith this domain were generated and transfected into COS 7 cells (Figure
5.5).
Those cells that were transfected with eGFP-ApO vectors containing the
putative NLS were detected in the nucleolus (Figure 5.5 a, b, e and f),
whereas cells transfected with eGFP-ApO vectors without the NLS remained
in the cytoplasm (Figure 5.5 c and d). A similar sub-cellular localization
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pattern was observed with fibrillarin control when compared with the eGFP-
ApO NLS constructs (Figure 5.5 g). These data strongly support the
hypothesis that the putative APO-NLS does function as a signal to direct
proteins to the nucleus and more specifically to the nucleoli.
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Figure 5.1: Sub-cellular localisation of APO fusion proteins
a) /3-gal staining of gene trapped ES Gt411For/+ cells.
b) COS 7 cells transfected with full-length ApO fused to eGFP
Arrows indicate nucleoli.= n Scale bar 10/xM
Figure 5.2: Sub-cellular localisation of APO fusion proteins and fibrillarin
Transfected COS 7 cells with eGFP-Fl-APO Bright field (a) and fluorescent
microscopy (c).
COS 7 cells transfected with nucleoli specific protein fibrillarin
bright field (b) and fluorescence (d).





Figure 5.3: Three dimensional sectioning of eGFP-ApO
transfected COS 7 cells.
Schematic illustration of virtual sectioning of cells (a)
Image of COS 7 cells transfected with eGFP-Fl-ApO (1-stop) and
DAPI-stained (b).
Virtual sectioning compiled by serial photography (c)
Computer generated side profile of eGFP-Fl-4pO (1-stop) (d)
Lanes 1 and 5
Lanes 2 and 6
Lanes 3 and 7
CeGFP^)
CeGFP^>
b) Cytoplasm c) Nuclear
5 6 7 8
60-
26-








Figure 5.4: Analysis of fractionated protein lysates from transiently
transfected COS 7 cells by Western blot.
a). Schematic illustration of eGFP clones transfected into COS 7 cells.
b). Cytoplasmic fractions analysed by Western blot with eGFP
antibody of COS 7 cells transfected with eGFP tagged fusions.
Lane 1 eGFP vector only, lane 2 eGFP-Fl-ApO, lane 3 eGFP-ApO (552-stop)
and lane 4 mock transfection.
c). Nuclear fractions analysed by Western blot with eGFP
antibody of COS 7 cells transfected with eGFP tagged fusions.
Lane5 eGFP vector only, lane 6 eGFP-Fl-/f/?0, lane 7 eGFP-ApO (552-stop)
and lane 8 mock transfection.










Figure 5.5: Testing putative NLS with eGFP-ApO fusions.
Schematic diagram of eGFP-ApO fusions transfected into COS 7 cells
and DAPI stained COS 7 cells transfected with full length ApO
(a) and various truncated forms ofApO fused to eGFP (b-f).
Fibrillarin-eGFP fusion (g) and eGFP alone (h) are shown as controls.
Scale bar 10/rM
5.3 Discussion
Using eGFP-ApO reporter constructs it has been shown that this protein
can localise to the nucleolus and a putative nuclear/nucleolar localisation
signal sequence has been defined by deletion analysis. Recombinant eGFP-
APO protein that contain the putative NLS always localise to the nucleoli,
whilst constructs without the putative NLS remain in the cytoplasm. To
unequivocally prove this it would be necessary to clone the putative NLS
(RVNRRPRKRKRRGKR) alone in-frame with the eGFP protein and observe
the fluorescent signal when transfected into COS 7 cells. One would expect
the eGFP-NLS to traffic to the nucleolus if the hypothesis was correct.
Furthermore, to characterise the putative NLS signal sequence more
fully, single codon mutations could be introduced by site direct mutagenesis.
The mutations which prevent the trafficking to the nucleus would define the
NLS more specifically.
A comparison of the aminopeptidase O NLS sequence between mouse,




Fugu (puffer fish) LSRSHGKSKKRKR
There is not a conserved motif, although the sequence does contain basic
amino acids which are common in canonical NLS sequences. An experiment
with the eGFP-APO fusion proteins from other species with and without the
putative NLS could be done to ascertain if this domain is functionally
conserved between species.
The eGFP-APO fusions with the NLS sequence localise to the nucleoli. It
is possible a nucleoli specific signal has been identified. Several examples
where short nucleolar targeting signals (NTS) are able to traffic heterologous
proteins to the nucleolus have been demonstrated in viral proteins (Kalland et
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al., 1994; Nosaka et al., 1989) and in the heat shock chaperone proteins
(HSC70/HSP70) which conditionally localise to the nucleolus as part of the
cellular response to stress (Dang and Lee, 1989; Hunt and Morimoto, 1985).
A common feature of these NTSs is that they contain regions of basic amino
acids, for example the human immunodeficiency virus (HIV) tat protein is:
(GRKKRRQRRRAP) and HSP 70 is: (KRKHKKDISQNKRAVRR). This is
very much in keeping with murine APO signal sequence which is:
RVNRRPRKRKRRGKR.
Whilst the experimental evidence for the putative NLS is compelling, one
should be aware that over expression of a recombinant protein from a strong
promoter can have possible misleading results. Proteins expressed at high
concentrations can lead to misfolding and incorrect localisation (Garcia-Mata
et al., 1999), although it has been demonstrated that a nucleolar protein
fibrillarin expressed in the same system localises correctly (Newton et al.,
2003). To determine the physiological relevance and show that APO protein
truly localises to the nucleoli one should look at the endogenous protein in
endothelial cells with an APO specific antibody.
Purification of nucleoli from HeLa cell lines and mass spectrophotometry
analysis of the constituent proteins has not identified aminopeptidase O in this
sample (www. 1amondlab.com/Nondb (Andersen et al., 2002; Scherl et al.,
2002). This may reflect, however, the cell line used, as it has been found in
this study that ApO is expressed in the vasculature and, therefore, may not be
represented in HeLA cells.
The aminopeptidase O has an armadillo repeat in the C-terminus and has
been described as a member of the armadillo repeat aminopeptidases (Chapter
3 section and Diaz-Pereles 2005). Many proteins involved with the transfer of
proteins to the nucleus have armadillo/HEAT repeats such as the importin
family of nuclear transport proteins (Malik et al., 1997). The armadillo repeats
form a grooved structure in which basic peptides of the NLS are able to bind
(Conti et al., 1998). Interestingly, APO has a putative NLS sequence
immediately upstream of the armadillo repeat motif. The protein was able to
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translocate to the nucleoli when the armadillo repeat was absent (Figure 5.4 b
and f) indicating that the ARM repeat is not essential for nucleolar
localisation. Perhaps the APO ARM motif binds to other proteins (as yet
undefined) and by virtue of the NLS guides the new protein complex to the
nucleolus acting as nucleolar cargo transport protein. Performing
immunoprecipitation on endothelial or transfected cells, followed by two
dimensional gel electrophoresis might allow their identification (Delahunty
and Yates, 2005).
Another important consideration is that ApO alternative splicing can
generate isoforms without the NLS (Chapter 3 Figure 3.2). Alternative
splicing is a mechanism of gene control that can yield proteins with different
functions from the same gene such as VEGF where splicing gives rise to
functionally distinct isoforms with different signalling properties (Robinson
and Stringer, 2001). The ApO gene has a number of alternative splice variants
which remove regions of the gene including those that encode the catalytic
domain and the NLS sequence. These will presumably have important
functional consequences for ApO and its associated proteins. For example
transcripts which do not have the putative NLS would not localise to the
nucleoli and it would be expected that they perform a different function to
transcripts that are in the nucleoli. The nucleoli are sites for a number of
different cellular processes ranging from ribosome biogenesis, cell cycle
regulation, DNA damage repair, pre-mRNA processing (Desterro et al., 2003;
Olson et al., 2002; Pederson, 1998; Tsai and McKay, 2002). It is possible to
speculate that ApO may play a critical role in one or more of these processes.
Furthermore, because ApO is expressed in the vasculature and the relationship
between angiogenesis and diseases such as cancer, one could contemplate that
ApO may offer a potential therapeutic target.
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Chapter 6:
The expression and purification of
fusion proteins to raise an antibody
against aminopeptidase O
6.1 Introduction
The experiments in chapter 5 demonstrate there is a putative NLS signal
in the APO protein. To determine whether this has a physiological function in
vivo and does in fact localise to the nucleolus, the endogenous protein would
have to be studied. One approach to facilitate this study would be to generate
an antibody against the APO protein. An antibody could also be used to purify
the aminopeptidase O protease by immunoprecipitation. The purified protein
could then be tested in enzyme assays to determine substrate specificity.
There are different methods available to generate the protein used to raise
an antibody. One approach is to analyse the protein sequence computationally
and use software that will predict antigenic epitopes. There are a number of
programmes in existence, for example
(http://bio.dfci.harvard.edu/Tools/antigenic.htmn. The desired peptide/s is
then synthetically manufactured before injecting into the host animal. Another
approach would be to clone the gene into an expression vector in- frame with
a tag that allows easy purification such as a GST or 6XHistidine which bind
sepharose and charged nickel respectively. The fusion protein is expressed
and purified from contaminating proteins prior to injection into the recipient
animal.
The approach taken in this thesis was to express a GST-F1-APO protein.
The APO protein used did not contain the catalytic domain which was
predicted less likely to cross-react with other aminopeptidases. The raising of
an antibody against the APO protein and subsequent testing by Western blot
on COS 7 cell lysates transfected with eGFP tagged murine APO proteins is
described in this chapter.
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6.2 Results
6.2.1 Expression and purification of GST-F1-APO (minus
catalytic domain)
The F1-ApO 2.3 kb (Figure 3.lg) was cloned into the bacterial expression
vector pGEX 4T-1 and expressed in protease deficient bacteria (BL21). Upon
IPTG induction an N-terminal GST tagged Fl-APO fusion protein (116 kDa)
was generated. The expression of the fusion protein was optimised using
different concentrations of IPTG, temperature, and time of induction (hours).
The conditions that yielded the highest fraction of solubilised full length
fusion protein (0.4mM IPTG induction at 37°C for 3 hours) were identified
and adhered to in further experiments (Figure 6.1a).
The bacterial pellet was mechanically lysed by sonication. The soluble
fraction was passed over a glutathione column to bind the GST tagged
protein. Unbound proteins were removed by washing. The retained GST
bound proteins were eluted from the column with reduced glutathione and
collected as fractions (Figure 6.2a). There were a number of smaller
fragments copurifying with the GST-F1-APO fusion protein (Figure 6.2a). To
test if these were bacterial contaminating proteins or degraded breakdown
products of the fusion protein, a Western blot with antibody against GST was
carried out (Figure 6.2b). The result indicated that many of the additional
bands were degraded fragments of the GST-F1-APO fusion protein.
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Figure 6.1: Optimisation of GST-FK4/>0 (1-stop) expression at 37°C using
0.4mM IPTG.
a). Untransformed wild type BL21 bacteria (1) transformed BL21 pellet (p) and
supernatant (s) at different time of induction (hours).
red arrow indicates purified GST fusion protein (GST-F1-APO) at the expected
size of 116 kDa.
Figure 6.2: Purification of recombinant GST tagged APO protein
a) Purification of GST-F1-APO and b) Western blot with anti-GST antibody.
Negative control, BL21 bacteria without vector (1), BL21 transformed
GST-Fl-APO(l-stop) no induction (2), BL21 GST-Fl-zlpO (1-stop)
induced with EPTG (3), first wash after binding supernatant to
GST-sepharose column (4), final wash (5), elution from column (6).
Red arrow indicates purified GST fusion protein at the expected size of 116 kDa.
6.2.2 Raising and testing of anti-APO antibody
Approximately lmg of the purified full length GST-APO fusion protein
was injected into a rabbit (Scottish Cell Diagnostics). Preimmune sera, first,
second and third bleeds (at 8, 12 and 16 weeks, respectively) were collected.
To demonstrate if the raised antibody could detect APO protein, a Western
blot of COS 7 cells that had been transiently transfected with the cDNA
encoding eGFP-Fl-APO protein was performed. Identical blots were
hybridised with an antibody against eGFP and the preimmune sera, and the
first, second and third bleeds of the rabbit immunised against APO. The
preimmune sera did not detect any bands on the Western blot (Figure 6.3a).
The antibody against eGFP detected proteins of the predicted sizes (Figure
6.3b) and the third bleed from the rabbit detected a similar band in the lane
loaded with lysate from cells transfected with a cDNA encoding the eGFP-
APO fusion protein.
The diffuse background on the Western blots resulted in a loss of specific
signal with long exposure. To reduce the signal to noise ratio, different
dilutions of the antibody were tried (Figure 6.3 c, d and e), but this did not
resolve the problem. Similar experiments were conducted with the first and
second bleeds but the results were the same (data not shown).
Many different conditions and additives were tried to reduce the
background interference, including using protein membranes from different
suppliers and a variety of blocking agents (5 and 10% milk, BSA, gelatin all
with Tween 20 at a maximum concentration of 2%) with increased blocking
and washing times. None of the conditions mentioned dramatically improved
the signal to noise ratio (data not shown). The antibody was also immuno-
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6.2.3 Immuno-affinity purification using a His tagged Fl-APO
The anti APO was purified from serum using a different immuno-affinity
purification procedure (Harlow E, 1999). This involved the generation of an
N-terminal His tagged Fl-APO (without catalytic domain) fusion protein
which was then purified on a charged nickel column. The purified fusion
protein was irreversibly bound by cyanogens bromide linkage to sepharose
beads and the rabbit serum was then passed over the beads to capture the
aminopeptidase antibody (Figure 6.4).
The expression of the fusion protein was optimised using different
conditions (Section 6.2.1). In this expression system ImM IPTG induction at
37°C for 3 hours yielded the highest levels of fusion protein. A Western blot
with an antibody to the His tag was used to verify that the induced band was
the desired fusion protein, although there were some additional breakdown
protein products (Figure 6.5).
The fusion protein yield was low with the majority of the protein in the
insoluble aggregate fraction (data not shown). It was decided to solubilise the
His tagged fusion protein from the aggregates with 6M urea.
Initial attempts to bind the His-Fl-APO protein using the charged nickel
colums for 1 hour failed with no protein detected in the eluted fraction (Figure
6.6 a). However, when this was increased to overnight incubation a significant
amount of fusion protein was detected in the eluted fraction (Figure 6.6 b).
This purified fusion protein was then bound to the activated cyanogen
bromide sepharose beads. These beads were then used to purify the anti-APO
antibody from serum and tested on a Western blot against various eGFP
tagged APO fusions.
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Clone F1-ApO into pET32a His tagged Vector
Express and purify His tagged Fl-APO
Dialysis and concentrate purified His-APO fusion protein
Bind His-APO fusion protein to activated cyanogen bromide
(CnBr) sepharose beads
Run serum over His-APO bound CnBr column
Wash and elute purified antibody from beads
Test purified antibody by Western blotting
Figure 6.4: Schematic diagram illustrating immuno affinity
purification of anti APO from sera.
a) M BL21 un in
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Figure 6.5: Expression of HisTagged Fl-APO (1-stop).
a) Coomassie stained gel of protein lysates from untransformed BL21
bacteria or transformed His-Fl-APO (1-stop) BL21 cells uninduced
(un) or induced (in) with IPTG.
b) Western blot analysis ofBL21 cell lysates either uninduced (un) or
induced (in) with 1 mM IPTG for 3 hours using an anti His antibody.
Red arrow marks full length fusion (116kDa).
Blue arrows indicate breakdown products.
Figure 6.6: Expression and purification of His tagged F1-ApO
(1-stop) with out catalytic domain under two different purification
conditions.
(a) 2 hours and (b) overnight.
Marker (M), BL21 untransformed (1), uninduced (2), induced (3),
solubilised fraction (4), first wash (5) and elution from column (6).
6.2.4 Testing of immuno purified ANTI APO on recombinant
APO protein
Western blot analysis using the commercial anti eGFP antibody detected
the eGFP protein and tagged eGFP-Fl-APO (1-stop) eGFP-CT- APO (552-
stop), and eGFP-NT-APO (1-281) (Figure 6.7 a). The purified anti APO
antibody detected similarly sized bands in the eGFP-Fl-APO and eGFP-NT
but not the eGFP-CT-APO protein product (Figure 6.7 b). A possible reason
might be that the antigenic epitopes were not present on the C-terminus of the
protein.
Antibody dilution at 1 in 5000 resulted in an intense specific signal with
short exposure times typically less than 1 minute (Figure 6.7 c). The signal to
noise ratio was very low with long exposures and the diffuse high background
observed with the unpurified sera was eliminated (data not shown). This
result indicated that the antibody purification had been successful. The
additional band present with the eGFP-NT-APO on both the Westerns was
assumed to be degraded APO protein (Figure 6.7 a and b, lane 4).
6.2.5 Testing immuno purified antibody on mouse tissues by
Western blot
To assess whether this immunopurified antibody could be used to detect
APO in mouse tissue lysates, total protein was extracted from wild type mice
and mice carrying the heterozygous and homozygous GT411 gene trap. One
would have expected APO-/3geo fusion proteins associated with the gene trap
integration to shift in the heterozygote and homozygote tissues when
compared to wild type APO protein. Attempts to use the immuno-purified
anti APO antibody on mouse tissues were unsuccessful (data not shown).
Given that the anti APO did not work on tissues we tried a control
experiment was attempted with a commercial antibody against /3-gal. APO-
/3geo fusion proteins (60+156kDa) were detected in the heterozygote
ApOG,4"For/+ and homozygote ^pQGt4"For/G,4"For hearts (Figure 6.8).
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Lanes 1 Cj-GFP^)
Lanes 2 CeGFtQ 1 31 "A i-stop
Lanes 3 CeGFTy ^}P3 [x 552-stop
Lanes 4 CeGFP^) X 1-281
b) 1 2 3 4 5 c) 1 2 345
Anti eGFP Anti APO
Figure 6.7: Testing of the immunopurified APO antibody using
COS 7 cells transfected with a range of eGFP- APO fusion proteins.
a). Schematic illustration of eGFP clones transfected into COS 7 cells.
Western blot analysis of protein lysates isolated from COS 7 cells
transiently transfected with eGFP alone (1), eGFP-Fl-ApO (2),
eGFP-C-Termyl/>G (3), eGFP-N-Term-^/>(9 (4) and mock transfected
cells (5). Probed with either the anti eGFP (b), or the immunopurified
anti APO antibody (c).
Asterisks indicate putative breakdown products.
Figure 6.8: Western blot analysis of protein lysates isolated
from adult mouse hearts with an anti /3gal antibody to detect
fusion proteins.
Wild type (1), heterozygous aminopeptidase O ct4iiFor/+ (2),
homozygous aminopeptidase O Gt4iiFor/Gt4iiFor (3^ an(j
ES cell expressing OCT4-IRES- /3geo (4), and wild type ES cell (5).
The heterozygote ApOGl4"For/+ signal was approximately half the intensity of
the homozygote ApOGt4I,For/Gt4IlFor^ The positive control (gifted by Dr. Tom
Burdon) was a protein lysate from ES cells expressing OCT4-IRES-/3geo
(156kDa) (Figure 6.8, lane 4). The negative control was a protein lysate from
wild type ES cells (Figure 6.8, lane 5). The bands seen in the heterozygote
ApOGl4IIFor/+ and homozygote dpOGt4IIFor/Gt4llFor hearts with the commercial
/3-gal antibody were larger than the OCT4-IRES-/3geo control indicating that
they were authentic and not artefactual bands.
6.2.6 Immunohisochemistry with APO antibody on paraffin
embedded kidney sections.
To assess the purified aminopeptidase antibody applicability for
immunohistochemistry it was tested on paraffin embedded kidney sections.
The lacZ staining of ApOGt4IIFor/+ and homozygote ApOGt4nFor/Gt411For adult
kidney sections had demonstrated staining of the glomeruli and afferent
vessels and was considered a suitable tissue to optimise the
immunohistochemistry protocol. The ApO-LACZ reporter staining within the
glomeruli when compared to the afferent vessels appears to be stronger
indicating higher expression in this region of the tissue. The purified APO
antibody indicated specific staining of the glomeruli which is comparable to
the /Sgal staining in kidney cryosections (Figure 6.9 a, b and c). However,
there was no apparent staining of the vessels leading into the glomerulus,
which may be due to the fact that APO expression is lower and beyond the
sensitivity of the antibody. The immunohistochemistry procedure would
require additional trouble shooting to maximise the protocol, for example a
nickel staining method could be tried (Paraffin embedded sections cut by Eli
Mohammed and staining performed by Julie Buchannan).
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Figure 6.9: Testing of immunoprurified APO antibody on parafin
embedded kidney section.
a) Immunohistochemistry of paraffin embedded adult kidney with GT411
purified antibody X10.
b) /3gal stained adult kidney homozygote ^/?0Gt41IFor/Gt41,Forcryosection.
c) High power of boxed region showing APO specific staining of cells
within the glomerulus X40 (b) gm=glomeruli, aa=afferent arteries.
6.2.7 Immuno Precipitations (IP) of recombinant APO protein
One strategy to isolate purified catalytically active enzyme is to IP the
endogenous protein from tissues. This approach has been taken with matrix
metallo-proteases where they are then assayed with known substrates in
techniques such as zymography. It was decided to test whether antibody APO
could IP eGFP tagged APO fusions from transiently transfected COS 7 cells.
The control EP with anti eGFP antibody captured the eGFP (26 kDa),
eGFP-Fl-APO (1-stop) and eGFP-CT-APO (552-stop) proteins (Figure 6.10
b). The eGFP-Fl-ApO protein (lane 2) had a ladder of faint bands (largest 116
kDa) and these were assumed to be breakdown products. Note the strong band
at 40 kDa. The eGFP-CT-APO protein was also captured (Figure 6.10 b, lane
3), although there are a number of breakdown products, including a strong
band at 40 kDa and one at the same position as the eGFP protein alone (26
kDa).
The APO antibody immunoprecipitated bands shown in lane 2 (Figure
6.10 c), however, these were too small to be the full length fusion (116 kDa)
and were again assumed to be breakdown products. It was very similar to the
bands observed in the eGFP-Fl-APO (Figure 6.10 b lane 2).The APO
antibody did not IP the C-Terminal fusion successfully. It is likely that the C-
terminus does not contain epitopes recognised by the APO antibody and this
concurs with the Western data (see section 6.2.4). The mock transfections
served as a negative control (Figure 6.10 b and c, lane 4). In both Western


















Figure 6.10: Immunoprecipitation of protein lysates from COS 7
cells transiently transfected with eGFP-fusions.
a) Schematic diagram of eGFP-ApO fusions used in transfections.
b) and c) Western blots ofwith eGFP antibody eGFP lane 1,
eGFP-Fl-APO (1-stop) lane 2, eGFP-C-terminal-APO (552-stop) lane 3,
or mock transfected lane 4. Using anti-eGFP (b) or anti-APO (c)
antibodies and then subsequently analysed by Western blot using
anti eGFP antibody. Asterisks indicate faint full length eGFP-APO fusion
(red) and breakdown products (black).
6.3 Discussion
Antibodies provide a powerful approach to characterise gene expression
more fully. There are several advantages to this strategy. Firstly, the
endogenous gene product can be directly analysed at the cellular and tissue
level. Secondly, immunoprecipitation of endogenous protein enables
functional activity to be assayed. Thirdly, interacting proteins can be
discovered by co-immunoprecipitation. Taken together antibodies provide a
valuable resource to evaluate and determine gene function.
In this study an antibody was raised in a rabbit against the full length
murine aminopeptidase O (without catalytic domain) and its efficacy tested by
Western blotting, immunoprecipitation and immunohistochemistry. It was
demonstrated that the APO antibody can detect transiently expressed
aminopeptidase O protein from COS 7 cells but not the endogenous protein
from whole tissue lysates. It is possible to speculate that failure of the
antibody to detect endogenous APO proteins may be due to protein instability
or that the protein lysate preparation caused solubility difficulties. These
hypotheses seem less credible since the APO-/3geo fusion protein was
detected with a commercial /3-gal antibody. Perhaps the purified
aminopeptidase O antibody developed in-house was inferior to commercial
preparations.
The APO antibody was successfully used to IP recombinant fusion
protein from COS 7 cell lysates. The C-terminal (552-stop) APO fusion
protein was not captured by the APO antibody. Similarly the antibody did not
detect this C-terminal fusion protein by Western blot either. A plausible
explanation may be that the C-terminal portion of the protein did not contain
antigenic epitopes.
Other experiments which should now be undertaken would be to IP
endogenous APO from tissues or a mouse endothelial cell line such as the
murine cell endothelial cells (MCEC) (Lidington et al., 2002). This would
allow purification of the protease which could then be assayed with
fluorogenic substrates to confirm its aminopeptidase activity (Grant et ah,
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2002). Additionally, interacting partners could be resolved by 2-D





7.1 Summary and prospective
During a gene trap screen designed to identify novel regulated genes in
cardiovascular development, the ES clone GT411 was isolated. Originally the
EST database contained only a short contig for this gene. The full length
open reading frame was determined using 5'RACE. The gene was identified
to be a novel aminopeptidase but during the course of the research its human
orthologue was cloned and named Aminopeptidase O (APO) (Diaz-Perales et
al., 2005).
Aminopeptidase O contains several functional domains. First, a protease
domain has been identified indicating that it is a member of the Ml family of
aminopeptidases. These enzymes are involved in a number of important
biological processes including angiogenesis, maintenance of blood pressure
and inflammatory pathways (Haeggstrom, 2004; Mitsui et al., 2004; Sato,
2003). Secondly, prediction of an armadillo repeat structure suggests that ApO
may be implicated in the transport of proteins to the nucleus (Malik et al.,
1997). In addition, characterisation of a putative nuclear localisation signal
sequence (NLS) was undertaken using eGFP-4/><9 fusions with and without
the NLS sequence. The eGFP-ApO fusion proteins with the NLS were
directed to the nucleoli while those without were retained in the cytoplasm. A
comparison of the NLS protein sequence between mouse, rat, human and
puffer fish did not show an absolutely conserved NLS, although the sequence
did contain a stretch of basic amino acids which are common in canonical
NLS sequences. An experiment with the eGFP-APO fusion proteins from
other species with and without the putative NLS could be done to ascertain if
this domain is functionally conserved between species.
Analysis from Northern blot and RT-PCR data has shown that ApO has
alternatively spliced isoforms which in some instances can remove the
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catalytic domain and the NLS. It would be predicted that transcripts that do
not contain these domains would have different functional activity.
A novel regulatory mechanism of enzyme function has been described for
the aminopeptidase thytotropin releasing hormone degredation enzyme. This
gene expresses an isoform which does not contain the catalytic domain and
can bind as a heterodimer to the isoform that contains the catalytic domain
preventing enzymatic activity (Chavez-Gutierrez et al., 2005). It is possible
that the ApO isoform without the catalytic domain could act in a similar
manner as a negative regulator ofApO enzyme function.
Splicing enables expression of functionally diverse proteins from a single
gene. There are alternative splicing events for the ApO gene involving the
catalytic domain and the NLS. The function of these domains could be
investigated by a gene targeting knock-in strategy whereby only one particular
isoform is expressed. A similar approach was taken with the zinc finger
transcription factor ZBP-89 where a splice isoform lacking the amino terminal
residues 1-127 of the full-length protein was knocked in to define its function.
The ZBP 89AN homozygous mice expressing ZBP 89AN protein had a
phenotype and it was concluded that the amino terminus of the protein was
required for gastrointestinal homeostasis (Law et ah, 2006).
The gene trap mice did not appear to have a phenotype. Specifically,
analysis of 8.5, 9.5 and 10.5 d.p.c. embryos and sections of adult tissues did
not show a gross morphological abnormality in the vasculature. Moreover,
using the aortic ring assay, no discernable phenotype was observed.
The recent publication of the human aminopeptidase O orthologue and
the demonstration that it can enzymatically cleave Ang III into Ang IV clearly
implicates APO's involvement in the renin angiotensin system in the
maintenance of blood pressure. Comparison of heart and kidney weights
dissected from 1 month old wild type, heterozygous ApOGt4IIFor/Jr and
homozygous ^pQG,4"For/Gt4"For gene trap mice did not demonstrate any
statistically significant differences using T-tests. A limitation of this
experiment was that the mice were young and a high blood pressure
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phenotype might take longer to develop. This experiment could be performed
on older mice and one could also compare and look for thickening of the aorta
by paraffin embedded sectioning. Although it has been recently demonstrated
that APO can cleave Ang III into Ang IV in an in vitro enzyme assay (Diaz-
Perales et al., 2005), there is at present no evidence to show that this occurs in
vivo. Indeed the vasoactive peptides of the renin angiotensin system are
systemically transported in the blood and are either enzymatically cleaved by
secreted enzymes or cleaved by membrane bound enzymes. APO does not
contain transmembrane domains or signal peptides to direct it to the cell
membrane. It is, therefore, unlikely that APO is physiologically able to
participate directly in the catabolism of the vasoactive peptide Ang III.
The absence of a phenotype in the gene trap mice might be explained by
the fact that the integration has occurred in the last intron of the ApO gene.
This removes 46 amino acids from the protein and it is possible that it may
retain all or part of its normal function despite being fused to the /3geo gene.
Future research in this area could involve trying to determine the function
of aminopepetidase O. One strategy might be to ablate the ApO gene by
homologous recombination strategies either involving the generation of a
complete null or a conditional knockout. Phenotypic analysis ofmutant mice
may allow functionality to be ascribed to the gene. Many gene knockout
studies have not resulted in a phenotype and a possible cause is that there may
be genetic redundancy. The closest relative to aminopeptidase O is
aminopeptidase B and this might be a candidate for redundancy. One way to
increase the severity of a phenotype is to cross the mutant lines to generate a
double knock out (Heber et al., 2000).
Other strategies that could be used to determine gene function include
morpholino antisense technology against the frog or zebra fish ApO
orthologues (Summerton et al., 1997) and RNA interference (RNAi) where a
short double stranded RNA specific to the APO gene is introduced into an
endothelial cell line (HUVECS) and analysed with an endothelial cell assay
(Fukasawa et al., 2006). The effect of these strategies might be to down-
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regulate the endogenous gene expression which in turn may cause a
phenotype.
In conclusion the murine ApO gene was isolated using a gene trapping
screen designed to discover novel genes involved in cardiovascular
development. Although this approach was successful in isolating this gene
and demonstrated that the APO was expressed in the vasculature, it was a
labour intensive strategy. A desirable consequence of gene trapping is that it
may be mutagenic when transmitted through the germ line although in this
instance no apparent phenotype was evident. With the benefit of hindsight
and with recent technological advances, one could take different approaches
to identify genes involved with vascular development. For example, a
subtractive screen comparing the gene expression of an endothelial cell line
with a different cell type might identify genes that are required solely for
vascular function.
Germline transmission of the GT411 ES cells demonstrated LacZ
reporter expression in developing embryonic and adult vasculature.
Understanding the function of ApO therefore might provide insight into
vascular biology in both normal developmental and pathological conditions.
These could include processes such as angiogenesis, maintenance of blood
pressure as well as its deregulation in diseases such as cancer and




Adams, J. M. (2003). Ways of dying: multiple pathways to apoptosis. Genes Dev
17,2481-95.
Ahmad, S. and Ward, P. E. (1990). Role of aminopeptidase activity in the
regulation of the pressor activity of circulating angiotensins. JPharmacol Exp
Ther 252, 643-50.
Andersen, J. S., Lyon, C. E., Fox, A. H., Leung, A. K., Lam, Y. W., Steen, H.,
Mann, M. and Lamond, A. I. (2002). Directed proteomic analysis of the human
nucleolus. Curr Biol 12,1-11.
Andrade, M. A., Petosa, C., O'Donoghue, S. I., Muller, C. W. and Bork, P.
(2001). Comparison of ARM and HEAT protein repeats. JMol Biol 309, 1-18.
Antoine, N., Greimers, R., De Roanne, C., Kusaka, M., Heinen, E., Simar, L. J.
and Castronovo, V. (1994). AGM-1470, a potent angiogenesis inhibitor, prevents
the entry of normal but not transformed endothelial cells into the G1 phase of
the cell cycle. Cancer Res 54, 2073-6.
Bailey,J.A. Yavor,A.M., Viggiano,I., Misceo,D., Horvath,J.E., Archidiacono,N.,
Schwarz,S., Rocchi,M and Eichler,E.E. (2002). Human specific duplication and
mosaic trnscripts: the recent paralogous structure of chromosome 22. Am J
Hum Genet 70,83-100
Bain, G., Ray, W. J., Yao, M. and Gottlieb, D. I. (1996). Retinoic acid promotes
neural and represses mesodermal gene expression in mouse embryonic stem
cells in culture. Biochem Biophys Res Commun 223, 691-4.
Baker, D., Silen, J. L. and Agard, D. A. (1992). Protease pro region required for
folding is a potent inhibitor of the mature enzyme. Proteins 12, 339-44.
Benita, Y., Oosting, R. S., Lok, M. C., Wise, M. J. and Humphery-Smith, I.
(2003). Regionalized GC content of template DNA as a predictor of PCR
success. Nucleic Acids Res 31, e99.
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K.,
Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z. et al. (2000). Matrix
metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat
Cell Biol 2, 737-44.
135
Bjornsson, J. M., Larsson, N., Brun, A. C., Magnusson, M., Andersson, E.,
Lundstrom, P., Larsson, J., Repetowska, E., Ehinger, M., Humphries, R. K. et
al. (2003). Reduced proliferative capacity of hematopoietic stem cells deficient in
Hoxb3 and Hoxb4. Mol Cell Biol 23, 3872-83.
Blacher, S., Devy, L., Burbridge, M. F., Roland, G., Tucker, G., Noel, A. and
Foidart, J. M. (2001). Improved quantification of angiogenesis in the rat aortic
ring assay. Angiogenesis 4, 133-42.
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson,
M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S. et al. (1997). A
metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from
cells. Nature 385, 729-33.
Bogerd, H. P., Benson, R. E., Truant, R., Herold, A., Phingbodhipakkiya, M.
and Cullen, B. R. (1999). Definition of a consensus transportin-specific
nucleocytoplasmic transport signal. J Biol Chem 274, 9771-7.
Brock, T. G., Lee, Y. J., Maydanski, E., Marburger, T. L., Luo, M., Paine, R.,
3rd and Peters-Golden, M. (2005). Nuclear localization of leukotriene A4
hydrolase in type II alveolar epithelial cells in normal and fibrotic lung. Am J
Physiol Lung Cell Mol Physiol 289, L224-32.
Brooks, P. C., Silletti, S., von Schalscha, T. L., Friedlander, M. and Cheresh, D.
A. (1998). Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase
fragment with integrin binding activity. Cell 92, 391-400.
Brun, A. C., Bjornsson, J. M., Magnusson, M., Larsson, N., Leveen, P., Ehinger,
M., Nilsson, E. and Karlsson, S. (2004). Hoxb4-deficient mice undergo normal
hematopoietic development but exhibit a mild proliferation defect in
hematopoietic stem cells. Blood 103, 4126-33.
Byrom, J., Mudaliar, V., Redman, C. W., Jones, P., Strange, R. C. and Hoban,
P. R. (2004). Loss of heterozygosity at chromosome 9q22-31 is a frequent and
early event in ovarian tumors. Int J Oncol 24,1271-7.
Cadel, S., Foulon, T., Viron, A., Balogh, A., Midol-Monnet, S., Noel, N. and
Cohen, P. (1997). Aminopeptidase B from the rat testis is a bifunctional enzyme
structurally related to leukotriene-A4 hydrolase. Proc Natl Acad Sci USA 94,
2963-8.
Cao, Y., Ji, R. W., Davidson, D., Schaller, J., Marti, D., Sohndel, S., McCance, S.
G., O'Reilly, M. S., Llinas, M. and Folkman, J. (1996). Kringle domains of
human angiostatin. Characterization of the anti-proliferative activity on
endothelial cells. J Biol Chem 271, 29461-7.
136
Carlson, C. M. and Largaespada, D. A. (2005). Insertional mutagenesis in mice:
new perspectives and tools. Nat Rev Genet 6, 568-80.
Carmeliet, P. and Jain, R. K. (2000). Angiogenesis in cancer and other diseases.
Nature 407, 249-57.
Cebe-Suarez, S., Zehnder-Fjallman, A. and Ballmer-Hofer, K. (2006). The role
ofVEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 63,
601-15.
Chavez-Gutierrez, L., Bourdais, J., Aranda, G., Vargas, M. A., Matta-Camacho,
E., Ducancel, F., Segovia, L., Joseph-Bravo, P. and Charli, J. L. (2005). A
truncated isoform of pyroglutamyl aminopeptidase II produced by exon
extension has dominant-negative activity. JNeurochem 92, 807-17.
Chubinskaya, S., Mikhail, R., Deutsch, A. and Tindal, M. H. (2001). ADAM-10
protein is present in human articular cartilage primarily in the membrane-
bound form and is upregulated in osteoarthritis and in response to IL-1 alpha in
bovine nasal cartilage. JHistochem Cytochem 49, 1165-76.
Coates, J. C. (2003). Armadillo repeat proteins: beyond the animal kingdom.
Trends Cell Biol 13, 463-71.
Conlon, R. A. and Rossant, J. (1992). Exogenous retinoic acid rapidly induces
anterior ectopic expression of murine Hox-2 genes in vivo. Development 116,
357-68.
Conti, E. and Izaurralde, E. (2001). Nucleocytoplasmic transport enters the
atomic age. Curr Opin Cell Biol 13, 310-9.
Conti, E., Uy, M., Leighton, L., Blobel, G. and Kuriyan, J. (1998).
Crystallographic analysis of the recognition of a nuclear localization signal by
the nuclear import factor karyopherin alpha. Cell 94,193-204.
Dang, C. V. and Lee, W. M. (1989). Nuclear and nucleolar targeting sequences
of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins. JBiol Chem 264,
18019-23.
Das, S., Mandal, M., Chakraborti, T., Mandal, A. and Chakraborti, S. (2003).
Structure and evolutionary aspects of matrix metalloproteinases: a brief
overview. Mol Cell Biochem 253, 31-40.
Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V.,
Ryan, T. E., Bruno, J., Radziejewski, C., Maisonpierre, P. C. et al. (1996).
Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap
expression cloning. Cell 87,1161-9.
137
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N. and Williams, L.
T. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial
growth factor. Science 255, 989-91.
Decatur, W. A. and Fournier, M. J. (2003). RNA-guided nucleotide modification
of ribosomal and other RNAs. JBiol Chem 278, 695-8.
Delahunty, C. and Yates, J. R., 3rd. (2005). Protein identification using 2D-LC-
MS/MS. Methods 35, 248-55.
Deng, J. M. and Behringer, R. R. (1995). An insertional mutation in the BTF3
transcription factor gene leads to an early postimplantation lethality in mice.
Transgenic Res 4, 264-9.
Deshayes, F. and Nahmias, C. (2005). Angiotensin receptors: a new role in
cancer? Trends Endocrinol Metab 16, 293-9.
Desterro, J. M., Keegan, L. P., Lafarga, M., Berciano, M. T., O'Connell, M. and
Carmo-Fonseca, M. (2003). Dynamic association of RNA-editing enzymes with
the nucleolus. J Cell Sci 116,1805-18.
Diaz-Perales, A., Quesada, V., Sanchez, L. M., Ugalde, A. P., Suarez, M. F.,
Fueyo, A. and Lopez-Otin, C. (2005). Identification of human aminopeptidase
O, a novel metalloprotease with structural similarity to aminopeptidase B and
leukotriene A4 hydrolase. JBiol Chem 280,14310-7.
Doetschman, T., Gregg, R. G., Maeda, N., Hooper, M. L., Melton, D. W.,
Thompson, S. and Smithies, O. (1987). Targetted correction of a mutant HPRT
gene in mouse embryonic stem cells. Nature 330, 576-8.
Dumont, D. J., Gradwohl, G., Fong, G. H., Puri, M. C., Gertsenstein, M.,
Auerbach, A. and Breitman, M. L. (1994). Dominant-negative and targeted null
mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role
in vasculogenesis of the embryo. Genes Dev 8, 1897-909.
Early, P., Huang, H., Davis, M., Calame, K. and Hood, L. (1980a). An
immunoglobulin heavy chain variable region gene is generated from three
segments of DNA: VH, D and JH. Cell 19, 981-92.
Early, P., Rogers, J., Davis, M., Calame, K., Bond, M., Wall, R. and Hood, L.
(1980b). Two mRNAs can be produced from a single immunoglobulin mu gene
by alternative RNA processing pathways. Cell 20, 313-9.
138
Egeblad, M. and Werb, Z. (2002). New functions for the matrix
metalloproteinases in cancer progression. Nat Rev Cancer 2,161-74.
Ema, M., Faloon, P., Zhang, W. J., Hirashima, M., Reid, T., Stanford, W. L.,
Orkin, S., Choi, K. and Rossant, J. (2003). Combinatorial effects of Flkl and
Tall on vascular and hematopoietic development in the mouse. Genes Dev 17,
380-93.
Estreicher, A., Muhlhauser, J., Carpentier, J. L., Orci, L. and Vassalli, J. D.
(1990). The receptor for urokinase type plasminogen activator polarizes
expression of the protease to the leading edge of migrating monocytes and
promotes degradation of enzyme inhibitor complexes. J Cell Biol 111, 783-92.
Eter, N. and Spitznas, M. (2002). DMSO mimics inhibitory effect of thalidomide
on choriocapillary endothelial cell proliferation in culture. Br J Ophthalmol 86,
1303-5.
Evans, M. J., Carlton, M. B. and Russ, A. P. (1997). Gene trapping and
functional genomics. Trends Genet 13, 370-4.
Fang, J., Shing, Y., Wiederschain, D., Yan, L., Butterfield, C., Jackson, G.,
Harper, J., Tamvakopoulos, G. and Moses, M. A. (2000). Matrix
metalloproteinase-2 is required for the switch to the angiogenic phenotype in a
tumor model. Proc Natl Acad Sci USA 97, 3884-9.
Favor, J. and Neuhauser-Klaus, A. (2000). Saturation mutagenesis for dominant
eye morphological defects in the mouse Mus musculus. Mamm Genome 11, 520-
5.
Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Semin
Oncol 29,15-8.
Folkman, J. and Klagsbrun, M. (1987). Angiogenic factors. Science 235, 442-7.
Forrester, L. M., Nagy, A., Sam, M., Watt, A., Stevenson, L., Bernstein, A.,
Joyner, A. L. and Wurst, W. (1996). An induction gene trap screen in
embryonic stem cells: Identification of genes that respond to retinoic acid in
vitro. Proc Natl Acad Sci USA 93, 1677-82.
Friedrich, G. and Soriano, P. (1991). Promoter traps in embryonic stem cells: a
genetic screen to identify and mutate developmental genes in mice. Genes Dev 5,
1513-23.
Fujimoto, Y., Sasaki, T., Tsuchida, A. and Chayama, K. (2001). Angiotensin II
type 1 receptor expression in human pancreatic cancer and growth inhibition by
angiotensin II type 1 receptor antagonist. FEBS Lett 495, 197-200.
139
Fukasawa, K., Fujii, H., Saitoh, Y., Koizumi, K., Aozuka, Y., Sekine, K.,
Yamada, M., Saiki, I. and Nishikawa, K. (2006). Aminopeptidase N
(APN/CD13) is selectively expressed in vascular endothelial cells and plays
multiple roles in angiogenesis. Cancer Lett.
Garcia-Mata, R., Bebok, Z., Sorscher, E. J. and Sztul, E. S. (1999).
Characterization and dynamics of aggresome formation by a cytosolic GFP-
chimera. J Cell Biol 146, 1239-54.
Geballe, A. P. and Morris, D. R. (1994). Initiation codons within 5'-leaders of
mRNAs as regulators of translation. Trends Biochem Sci 19, 159-64.
Gerety, S. S., Wang, H. U., Chen, Z. F. and Anderson, D. J. (1999). Symmetrical
mutant phenotypes of the receptor EphB4 and its specific transmembrane
ligand ephrin-B2 in cardiovascular development. Mol Cell 4, 403-14.
Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S.,
Frazier, W. A. and Bouck, N. P. (1990). A tumor suppressor-dependent
inhibitor of angiogenesis is immunologically and functionally indistinguishable
from a fragment of thrombospondin. Proc Natl Acad Sci USA 87, 6624-8.
Gorlich, D. (1997). Nuclear protein import. Curr Opin Cell Biol 9, 412-9.
Gossler, A., Joyner, A. L., Rossant, J. and Skarnes, W. C. (1989). Mouse
embryonic stem cells and reporter constructs to detect developmentally
regulated genes. Science 244, 463-5.
Grant, S. K., Sklar, J. G. and Cummings, R. T. (2002). Development of novel
assays for proteolytic enzymes using rhodamine-based fluorogenic substrates. J
Biomol Screen 7, 531-40.
Graveley, B. R. (2001). Alternative splicing: increasing diversity in the
proteomic world. Trends Genet 17,100-7.
Greco, S., Muscella, A., Elia, M. G., Salvatore, P., Storelli, C., Mazzotta, A.,
Manca, C. and Marsigliante, S. (2003). Angiotensin II activates extracellular
signal regulated kinases via protein kinase C and epidermal growth factor
receptor in breast cancer cells. J Cell Physiol 196, 370-7.
Griffith, E. C., Su, Z., Niwayama, S., Ramsay, C. A., Chang, Y. H. and Liu, J. O.
(1998). Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin
by methionine aminopeptidase 2. ProcNatl Acad Sci USA 95, 15183-8.
Griffith, E. C., Su, Z., Turk, B. E., Chen, S., Chang, Y. H., Wu, Z., Biemann, K.
and Liu, J. O. (1997). Methionine aminopeptidase (type 2) is the common target
for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 4, 461-71.
140
Gyapay, G., Schmitt, K., Fizames, C., Jones, H., Vega-Czarny, N., Spillett, D.,
Muselet, D., Prud'homme, J. F., Dib, C., Auffray, C. et al. (1996). A radiation
hybrid map of the human genome. Hum Mol Genet 5, 339-46.
Haeggstrom, J. Z. (2004). Leukotriene A4 hydrolase/aminopeptidase, the
gatekeeper of chemotactic leukotriene B4 biosynthesis. JBiol Chem 279, 50639-
42.
Hajitou, A., Sounni, N. E., Devy, L., Grignet-Debrus, C., Lewalle, J. M., Li, H.,
Deroanne, C. F., Lu, H., Colige, A., Nusgens, B. V. et al. (2001). Down-
regulation of vascular endothelial growth factor by tissue inhibitor of
metalloproteinase-2: effect on in vivo mammary tumor growth and
angiogenesis. Cancer Res 61, 3450-7.
Hanahan, D. and Folkman, J. (1996). Patterns and emerging mechanisms of the
angiogenic switch during tumorigenesis. Cell 86, 353-64.
Handwerger, K. E. and Gall, J. G. (2006). Subnuclear organelles: new insights
into form and function. Trends Cell Biol 16,19-26.
Harlow E, L. D. (1999). Using Antibodies a laboratory Manual: Cold Spring
Harbor Laboratory Press.
Heber, S., Herms, J., Gajic, V., Hainfellner, J., Aguzzi, A., Rulicke, T., von
Kretzschmar, H., von Koch, C., Sisodia, S., Tremml, P. et al. (2000). Mice with
combined gene knock-outs reveal essential and partially redundant functions of
amyloid precursor protein family members. JNeurosci 20, 7951-63.
Herrick, T. M. and Cooper, J. A. (2002). A hypomorphic allele of dabl reveals
regional differences in reelin-Dabl signaling during brain development.
Development 129, 787-96.
Hesp, J. R. and Hooper, N. M. (1997). Proteolytic fragmentation reveals the
oligomeric and domain structure of porcine aminopeptidase A. Biochemistry 36,
3000-7.
Hill, D. P. and Wurst, W. (1993). Gene and enhancer trapping: mutagenic
strategies for developmental studies. Curr Top Dev Biol 28, 181-206.
Hobson, B. and Denekamp, J. (1984). Endothelial proliferation in tumours and
normal tissues: continuous labelling studies. Br J Cancer 49, 405-13.
Hoi, E. M., van Leeuwen, F. W. and Fischer, D. F. (2005). The proteasome in
Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+l. Trends
Mol Med 11, 488-95.
141
Howard, L., Maciewicz, R. A. and Blobel, C. P. (2000). Cloning and
characterization ofADAM28: evidence for autocatalytic pro-domain removal
and for cell surface localization ofmature ADAM28. Biochem J 348 Pt 1, 21-7.
Huber, A. H., Nelson, W. J. and Weis, W. I. (1997). Three-dimensional structure
of the armadillo repeat region of beta-catenin. Cell 90, 871-82.
Huber, T. L., Kouskoff, V., Fehling, H. J., Palis, J. and Keller, G. (2004).
Haemangioblast commitment is initiated in the primitive streak of the mouse
embryo. Nature 432, 625-30.
Hughes, T. A. and Brady, H. J. (2005a). E2F1 up-regulates the expression of the
tumour suppressor axin2 both by activation of transcription and by mRNA
stabilisation. Biochem Biophys Res Commun 329,1267-74.
Hughes, T. A. and Brady, H. J. (2005b). Expression of axin2 is regulated by the
alternative 5'-untranslated regions of its mRNA. JBiol Chem 280, 8581-8.
Hunt, C. and Morimoto, R. I. (1985). Conserved features of eukaryotic hsp70
genes revealed by comparison with the nucleotide sequence of human hsp70.
ProcNatl Acad Sci USA 82, 6455-9.
Ikemura, H., Takagi, H. and Inouye, M. (1987). Requirement of pro-sequence
for the production of active subtilisin E in Escherichia coli. JBiol Chem 262,
7859-64.
Imanishi, T., Hano, T. and Nishio, I. (2004). Angiotensin II potentiates vascular
endothelial growth factor-induced proliferation and network formation of
endothelial progenitor cells. Hypertens Res 27,101-8.
Itoh, T., Ikeda, T., Gomi, H., Nakao, S., Suzuki, T. and Itohara, S. (1997).
Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix
metalloproteinase 2)-deficient mice. JBiol Chem 272, 22389-92.
Iwase, A., Nomura, S. and Mizutani, S. (2001). Characterization of a secretase
activity for placental leucine aminopeptidase. Arch Biochem Biophys 393, 163-9.
Jacob, R., Peters, K. and Nairn, H. Y. (2002). The prosequence of human
lactase-phlorizin hydrolase modulates the folding of the mature enzyme. JBiol
Chem 277,8217-25.
Joseph, R., Dou, D and Tsang, W. (1995). Neuronatin mRNA: alternatively
spliced forms of a novel brain-specific mammalian developmental gene Brain
Research, 92-98
142
Kalderon, D., Roberts, B. L., Richardson, W. D. and Smith, A. E. (1984). A
short amino acid sequence able to specify nuclear location. Cell 39, 499-509.
Kalland, K. H., Szilvay, A. M., Brokstad, K. A., Saetrevik, W. and Haukenes, G.
(1994). The human immunodeficiency virus type 1 Rev protein shuttles between
the cytoplasm and nuclear compartments. Mol Cell Biol 14, 7436-44.
Kato, T., Kure, T., Chang, J. H., Gabison, E. E., Itoh, T., Itohara, S. and Azar,
D. T. (2001). Diminished corneal angiogenesis in gelatinase A-deficient mice.
FEBS Lett 508, 187-90.
Kessel, M. and Gruss, P. (1991). Homeotic transformations of murine vertebrae
and concomitant alteration of Hox codes induced by retinoic acid. Cell 67, 89-
104.
Kester, W. R. and Matthews, B. W. (1977). Crystallographic study of the
binding of dipeptide inhibitors to thermolysin: implications for the mechanism
of catalysis. Biochemistry 16, 2506-16.
Kim, S. and Iwao, H. (2000). Molecular and cellular mechanisms of angiotensin
II-mediated cardiovascular and renal diseases. Pharmacol Rev 52, 11-34.
Klymkowsky, M. W. (1999). Plakophilin, armadillo repeats, and nuclear
localization. Microsc Res Tech 45, 43-54.
Kondo, T., Takahashi, N. and Muramatsu, M. (1992). The regulation of the
murine Hox-2.5 gene expression during cell differentiation. Nucleic Acids Res
20, 5729-35.
Kozak, M. (2002). Pushing the limits of the scanning mechanism for initiation of
translation. Gene 299,1-34.
Kudelka, A. P., Verschraegen, C. F. and Loyer, E. (1998). Complete remission of
metastatic cervical cancer with the angiogenesis inhibitor TNP-470. NEngl J
Med 338, 991-2.
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of
the head of bacteriophage T4. Nature 227, 680-5.
Lakka, S. S., Gondi, C. S., Dinh, D. H., Olivero, W. C., Gujrati, M., Rao, V. H.,
Sioka, C. and Rao, J. S. (2005). Specific interference of urokinase-type
plasminogen activator receptor and matrix metalloproteinase-9 gene expression
induced by double-stranded RNA results in decreased invasion, tumor growth,
and angiogenesis in gliomas. JBiol Chem 280, 21882-92.
143
Lamkanfi, M., Declercq, W., Vanden Berghe, T. and Vandenabeele, P. (2006).
Caspases leave the beaten track: caspase-mediated activation ofNF-kappaB. J
Cell Biol 173, 165-71.
Lander, E. S. Linton, L. M. Birren, B. Nusbaum, C. Zody, M. C. Baldwin, J.
Devon, K. Dewar, K. Doyle, M. FitzHugh, W. et al. (2001). Initial sequencing
and analysis of the human genome. Nature 409, 860-921.
Law, D. J., Labut, E. M., Adams, R. D. and Merchant, J. L. (2006). An isoform
of ZBP-89 predisposes the colon to colitis. Nucleic Acids Res 34, 1342-50.
Lee, H. J., Tomioka, M., Takaki, Y., Masumoto, H. and Saido, T. C. (2000).
Molecular cloning and expression of aminopeptidase A isoforms from rat
hippocampus. Biochim Biophys Acta 1493, 273-8.
Leung, A. K., Andersen, J. S., Mann, M. and Lamond, A. I. (2003).
Bioinformatic analysis of the nucleolus. Biochem J 376, 553-69.
Lichun, Y., Ching Tang, C. M., Wai Lau, K. and Lung, M. L. (2004). Frequent
loss of heterozygosity on chromosome 9 in Chinese esophageal squamous cell
carcinomas. Cancer Lett 203, 71-7.
Lidington, E. A., Rao, R. M., Marelli-Berg, F. M., Jat, P. S., Haskard, D. O. and
Mason, J. C. (2002). Conditional immortalization of growth factor-responsive
cardiac endothelial cells from H-2K(b)-tsA58 mice. Am JPhysiol Cell Physiol
282, C67-74.
Lijnen, H. R. (2001). Elements of the fibrinolytic system. Ann N YAcad Sci 936,
226-36.
Limongi, P., Resnati, M., Hernandez-Marrero, L., Cremona, O., Blasi, F. and
Fazioli, F. (1995). Biosynthesis and apical localization of the urokinase receptor
in polarized MDCK epithelial cells. FEBS Lett 369, 207-11.
Lorenz, I. C., Marcotrigiano, J., Dentzer, T. G. and Rice, C. M. (2006).
Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature
442, 831-5.
Malik, H. S., Eickbush, T. H. and Goldfarb, D. S. (1997). Evolutionary
specialization of the nuclear targeting apparatus. ProcNatlAcad Sci US A 94,
13738-42.
Marchio, S., Lahdenranta, J., Schlingemann, R. O., Valdembri, D., Wesseling,
P., Arap, M. A., Hajitou, A., Ozawa, M. G., Trepel, M., Giordano, R. J. et al.
(2004). Aminopeptidase A is a functional target in angiogenic blood vessels.
Cancer Cell 5, 151-62.
144
Matsumoto, H., Rogi, T., Yamashiro, K., Kodama, S., Tsuruoka, N., Hattori, A.,
Takio, K., Mizutani, S. and Tsujimoto, M. (2000). Characterization of a
recombinant soluble form of human placental leucine
aminopeptidase/oxytocinase expressed in Chinese hamster ovary cells. Eur J
Biochem 267, 46-52.
Mazar, A. P., Henkin, J. and Goldfarb, R. H. (1999). The urokinase
plasminogen activator system in cancer: implications for tumor angiogenesis
and metastasis. Angiogenesis 3,15-32.
Mazzieri, R., Masiero, L., Zanetta, L., Monea, S., Onisto, M., Garbisa, S. and
Mignatti, P. (1997). Control of type IV collagenase activity by components of the
urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Embo J16, 2319-32.
Meyer, M., Clauss, M., Lepple-Wienhues, A., Waltenberger, J., Augustin, H. G.,
Ziche, M., Lanz, C., Buttner, M., Rziha, H. J. and Dehio, C. (1999). A novel
vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates
angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1)
receptor tyrosine kinases. Embo J18, 363-74.
Middleton, J., Americh, L., Gayon, R., Julien, D., Aguilar, L., Amalric, F. and
Girard, J. P. (2004). Endothelial cell phenotypes in the rheumatoid synovium:
activated, angiogenic, apoptotic and leaky. Arthritis Res Ther 6, 60-72.
Millauer, B., Wizigmann-Voos, S., Schnurch, H., Martinez, R., Moller, N. P.,
Risau, W. and Ullrich, A. (1993). High affinity VEGF binding and
developmental expression suggest Flk-1 as a major regulator of vasculogenesis
and angiogenesis. Cell 72, 835-46.
Millichip, M. I., Dallas, D. J., Wu, E., Dale, S. and McKie, N. (1998). The
metallo-disintegrin ADAMI0 (MADM) from bovine kidney has type IV
collagenase activity in vitro. Biochem Biophys Res Commun 245, 594-8.
Mitsui, T., Nomura, S., Itakura, A. and Mizutani, S. (2004). Role of
aminopeptidases in the blood pressure regulation. Biol Pharm Bull 27, 768-71.
Mitsui, T., Nomura, S., Okada, M., Ohno, Y., Kobayashi, H., Nakashima, Y.,
Murata, Y., Takeuchi, M., Kuno, N., Nagasaka, T. et al. (2003). Hypertension
and angiotensin II hypersensitivity in aminopeptidase A-deficient mice. Mol
Med 9, 57-62.
Miyajima, A., Kosaka, T., Asano, T., Asano, T., Seta, K., Kawai, T. and
Hayakawa, M. (2002). Angiotensin II type I antagonist prevents pulmonary
metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res
62, 4176-9.
145
Miyashita, H., Yamazaki, T., Akada, T., Niizeki, O., Ogawa, M., Nishikawa, S.
and Sato, Y. (2002). A mouse orthologue of puromycin-insensitive leucyl-specific
aminopeptidase is expressed in endothelial cells and plays an important role in
angiogenesis. Blood 99, 3241-9.
Mizutani, S., Goto, K., Mizuno, K., Itakura, A., Kurauchi, O., Kikkawa, F. and
Tomoda, Y. (1995). Interaction between pregnancy-induced bioactive peptides
and the placental proteases. Reprod Fertil Dev 7,1431-6.
Mizutani, S. and Tomoda, Y. (1996). Effects of placental proteases on maternal
and fetal blood pressure in normal pregnancy and preeclampsia. Am J
Hypertens 9, 591-7.
Mizutani, S., Yamada, R., Kurauchi, O., Ito, Y., Narita, O. and Tomoda, Y.
(1987). Serum aminopeptidase A (AAP) in normal pregnancy and pregnancy
complicated by pre-eclampsia. Arch Gynecol 240, 27-31.
Modrek, B., Lee,C. (2002). A genomic view of alternative splicing Nature
Genetics 30,13-19
Morriss-Kay, G. M., Murphy, P., Hill, R. E. and Davidson, D. R. (1991). Effects
of retinoic acid excess on expression of Hox-2.9 and Krox-20 and on
morphological segmentation in the hindbrain of mouse embryos. Embo J10,
2985-95.
Moses, M. A. (1997). The regulation of neovascularization ofmatrix
metalloproteinases and their inhibitors. Stem Cells 15,180-9.
Moss, T. and Stefanovsky, V. Y. (2002). At the center of eukaryotic life. Cell 109,
545-8.
Neurath, H. (1999). Proteolytic enzymes, past and future. Proc Natl Acad Sci US
A 96, 10962-3.
Newton, K., Petfalski, E., Tollervey, D. and Caceres, J. F. (2003). Fibrillarin is
essential for early development and required for accumulation of an intron-
encoded small nucleolar RNA in the mouse. Mol Cell Biol 23, 8519-27.
Nicosia, R. F. (1998). What is the role of vascular endothelial growth factor-
related molecules in tumor angiogenesis? Am JPathol 153,11-6.
Nicosia, R. F. and Ottinetti, A. (1990a). Growth of microvessels in serum-free
matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab
Invest 63, 115-22.
146
Nicosia, R. F. and Ottinetti, A. (1990b). Modulation of microvascular growth
and morphogenesis by reconstituted basement membrane gel in three-
dimensional cultures of rat aorta: a comparative study of angiogenesis in
matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Biol 26, 119-28.
Nosaka, T., Siomi, H., Adachi, Y., Ishibashi, M., Kubota, S., Maki, M. and
Hatanaka, M. (1989). Nucleolar targeting signal of human T-cell leukemia virus
type I rex-encoded protein is essential for cytoplasmic accumulation of
unspliced viral mRNA. Proc Natl Acad Sci USA 86, 9798-802.
Nouet, S. and Nahmias, C. (2000). Signal transduction from the angiotensin II
AT2 receptor. Trends Endocrinol Metab 11,1-6.
Nowak, M. A., Boerlijst, M. C., Cooke, J. and Smith, J. M. (1997). Evolution of
genetic redundancy. Nature 388, 167-71.
O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Cao, Y.,
Moses, M., Lane, W. S., Sage, E. H. and Folkman, J. (1994a). Angiostatin: a
circulating endothelial cell inhibitor that suppresses angiogenesis and tumor
growth. Cold Spring Harb Symp Quant Biol 59, 471-82.
O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M.,
Lane, W. S., Cao, Y., Sage, E. H. and Folkman, J. (1994b). Angiostatin: a novel
angiogenesis inhibitor that mediates the suppression of metastases by a Lewis
lung carcinoma. Cell 79, 315-28.
Obermann, E. C., Meyer, S., Hellge, D., Zaak, D., Filbeck, T., Stoehr, R.,
Hofstaedter, F., Hartmann, A. and Knuechel, R. (2004). Fluorescence in situ
hybridization detects frequent chromosome 9 deletions and aneuploidy in
histologically normal urothelium of bladder cancer patients. Oncol Rep 11, 745-
51.
Ofner, L. D. and Hooper, N. M. (2002a). The C-terminal domain, but not the
interchain disulphide, is required for the activity and intracellular trafficking of
aminopeptidase A. Bioc/tem J 362, 191-7.
Ofner, L. D. and Hooper, N. M. (2002b). Ectodomain shedding of cystinyl
aminopeptidase from human placental membranes. Placenta 23, 65-70.
Olson, M. O., Hingorani, K. and Szebeni, A. (2002). Conventional and
nonconventional roles of the nucleolus. Int Rev Cytol 219,199-266.
Orning, L., Gierse, J. K. and Fitzpatrick, F. A. (1994). The bifunctional enzyme
leukotriene-A4 hydrolase is an arginine aminopeptidase of high efficiency and
specificity. JBiol Chem 269,11269-73.
147
Otani, A., Takagi, H., Oh, H., Koyama, S. and Honda, Y. (2001). Angiotensin II
induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal
endothelial cells. Diabetes 50, 867-75.
Oudit, G. Y., Crackower, M. A., Backx, P. H. and Penninger, J. M. (2003). The
role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 13, 93-101.
Page, N. M. (2002). The endocrinology of pre-eclampsia. Clin Endocrinol (Oxf)
57, 413-23.
Pall, G. S., Wallis, J., Axton, R., Brownstein, D. G., Gautier, P., Buerger, K.,
Mulford, C., Mullins, J. J. and Forrester, L. M. (2004). A novel transmembrane
MSP-containing protein that plays a role in right ventricle development.
Genomics 84,1051-9.
Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn,
A., Ashmun, R. A., Shapiro, L. H., Arap, W. and Ruoslahti, E. (2000).
Aminopeptidase N is a receptor for tumor-homing peptides and a target for
inhibiting angiogenesis. Cancer Res 60, 722-7.
Pawlikowski, M. and Kunert-Radek, J. (1997). Angiotensin IV stimulates the
proliferation of rat anterior pituitary cells in vitro. Biochem Biophys Res
Commun 232, 292-3.
Pederson, T. (1998). The plurifunctional nucleolus. Nucleic Acids Res 26, 3871-6.
Peifer, M., Orsulic, S., Sweeton, D. and Wieschaus, E. (1993). A role for the
Drosophila segment polarity gene armadillo in cell adhesion and cytoskeletal
integrity during oogenesis. Development 118, 1191-207.
Pickart, C. M. (2004). Back to the future with ubiquitin. Cell 116,181-90.
Prince, V. E. and Pickett, F. B. (2002). Splitting pairs: the diverging fates of
duplicated genes. Nat Rev Genet 3, 827-37.
Puente, X. S., Sanchez, L. M., Overall, C. M. and Lopez-Otin, C. (2003). Human
and mouse proteases: a comparative genomic approach. Nat Rev Genet 4, 544-
58.
Quwailid, M. M., Hugill, A., Dear, N., Vizor, L., Wells, S., Horner, E., Fuller, S.,
Weedon, J., McMath, H., Woodman, P. et al. (2004). A gene-driven ENU-based
approach to generating an allelic series in any gene. Mamm Genome 15, 585-91.
Ragno, P. (2006). The urokinase receptor: a ligand or a receptor? Story of a
sociable molecule. Cell Mol Life Sci 63, 1028-37.
148
Rapaport, D. (2003). Finding the right organelle. Targeting signals in
mitochondrial outer-membrane proteins. EMBO Rep 4, 948-52.
Rawlings, N. D., O'Brien, E. and Barrett, A. J. (2002). MEROPS: the protease
database. Nucleic Acids Res 30, 343-6.
Reaux, A., Fournie-Zaluski, M. C., David, C., Zini, S., Roques, B. P., Corvol, P.
and Llorens-Cortes, C. (1999). Aminopeptidase A inhibitors as potential central
antihypertensive agents. Proc Natl Acad Sci USA 96,13415-20.
Reinartz, J., Schafer, B., Batrla, R., Klein, C. E. and Kramer, M. D. (1995).
Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte
cell line (HaCaT) to vitronectin. Exp Cell Res 220, 274-82.
Roberts, C. M., Tani, P. H., Bridges, L. C., Laszik, Z. and Bowditch, R. D.
(1999). MDC-L, a novel metalloprotease disintegrin cysteine-rich protein family
member expressed by human lymphocytes. JBiol Chem 274, 29251-9.
Robinson, C. J. and Stringer, S. E. (2001). The splice variants of vascular
endothelial growth factor (VEGF) and their receptors. J Cell Sci 114, 853-65.
Rogi, T., Tsujimoto, M., Nakazato, H., Mizutani, S. and Tomoda, Y. (1996).
Human placental leucine aminopeptidase/oxytocinase. A new member of type II
membrane-spanning zinc metallopeptidase family. JBiol Chem 271, 56-61.
Rogozin, I. B., Kochetov, A. V., Kondrashov, F. A., Koonin, E. V. and Milanesi,
L. (2001). Presence of ATG triplets in 5' untranslated regions of eukaryotic
cDNAs correlates with a 'weak' context of the start codon. Bioinformatics 17,
890-900.
Rosenthal, R. P. H. N. (1999). Heart Development: Academic Press.
Roy, R., Zhang, B. and Moses, M. A. (2006). Making the cut: protease-mediated
regulation of angiogenesis. Exp Cell Res 312, 608-22.
Rozenfeld, R., Muller, L., Messari, S. E. and Llorens-Cortes, C. (2004). The C-
terminal domain of aminopeptidase A is an intramolecular chaperone required
for the correct folding, cell surface expression, and activity of this monozinc
aminopeptidase. JBiol Chem 279, 43285-95.
Rudberg, P. C., Tholander, F., Andberg, M., Thunnissen, M. M. and
Haeggstrom, J. Z. (2004). Leukotriene A4 hydrolase: identification of a common
carboxylate recognition site for the epoxide hydrolase and aminopeptidase
substrates. JBiol Chem 279, 27376-82.
149
Russell, W. L., Kelly, E. M., Hunsicker, P. R., Bangham, J. W., Maddux, S. C.
and Phipps, E. L. (1979). Specific-locus test shows ethylnitrosourea to be the
most potent mutagen in the mouse. Proc Natl Acad Sci US A 76, 5818-9.
Sam, M., Wurst, W., Kluppel, M., Jin, O., Heng, H. and Bernstein, A. (1998).
Aquarius, a novel gene isolated by gene trapping with an RNA-dependent RNA
polymerase motif. Dev Dyn 212, 304-17.
Sambrook , J., Fritsch, E.F., Maniatis.T. (1989). Molecular Cloning A
Laboratory Manual
Satchi-Fainaro, R., Puder, M., Davies, J. W., Tran, H. T., Sampson, D. A.,
Greene, A. K., Corfas, G. and Folkman, J. (2004). Targeting angiogenesis with a
conjugate ofHPMA copolymer and TNP-470. Nat Med 10, 255-61.
Sato, Y. (2003). Aminopeptidases and angiogenesis. Endothelium 10, 287-90.
Sato, Y. (2004). Role of aminopeptidase in angiogenesis. Biol Pharm Bull 27,
772-6.
Scherl, A., Coute, Y., Deon, C., Calle, A., Kindbeiter, K., Sanchez, J. C., Greco,
A., Hochstrasser, D. and Diaz, J. J. (2002). Functional proteomic analysis of
human nucleolus. Mol Biol Cell 13, 4100-9.
Schomburg, L., Kollmus, H., Friedrichsen, S. and Bauer, K. (2000). Molecular
characterization of a puromycin-insensitive leucyl-specific aminopeptidase,
PILS-AP. Eur JBiochem 267, 3198-207.
Seals, D. F. and Courtneidge, S. A. (2003). The ADAMs family of
metalloproteases: multidomain proteins with multiple functions. Genes Dev 17,
7-30.
Shastry, B. S. (1995). Genetic knockouts in mice: an update. Experientia 51,
1028-39.
Shi, X. and Jarvis, D. L. (2006). A new rapid amplification of cDNA ends
method for extremely guanine plus cytosine-rich genes. Anal Biochem.
Shibuya, M. (2006). Vascular endothelial growth factor (VEGF)-Receptor2: its
biological functions, major signaling pathway, and specific ligand VEGF-E.
Endothelium 13, 63-9.
Silen, J. L., Frank, D., Fujishige, A., Bone, R. and Agard, D. A. (1989). Analysis
of prepro-alpha-lytic protease expression in Escherichia coli reveals that the pro
region is required for activity. JBacteriol 171, 1320-5.
150
Simoneau, M., LaRue, H., Aboulkassim, T. O., Meyer, F., Moore, L. and Fradet,
Y. (2000). Chromosome 9 deletions and recurrence of superficial bladder
cancer: identification of four regions of prognostic interest. Oncogene 19, 6317-
23.
Skarnes, W. C. (2005). Two ways to trap a gene in mice. Proc Natl Acad Sci US
A 102, 13001-2.
Skarnes, W. C., Auerbach, B. A. and Joyner, A. L. (1992). A gene trap approach
in mouse embryonic stem cells: the lacZ reported is activated by splicing,
reflects endogenous gene expression, and is mutagenic in mice. Genes Dev 6,
903-18.
Skarnes, W. C., von Melchner, H., Wurst, W., Hicks, G., Nord, A. S., Cox, T.,
Young, S. G., Ruiz, P., Soriano, P., Tessier-Lavigne, M. et al. (2004). A public
gene trap resource for mouse functional genomics. Nat Genet 36, 543-4.
Sorek, R., Shamir, R. and Ast, G. (2004). How prevalent is functional
alternative splicing in the human genome? Trends Genet 20, 68-71.
Springman, E. B., Angleton, E. L., Birkedal-Hansen, H. and Van Wart, H. E.
(1990). Multiple modes of activation of latent human fibroblast collagenase:
evidence for the role of a Cys73 active-site zinc complex in latency and a
"cysteine switch" mechanism for activation. Proc Natl Acad Sci USA 87, 364-8.
Stanford, W. L., Caruana, G., Vallis, K. A., Inamdar, M., Hidaka, M., Bautch,
V. L. and Bernstein, A. (1998). Expression trapping: identification of novel
genes expressed in hematopoietic and endothelial lineages by gene trapping in
ES cells. Blood 92, 4622-31.
Stanford, W. L., Cohn, J. B. and Cordes, S. P. (2001). Gene-trap mutagenesis:
past, present and beyond. Nat Rev Genet 2, 756-68.
Summerton, J., Stein, D., Huang, S. B., Matthews, P., Weller, D. and Partridge,
M. (1997). Morpholino and phosphorothioate antisense oligomers compared in
cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 7, 63-70.
Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S.,
Sato, T. N. and Yancopoulos, G. D. (1996). Requisite role of angiopoietin-1, a
ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87, 1171-80.
Suto, K., Yamazaki, Y., Morita, T. and Mizuno, H. (2005). Crystal structures of
novel vascular endothelial growth factors (VEGF) from snake venoms: insight
into selective VEGF binding to kinase insert domain-containing receptor but
not to fms-like tyrosine kinase-1. J Biol Chem 280, 2126-31.
151
Takahashi, C., Sheng, Z., Horan, T. P., Kitayama, H., Maki, M., Hitomi, K.,
Kitaura, Y., Takai, S., Sasahara, R. M., Horimoto, A. et al. (1998). Regulation of
matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-
anchored glycoprotein RECK. Proc Natl Acad Sci USA 95, 13221-6.
Tarui, T., Miles, L. A. and Takada, Y. (2001). Specific interaction of angiostatin
with integrin alpha(v)beta(3) in endothelial cells. JBiol Chem 276, 39562-8.
Taylor, A. (1993). Aminopeptidases: structure and function. Faseb Jl, 290-8.
Testa, G., Zhang, Y., Vintersten, K., Benes, V., Pijnappel, W. W., Chambers, I.,
Smith, A. J., Smith, A. G. and Stewart, A. F. (2003). Engineering the mouse
genome with bacterial artificial chromosomes to create multipurpose alleles. Nat
Biotechnol 21, 443-7.
Thomas, K. R. and Capecchi, M. R. (1986). Introduction of homologous DNA
sequences into mammalian cells induces mutations in the cognate gene. Nature
324, 34-8.
Thomas, K. R. and Capecchi, M. R. (1987). Site-directed mutagenesis by gene
targeting in mouse embryo-derived stem cells. Cell 51, 503-12.
Thunnissen, M. M., Nordlund, P. and Haeggstrom, J. Z. (2001). Crystal
structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in
inflammation. Nat Struct Biol 8,131-5.
Torres, M., Stoykova, A., Huber, O., Chowdhury, K., Bonaldo, P., Mansouri,
A., Butz, S., Kemler, R. and Gruss, P. (1997). An alpha-E-catenin gene trap
mutation defines its function in preimplantation development. ProcNatl Acad
SciUSA 94, 901-6.
Townley, D. J., Avery, B. J., Rosen, B. and Skarnes, W. C. (1997). Rapid
sequence analysis of gene trap integrations to generate a resource of insertional
mutations in mice. Genome Res 7, 293-8.
Tsai, R. Y. and McKay, R. D. (2002). A nucleolar mechanism controlling cell
proliferation in stem cells and cancer cells. Genes Dev 16, 2991-3003.
Tsujimoto, M., Mizutani, S., Adachi, H., Kimura, M., Nakazato, H. and
Tomoda, Y. (1992). Identification of human placental leucine aminopeptidase as
oxytocinase. Arch Biochem Biophys 292, 388-92.
Tuteja, R. (2005). Type I signal peptidase: an overview. Arch Biochem Biophys
441, 107-11.
152
Uemura, H., Ishiguro, H., Nakaigawa, N., Nagashima, Y., Miyoshi, Y.,
Fujinami, K., Sakaguchi, A. and Kubota, Y. (2003). Angiotensin II receptor
blocker shows antiproliferative activity in prostate cancer cells: a possibility of
tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2, 1139-47.
Venter, J. C. Adams, M. D. Myers, E. W. Li, P. W. Mural, R. J. Sutton, G. G.
Smith, H. O. Yandell, M. Evans, C. A. Holt, R. A. et al. (2001). The sequence of
the human genome. Science 291, 1304-51.
von Melchner, H., DeGregori, J. V., Rayburn, H., Reddy, S., Friedel, C. and
Ruley, H. E. (1992). Selective disruption of genes expressed in totipotent
embryonal stem cells. Genes Dev 6, 919-27.
Voss, A. K., Thomas, T. and Gruss, P. (1998). Compensation for a gene trap
mutation in the murine microtubule-associated protein 4 locus by alternative
polyadenylation and alternative splicing. Dev Dyn 212, 258-66.
Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hanahan, D.,
Shapiro, S. D., Senior, R. M. and Werb, Z. (1998). MMP-9/gelatinase B is a key
regulator of growth plate angiogenesis and apoptosis of hypertrophic
chondrocytes. Cell 93, 411-22.
Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V.
and Chapman, H. A. (1996). Regulation of integrin function by the urokinase
receptor. Science 273,1551-5.
Wen, W., Meinkoth, J. L., Tsien, R. Y. and Taylor, S. S. (1995). Identification of
a signal for rapid export of proteins from the nucleus. Cell 82, 463-73.
Wente, S. R. (2000). Gatekeepers of the nucleus. Science 288, 1374-7.
Williams, C. L. (2003). The polybasic region of Ras and Rho family small
GTPases: a regulator of protein interactions and membrane association and a
site of nuclear localization signal sequences. Cell Signal 15, 1071-80.
Wobus, A. M., Kaomei, G., Shan, J., Wellner, M. C., Rohwedel, J., Ji, G.,
Fleischmann, B., Katus, H. A., Hescheler, J. and Franz, W. M. (1997). Retinoic
acid accelerates embryonic stem cell-derived cardiac differentiation and
enhances development of ventricular cardiomyocytes. JMol Cell Cardiol 29,
1525-39.
Wong, E. A. and Capecchi, M. R. (1987). Homologous recombination between
coinjected DNA sequences peaks in early to mid-S phase. Mol Cell Biol 7, 2294-
5.
153
Wright, J. W., Mizutani, S., Murray, C. E., Amir, H. Z. and Harding, J. W.
(1990). Aminopeptidase-induced elevations and reductions in blood pressure in
the spontaneously hypertensive rat. J Hypertens 8, 969-74.
Xu, Q., Modrek, B. and Lee, C. (2002). Genome-wide detection of tissue-specific
alternative splicing in the human transcriptome. Nucleic Acids Res 30, 3754-66.
Yamazaki, T., Akada, T., Niizeki, O., Suzuki, T., Miyashita, H. and Sato, Y.
(2004). Puromycin-insensitive leucyl-specific aminopeptidase (PILSAP) binds
and catalyzes PDK1, allowing VEGF-stimulated activation of S6K for
endothelial cell proliferation and angiogenesis. Blood 104, 2345-52.
Yan, D., Swain, P. K., Breuer, D., Tucker, R. M., Wu, W., Fujita, R.,
Rehemtulla, A., Burke, D. and Swaroop, A. (1998). Biochemical
characterization and subcellular localization of the mouse retinitis pigmentosa
GTPase regulator (mRpgr). JBiol C/tem 273, 19656-63.
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J. and
Holash, J. (2000). Vascular-specific growth factors and blood vessel formation.
Nature 407, 242-8.
Yu, Y. and Bradley, A. (2001). Engineering chromosomal rearrangements in
mice. Nat Rev Genet 2, 780-90.
Zhou, H. M., Weskamp, G., Chesneau, V., Sahin, U., Vortkamp, A., Horiuchi,
K., Chiusaroli, R., Hahn, R., Wilkes, D., Fisher, P. et al. (2004). Essential role
for ADAMI 9 in cardiovascular morphogenesis. Mol Cell Biol 24, 96-104.
Zhu, X. L., Ohta, Y., Jordan, F. and Inouye, M. (1989). Pro-sequence of
subtilisin can guide the refolding of denatured subtilisin in an intermolecular
process. Nature 339, 483-4.
154
Development of a PCR genotyping assay
Genomic DNA was extracted from adult tissues of mice that had
previously been genotyped with the /3-galactosidase staining protocol (see
methods). The wild type allele was amplified by PCR using primers Exon F
and Exon R (Figure Appendix 1.1a). The gene trap (mutant) allele was
amplified by PCR with the primers Exon F and EN2 (Figure Appendix 1.1b).
As expected the mutant PCR yielded products for the heterozygote
ApOG,4IIFor/+ and homozygous ^pQGt4,IFor/G,4nFor DNA, but not for the wild
type DNA (Figure Appendix 1.1c). Surprisingly, however, the wild type PCR
primers (Exon F-Exon R) yielded product for all the different genotypes
(Figure Appendix 1.1c). The expected result would have been that
homozygous ApOGt4UFor/Gt4UFor mice would not have yielded a PCR product.
The experiment was repeated several times on other homozygous /3gal
genotyped mice and on the same homozygous ApOGt4"For/Gt4,,Fc"' mouse used
in the knockout Northern analysis (Chapter 4). The result was the same despite
extreme care being taken to eliminate the possibility of cross contamination
during the purification of the DNA.
A genomic Southern was performed on PVU II restriction digested
genomic DNA from wild type, heterozygous and homozygous mice. Using
probe 1 (specific to wild type sequence) a band should only be seen in the wild
type and heterozygous lanes at 1975 bp. However, there is clearly a band in the
homozygote the same size (Figure Appendix l.ld, probe 1). Using probe 2
(specific to the gene trap vector) bands should be seen in lanes 2 and 3 at 1173
bp. This was the case with this probe (Figure l.ld, probe 2).
The experiment to design a PCR based genotyping assay was
unsuccessful. The PCR primers ExonF- ExonR should have enabled one to
determine which samples were homozygous dpOG'4"For/Gl4"For and wild type.
There was always a PCR fragment in the homozygous ApOa'4"For/Gt4IIFor
sample. To test if there was a de novo genomic duplication of this gene region
else where in the genome FISH analysis was carried out on wild type
metaphase chromosomes. This result indicated that there was only a single
copy on chromosome 13 (Figure 3.7). However, there is still the possibility that
there is duplication within the region itself. Indeed thorough sequence analysis
of chromosome 22 has reported that as much as 10% of this chromosome is
duplicated (Bailey et al., 2002).
Another explanation might be that the wild type genomic sequence has
undergone as a consequence of the gene trap integration a duplication event. It
certainly is not uncommon for the gene trap vector to integrate multiple times
(Pall et al., 2004). The Southern blot analysis with probe 1 supports this
hypothesis because a fragment of 1975 bp is observed in the homozygous
sample. Another experiment that could have been carried out was to perform
FISH analysis on metaphase spreads of both wild type and homozygous gene
trap GT411. A comparison of the wild type and homozygous metaphase
chromosomes might have allowed a duplication event in the homozygous DNA
to be seen. The data suggests the possibility that the endogenous gene locus
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d)
Probe 1 Probe 2
+/+ "
I






Figure Appendix 1.1: Development of genotyping assay for the GT411
gene trap mice.
a) Schematic diagram of the wild type genomic region wild type,
b) gene trap allele. Gene trap vector shown in blue.
c) Genotyping PCR on genomic DNA extracted from wild type,
heterozygous ApO Gt4IIFor/+ and homozygous^poGt4'IFor/Gt4IIFor samples.
d) Southern blot ofwild type, heterozygous ApO Gt4IIFor/+ and
homozygous ApOGt4nFor/G14"For genomic DNA with restriction enzyme
































Fib 1 EcoRI GAATTCATGAAGCCAGGTTTCAGCCCCCGTG
Fib 2 Asp718I GGTACCTCAGTTCTTCACCTTGGGAGGTG
Appendix 1.2 Table 1: Primers used in this study.
a)
M 1 2




eGFP C2 GFP tag
Appendix 1.3 In vitro translation of Full length ApO and
vectors used for cloning
a) Lane 1, Luciferase control (70kDa), Lane 2, F1-ApO (1-stop)
cloned into pcDNA3.1+ (116kDa)
and breakdown product (80kDa).
b) List of vectors used in study
APPENDIX 1.4
PRETTYSEQ of cutpaste-9746 from 1 to 3856. BUILD 16/06/05
I I I I I I
1 GAATTCGCCCTTAACCCGGAGTCTGCGGAAGTGTAGCTTGCAGCAAGCACCGCAGCTGAG 60
| I-... | ...-I | |
61 ACAGGTAACCTGCAGCTCCGGTGTCAAGCAGCCCGCTCCGGGTTATGCGGACCCACGACC 12 0
[ | | | | |
121 TCTGGTGGGGTGAGCAGGGAATTGAAAGTTGTGGAAAGATAACGAGTGCCAGTGGGTGCT 18 0
| | | | | |
181 TCTTATTTGGTAAACCAGCCATTTGTGATTCTGAGCTACTACAGGAGATTAGAAGCTTCA 240
| | | | | |
241 GCTGAGATTCAGCAAAGCTACCAACTGCAGACTACACCatggacataaagctggaccctt 300
1 MDIKLDPS8
| | | | | |
301 cccgggatgatctgcctctcatggccaacaccagccacatgcttgtgaagcactacatac 360
9 RDDL PLMANTSHMLVKHY I L28
| | | | | |
361 tggatttggatgtggactttggaaatcaagtcattgagggcaacatagtgcttttctttg 420
29 DLDVDFGNQVIEGNIVLFFG48
| | | | | |
421 gagatggaaacagatttaaaaaccagtcgcgttctacccaggaaaccttccagatggagt 480
49 DGNRFKNQSRSTQETFQMES68
| | | |__ |
481 cagaggaggctgacatatttaggacagctgaaccctgccatgttcctgagatggattcga 540
69 EEADIFRTAEPCHVPEMDSS88
| | | | | |
541 gtaccttctcacttaagatgggacatagagaatgtgcagtctgtggtaaaggtgatcaag 600
89 TFSLKMGHRECAVCGKGDQD 108
| | | | | |
601 atgcctttgataacgatggtacccatgacaaccaggaacgtgattctgagatctctagct 660
109 AFDNDGTHDNQERDSEISSS 128
1 1 1 1 1 1
661 caaagtactgctgtgacacagggaatcatgggaaaagggatttcttgctagtgttggact 720
129 KYCCDTGNHGKRDFLLVLDC 148
1 1 1 1 1 1
721 gctgtgatttatctgtgctaaaggtagaggaggtggatgtggctgctgtgccaggccttg 780
149 CDLSVLKVEEVDVAAVPGLE 168
1 1 1 1 1 1
781 agaaatttactaaagctccaaagctcttggctactcctgagaagctcaggtgtgagattg 840
169 KFTKAPKLLATPEKLRCE IV 188
1 1 1 1 1 1
841 tccgtgaccttgtggctctgcctgcagatgcttggagggagcagttagactgctacactc 900
189 RDLVALPADAWREQLDCYTR 208










1 1 1 1 1 1
1141 ccgttgccatgtcaacatggcaggctacagttcgagcagctgcatcttttgttgttttaa 1200
289 VAMSTWQATVRAAASFVVLM 308
1 1 | |^7 ----i |
1201 tgagtggagaaaattctgccaagcccacaccacttcgagaaggatacatgagttggcatt 1260
309 SGENSAKPTPLREGYMSWHY 328
| | | | | |
1261 actatgtgaccatgccaatgccggcctctacctttgcaattgcagtggggtgctggacag 1320
329 YVTMPMPASTFAIAVGCWTE 348
1 1 1 1 1 1
1321 aaatgaagcccaaggcatccccaccagatgatctgatgactgagcactctctccccctct 1380
349 MKPKASPPDDLMTEHSLPLS 368
1 |V | 1 1 1
1381 cgccatcggaagtggacttgaggtatgataacacctgcaatcatatggaatacccttgca 1440
369 PSEVDLRYDNTCNHMEYPCR 388
1 1 1 1 1 1
1441 ggttccagagtgcgtccgctgcctcccaggacatcattccttatcgagtgtttgccccag 1500
389 FQSASAASQDIIPYRVFAPV 408
| | | | | |
1501 tgtgccttgagggtgcctgccaagaagccctgctgtggctgatcccttcttgcctctcag 1560
409 CLEGACQEALLWLI PSCLSA 428
1 1 1 1 1 1
1561 ctgcacactctgtcctgggaacacaccctttctcccggctggacatactcgttgtcccca 1620
429 AHSVLGTHPFSRLDILVVPT 448
I | ^7_| 1 | |
1621 ccaactttccaagtctgggaatggccaacccacacatcatcttcctctctcagagcacct 1680
449 NFPSLGMANPHI IFLSQSTL 468
1681 taacaggcacgagccatctctgtgggacccgtctttgccatgaaattgctcactcctggt 1740
469 TGTSHLCGTRLCHEIAHSWF 488
1 1 1 1 1 1
1741 ttggcctagccattggggcccgagactggacagaggagtggctcagtgaaggatttgcca 1800
489 GLAIGARDWTEEWLSEGFAT 508
| | | 5^ | |
1801 cgcatttggaagatatattttgggctgaggcacagcagctgcccccccatgaggccctgg 1860
509 HLEDI FWAEAQQLPPHEALE 528
1861 agcagcaggagctgagggcttgcctgcgctggcaccgcctgcaggatgagcttcggaact 1920
529 QQELRACLRWHRLQDELRNS 548





- V 1 1 1 1 1
2041 acttaaagggctacttccttcttcggttcctaaccagaacacttggagagaaaatttatt 2100
589 LKGYFLLRFLTRTLGEKIYF 608




629 LQMLLENI PENKRLGLSVEN 648
| | | ^ | |
2221 acatcgtccgagattggcttgagtgttccggaatacctaaggcgctgcaggaggagcgca 2280
649 IVRDWLECSGIPKALQEERK 668
| | | | | |
2281 aggccgaggactgctcgccgagtaggctcgcacggcaagtaggctccgaggtggcgaaat 2340
669 AEDCSPSRLARQVGSEVAKW 688
1 1 1 1 1 1
2341 ggattcgagtcaaccgcagaccccgaaaacgcaaacgagggaagcgagaagtcgcctttg 2400
689 I R V N RRPRKRKRGKR E V A F E 708
---V-~| | | | I I
2401 aaaagctttctccagaccagatcgtcttgcttttggagtggctcttagagcagaagacgc 2460
709 KLSPDQIVLLLEWLLEQKTL 728
| | | | | |
2461 tgagccctcagacactgcactgtctccagcagacttaccatctcccagagcaggatgcag 2520
729 S PQTLHCLQQTYHLPEQDAE 748
V— I 1 1 1 1 1
2521 aggttcgccatcgatggtgtgaactggttattaagcacaagtacacaaaggcatacaatc 2580
74 9 VRHRWCELVI KHKYTKAYNQ 768
1 1 37 1 1 1
2581 aggtggagaggttcctactggaggaccaggccatgggcatatacctgtatggggagctga 2640
769 VERFLLEDQAMGIYLYGELM 788
1 1 1 1 1 1
2641 tggtgagtgaggacgccaggctgcagcagctagcccacaggtgc11tgagctggtgaagg 2 700
789 VSEDARLQQLAHRCFELVKE 808
1 1 | | I---X7
2701 aacacatggacagagcatcggcccaggtggtgactgaaatgctgttcTAAAGAGGACAGA 2760
809 HMDRASAQVVTEMLF 823




















Aminopeptidase catalytic HEIAH (E18) amino acid position 481
Nuclear localisation signal (NLS) RRPRKRKRGKR amino acid position 694
Armadillo repeat amino acid position 710-822
Putative start codons at amino acid position 1 and 332.
V= Exon Boundaries
AATAAA Polyadenylation signals
